Investigation into the mechanisms of platelet recruitment and migration during allergic inflammation by Shah, Sajeel Ahmad
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 













Download date: 05. Apr. 2019
Investigation into the mechanisms of 
platelet recruitment and migration during 
allergic inflammation 
 
Sajeel Ahmad Shah 
A thesis submitted for the degree of  
Doctor of Philosophy 
 
Supervisors: 
Dr Simon Pitchford and Prof. Clive Page 
 
Sackler Institute of Pulmonary Pharmacology 
Institute of Pharmaceutical Science 
School of Cancer and Pharmaceutical Sciences  
2018 




A dichotomy in platelet activation has been described, where along with well-known 
thrombotic and haemostatic responses, platelets can be activated via alternate pathways 
leading to inflammatory responses. Such activation pathways are believed to be involved in 
allergic inflammatory diseases such as asthma, where platelets can migrate extravascularly 
into lung airway walls and parenchyma in response to allergen. Understanding the 
mechanisms of platelet recruitment and migration in allergic inflammation could lead to novel 
drug approaches for the treatment of allergic conditions. 
The purpose of this research was to firstly develop and advance in-vitro and in-vivo 
models of platelet migration in response to allergen sensitization and challenge. Moreover, the 
mechanisms behind the allergic inflammatory actions of platelets by investigating the roles of 
platelet chemokine receptors. 
Platelet CCR1, CCR3, CCR4 and CXCR4 chemokine receptor expression was 
confirmed by flow cytometry and western blot analysis, using antibodies specific to each 
receptor. Several in-vitro chemotaxis assays were studied and developed for measuring human 
and mouse platelet motility. Platelet chemotaxis was recorded in-vitro towards eotaxin, fMLP, 
MDC and SDF-1α. Furthermore, increased platelet chemotaxis to eotaxin was recorded when 
platelets were harvested from mice sensitized to the experimental allergen ovalbumin, 
compared to platelets harvested from sham-sensitized mice.  
In other experiments, a house dust mite extract (HDM) sensitisation and exposure 
protocol was optimised to sensitise mice to allergen, to then be used for: 1. intravital-
microscopy preparations of mouse cremaster muscle; 2. lung immunohistochemistry assays. 
Intravital microscopy of fluorescently labelled platelets in the mouse cremaster muscle 
enabled recordings of platelet-endothelial wall interactions. After HDM challenge in the 
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cremaster muscle, increased platelet rolling and adhesion events were recorded in post 
capillary venules of HDM-sensitised mice compared with sham-sensitised mice. 
Immunohistochemical staining of extravascular platelets in cremaster muscle sections, and 
lungs similarly displayed an increased number of platelets in mice that were HDM-sensitised 
and HDM challenged.  
The roles of platelet chemokine CCR1, CCR3, CCR4, and CXCR4 receptors on platelet 
accumulation were investigated using antagonists to these receptors in-vivo. In response to 
allergen challenge, CCR3 receptor antagonism attenuated localized platelet adhesion and 
accumulation; whilst CXCR4 receptor antagonism decreased leukocyte migration. 
These results demonstrate that platelet migration can occur in response to a chemokine 
stimulus in-vitro and allergen exposure in-vivo, and suggests novel roles of platelet chemokine 
receptors in allergic inflammatory platelet function. 
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1.1 Platelet function in haemostasis and host defence 
1.1.1  Platelet structure and production 
Small, anuclear, spherical cell fragments called platelets, were first described in the 19th 
century, along with their vital roles in haemostasis and thrombosis (Osler, 1874; Bizzozero, 
1881). Under normal resting conditions, human platelets are roughly 3 µm at the widest point 
with a blood concentration of 1.5-3 x 108 platelets/mL (Hartwig and Italiano, 2003). Platelets 
are produced by the fragmentation of large polyploid megakaryocytes, in a process termed 
thrombopoiesis, and released into the circulation where they survive for 7-10 days (Hartwig 
and Italiano, 2003). Platelet production was believed to be restricted to the bone marrow. 
However, more recent evidence suggests that megakaryocytes can mature in the lung and 
release platelets into the pulmonary circulation, contributing an estimated 50% to the total 
platelet production (Wang et al., 2015; Lefrançais et al., 2017).  
Platelets do not replicate or include nuclei, but contain mRNA which they are able to 
translate and independently produce proteins, to supplement proteins produced by 
megakaryocytes (Yeaman, 2014). Platelets contain α-granules, dense δ-granules and 
lysosomal λ-granules, which can release a broad range of over 300 different proteins following 
degranulation (Coppinger et al., 2004), examples of which are displayed in Table 1. The 
secretion of such mediators from platelets are fundamentally important in platelet function 
(Smyth et al., 2009). Aging platelets are eventually cleared from the circulation through an 
intrinsic apoptosis mechanism in the liver and spleen (Kile, 2014).  
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Table 1: Platelet granule constituents adapted from Smyth et al., 2009 and Amison 2014 
α-granules Dense δ-granules Lysosomal λ-granules 
Adhesive glycoproteins 
• Fibrinogen 
• von Willebrand Factor 






• Factor V 
• Protein S 




• Transforming growth 
factor-β 
• Endothelial cell growth 
factor 
• Epidermal growth 
factor 
• Insulin-like growth 
factor-1 
Angiogenic factors 
• Vascular endothelial 
growth factor 
• Platelet factor 4 
Fibrinolytic inhibitors 
• α2-Plasmin inhibitor 
• Plasminogen activator 
inhibitor-1 
Multimerin 






• P-selectin (CD62P) 













• Protease nexin 1 
• Gas6 
• Amyloid β-protein 
precursor 
• Tissue factor pathway 
inhibitor 
• Factor XIII 
• α1-Protease inhibitor 
• Complement l inhibitor 
• High molecular weight 
kininogen  
• α2-Macroglobulin 








• MIP-Iα (CCL3)  
• RANTES (CCL5)  
• MCP-3 (CCL7)  
• Gro-α (CXCL1) 
• ENA-78 (CXCL5)  
• NAP-2 (CXCL7) 
• Interleukin-8 (CXCL8) 




Proline Carboxypeptidase A 
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1.1.2  Platelet aggregation 
The well-established mechanisms of platelet aggregation are critical for maintaining 
blood circulation by preventing haemorrhage. Circulating resting platelets are modulated by 
endothelial cells which promote protein C to prevent thrombin formation, and release 
prostaglandin I2 and nitric oxide that inhibit platelet function (Versteeg et al., 2013). 
Reciprocally, platelets help to maintain endothelial ultrastructure, promote endothelial cell 
growth and enhance barrier function of endothelial cells, by release of mediators such as 
endothelial cell growth factor, adenosine 5′-diphosphate (ADP), serotonin and sphingosine-1-
phosphate (Saba and Mason, 1975; King and Buchwald, 1984; Schaphorst et al., 2003; Ho-
Tin-Noé et al., 2011).  
Following vessel rupture, endothelial cells become damaged and platelets become 
exposed to the subendothelial matrix. Platelets bind von Willebrand factor through 
glycoprotein (GP) Ibα and bind collagen through GPVI and integrin α2β1, expressed on the 
subendothelial matrix. These adhesive events cause adhesion of platelets to the exposed 
damaged area, which along with thrombin, can initiate platelet activation. Consequently, the 
clotting cascade is initiated, with the first phase (initiation, or extrinsic phase) involving blood 
borne clotting factors acting on cells in the extravascular tissue that express tissue factor (TF). 
TF binds to factor (F) VII and triggers a cascade of clotting factors resulting in FXa converting 
FII (prothrombin) to FIIa (thrombin), thrombin then converts fibrinogen to fibrin. The 
amplification (intrinsic) phase is initiated by thrombin on activated platelets and involves a 
series of clotting factors that leads to further thrombin formation (Brass, 2010; Yeaman, 2014).  
Activation of platelets in aggregatory responses leads to shape change, granule release 
and surface expression of adhesion molecules and receptors (Gear and Polanowska-
Grabowska, 2002). Central to these aggregatory effects of platelets is the release of ADP, from 
dense δ-granules, which binds to P2Y1 and P2Y12 receptors; conformational changes of 
GPIIb/IIIa fibrinogen receptors and increased surface expression of GPIIb/IIIa receptors and 
mediation of GPIIb/IIIa expression by thromboxane A2 (TXA2), which also causes 
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vasoconstriction. These changes in platelets lead to the formation of a cross-linked, elastic 
fibrin clot over the area of injury, which can be attenuated by proteolytic feedback. This 
protective mechanism is a vitally important physiological process that prevents bleeding and 
enables wound repair (Smyth et al., 2009; Brass, 2010; Versteeg et al., 2013). 
1.1.3. Platelets and host defence 
The role of platelets in thrombosis and haemostasis is well understood and has led to 
the discovery of effective anti-platelet drugs to treat thrombosis. However, platelets are also 
important for host defence and inflammatory responses, which are distinct physiological 
processes to that of thrombosis and haemostasis (Page and Pitchford, 2014). The difference in 
platelet function in haemostasis compared with inflammation has led to the hypothesis that 
there is a dichotomy in platelet activation (Page, 1988), which has recently been confirmed 
experimentally using murine models of allergic airways disease (discussed below) (Amison 
et al., 2015; Pan et al., 2015). Indeed, platelets have been shown to be important in host 
defence against microbial infections (van den Boogaard et al., 2015; Hurley et al., 2016). 
Platelets are the first responders to sites of tissue injury, endothelial injury and infection, 
leading to haemostatic responses of platelets and key roles in the early intervention against 
infection. Platelets can target sites of bacteria-specific proteins through activation via 
complement C3a and C5a receptors (del Conde et al., 2005; Yeaman, 2010), and have been 
shown to undergo chemotaxis to exposed collagen through interactions with plasma factors 
(Lowenhaupt, 1978; Lowenhaupt et al., 1982). Furthermore, platelets can become activated in 
response to bacterial N-formylated peptides (NFP) via N-formyl peptide receptors (FPR) that 
are expressed on their surface (Czapiga et al., 2005). Activation via NFP leads to calcium 
mobilization, cytoskeletal rearrangements and chemotaxis (Czapiga et al., 2005). Therefore 
platelets have the potential to accumulate at sites of injury or infection, and initiate 
antimicrobial actions. 
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Platelets can detect microbial threats through the expression of receptors that recognise 
pathogen-associated molecular patterns. Platelets upregulate toll-like receptor (TLR)1 and 
TLR6 in vascular lesions that may involve bacterial infection (Shiraki et al., 2004). Platelets 
also constitutively express TLR2, TLR4 and TLR9, which have been suggested to have 
important roles in pathogen recognition (Aslam et al., 2006). Indeed TLR4 dependent 
signalling pathways are activated in response to lipopolysaccharide (LPS), which have been 
suggested to interact with the LPS receptor-signalling complex on platelets (Berthet et al., 
2012). Furthermore, platelet activation induced by high thrombin concentrations leads to 
increased TLR9 expression (Aslam et al., 2006). The expression of TLR receptors on platelets 
enable the detection of bacterial infections, which trigger signalling cascades important in host 
defence. 
Self-amplification of platelet responses occur through autocrine mechanisms involving 
ADP release from δ-granules, which activates P2Y1 and P2Y12 receptors leading to further 
degranulation and release of antimicrobial effector molecules. Platelets have been shown to 
internalise infectious microorganisms via phagocytosis, aiding the clearance of 
microorganisms (Youssefian et al., 2002). Platelets contain several direct acting antimicrobial 
proteins such as human β-defensin 2, CXCL4 (platelet factor 4, PF4), CXCL7 (β-
thromboglobulin, beta-TG), hydrogen peroxide and thymosin β4, which can be released upon 
platelet activation through degranulation (Tang et al., 2002). Platelet activation in response to 
microbial infection causes the release of chemokines such as PF4 and CCL5 (regulated upon 
activation normally T-cell expressed and secreted, RANTES) (Antczak et al., 2011; 
McMorran et al., 2012). In response to microbial infection, platelet activation can enhance 
neutrophil responses through direct interactions via platelet CD62P (P-selectin) binding to 
neutrophil CD162 (P-selectin glycoprotein ligand 1, PSGL-1) (Pan et al., 2015; Zuchtriegel et 
al., 2016). Once recruited, activated neutrophils can phagocytose pathogens and produce 
neutrophil extracellular traps, leading to the killing and digestion of pathogens. Platelets 
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therefore have important roles in the innate immune responses to foreign microorganisms, 
away from typical platelet aggregatory responses.  
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1.2 Platelets in allergic inflammation 
1.2.1  Asthma 
Asthma is a chronic allergic inflammatory disease of the airways, which affects 5.4 
million people in the UK. It is estimated that every 10 seconds someone has a potentially life 
threatening asthma attack. In 2016, 1,410 people died from asthma with two thirds of these 
deaths preventable. Hospital treatment of patients with asthma costs the NHS roughly 1 billion 
pounds a year (Asthma UK). Thus, there is a clear unmet clinical need for new therapeutic 
treatments for asthmatic patients. 
Patients with asthma suffer from symptoms such as shortness of breath, wheezing, chest 
tightness, and coughing. In acute asthma these symptoms worsen, and when patients do not 
respond to standard treatments in cases of severe asthma, this can lead to airway obstruction 
and respiratory arrest. The typical response to allergen challenge in asthmatic patients in the 
clinical laboratory involves an acute inflammatory response comprising of early and late phase 
responses, which are characterized by bronchoconstriction, inflammatory cell recruitment and 
mucus production. Following the acute phase response, a chronic inflammatory response can 
be initiated, involving persistent inflammatory cell recruitment to the lung resulting in airway 
wall remodelling (Barnes, 2011). This model has been widely used to investigate the 
mechanisms of asthma and to evaluate treatments and many animal models of allergic asthma 
are design to recapitulate this clinical scenario. 
In allergic asthma, patients are predisposed to react to perceived noxious inhaled 
allergens or other irritants including exercise, cold air and chemical irritants. Classically, 
within minutes of exposure to allergen the early phase response is initiated. This involves the 
activation of resident airway immune cells (for example mast cells), by allergen causing cross 
linking of immunoglobulin E (IgE) which bind to FcεRI receptors, leading to proinflammatory 
mediator release that cause bronchoconstriction and vasodilation (Barnes, 2011). The late 
phase response becomes evident 2-9 hours after the initial allergen exposure. Late phase 
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responses are characterized by leukocyte recruitment (including eosinophils, T cells and 
neutrophils) to the airways, leading to additional inflammatory mediator release, resulting in 
further bronchoconstriction, vasodilation and mucus secretion. This is followed by a chronic 
inflammatory response, which is associated with a T helper 2 cells (Th2) adaptive immune 
response, causing further tissue injury, and is associated with inappropriate repair mechanisms 
in the lung, leading to airway remodelling, changes in airway architecture that contributes over 
time to a loss of respiratory function if not appropriately treated. 
 There is no cure for allergic asthma, but current treatments include reliever therapies 
which treat the symptoms as they arise, preventer therapies which reduce the risk of symptoms 
occurring and combination therapies that help stop symptoms occurring and provide long 
lasting relief e.g. salmeterol (β2 agonist) with fluticasone propionate (corticosteroid). 
However, 5-10% of asthma patients are classified as insensitive or poorly responsive to 
corticosteroid treatments (Durham et al., 2011). Furthermore, long term corticosteroid 
treatment is associated with unwanted side effects such as oral candidiasis, pneumonia, cough 
and contact hypersensitivity. There are also major issues with patient compliance with inhaled 
therapies, therefore there is a clear unmet clinical need for improved treatments for asthma 
(Baddar et al., 2014; Ye et al., 2017). 
1.2.2  Allergen sensitization and exposure 
Sensitization to allergen is a mechanism involving genetic, environmental and 
immunological factors. This complex interplay between various factors makes association, 
linkage and predicting the predisposition of a patient to allergic disease challenging. The 
immunological factors involved in mucosal exposure to allergen are better understood, which 
begins with the epithelium acting as a physical barrier to inhaled allergen, pathogens, and 
pollutants. Epithelial cells control movement across the membrane through tight junctions, 
transporters and selective permeability to ions, which along with epithelial secretions, help 
maintain the mucus barrier. Epithelial cells also express innate immune receptors that enable 
detection of foreign viruses, bacteria and fungi, which can induce immune cells to cause an 
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inflammatory response (Van Ree et al., 2014). Indeed, allergen exposure can activate 
epithelial cells leading to CCL2 (monocyte chemoattractant protein 1) and CCL20 
(macrophage inflammatory protein-3α) chemokine release, which can recruit and activate 
dendritic cells (Hammad et al., 2009). Allergens can also bypass the barrier function of 
epithelial cells through various mechanisms, for example, house dust mite allergen has 
protease activity, which interferes with tight junctions and facilitates transepithelial allergen 
delivery (Wan et al., 1999; Van Ree et al., 2014).  
Following passage through the epithelial layer, allergens are recognized by dendritic 
cells or other cells capable of antigen presentation (APCs: antigen presenting cells) which 
reside in the basolateral layer. APCs subsequently undergo maturation and migration to the 
secondary lymphatic system. In regards to house dust mite allergen, antigen presenting 
CD11b+ dendritic cells then process and present antigens to T cells via major 
histocompatibility complex II (Plantinga et al., 2011; Lambrecht and Hammad, 2012). This 
leads to a Th2 mediated allergic inflammatory response, involving the secretion of cytokines 
interleukin (IL)-4, IL-5 and IL-13, and B cell immunoglobulin isotype switching. CD4+ T 
cells interact with B cells via CD40 and its ligand (CD40L), and stimulation with IL-4 and IL-
13, to cause an isotype switch from immunoglobulin G (IgG) to IgE production (Van Ree et 
al., 2014). Upon subsequent allergen exposure, allergen is recognised by allergen specific IgE, 
which is crosslinked with FcεRI receptors on the surface of lung mast cells and basophils 
leading to degranulation and release of proinflammatory mediators, for example histamine, 5-
hydroxytriptamine (5-HT), prostaglandins, and leukotrienes, contributing to allergic 
inflammatory responses and bronchospasm during the early phase response, that occurs within 
seconds and can last for 30 minutes to 1 hour (Stone et al., 2010). Resident immune cells 
become activated during this period to release various effector cytokines and chemokines to 
contribute to a late phase response, which is defined by inflammatory cell recruitment to the 
airways and the release of mucus, leading to further bronchospasm. One example of cytokine 
release during this period is IL-5 which causes the activation and differentiation of eosinophils 
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within the bone marrow, leading to their release into the circulation and trafficking to the 
inflamed tissue (Stone et al., 2010). 
1.2.3  Platelet activation in allergic inflammation 
Platelets have long been suggested to have an important role in allergic inflammatory 
diseases (Benveniste et al., 1972). Indeed, platelets possess the requisite components to act as 
inflammatory cells in the context of allergic inflammation. Intracellular platelet granules can 
be released upon activation by stimuli emanating from an allergic inflammatory response and 
they contain several inflammatory mediators such as free radical species, 5-HT, interleukin-
1β (IL-1β) (Lindemann et al., 2001; Denis et al., 2005), PF4 (Hayashi et al., 1994), RANTES, 
CXCL7 (Neutrophil activation protein-2, NAP-2; itself a product of processed platelet β-
thromboglobulin) and CCL17 (thymus activation regulated chemokine, TARC) (Oliveira and 
Lukacs, 2003; Smyth et al., 2009). Platelets also express a number of functional receptors 
which could have roles in allergic inflammatory responses, including immunoglobulin 
receptors (FcγRI, FcγRII, FcγRIII; FcεRI, FcεRII, FcαRI/CD89) (Joseph et al., 1997; 
Hasegawa and Matsubara, 2001; Pitchford et al., 2008; Semple and Freedman, 2010), 
chemokine receptors (CCR1, CCR3, CCR4 and CXCR4) (Clemetson et al., 2000; Kowalska 
et al., 2000; Abi-Younes et al., 2001), adhesion molecules (P-selectin, PSGL-1 and ICAM2) 
(Pitchford et al., 2005; Semple and Freedman, 2010) and toll-like receptors (TLR2, TLR4 and 
TLR9) (Cognasse et al., 2015), which are discussed in this chapter. Thus, these inflammatory 
mediators and receptors may contribute to allergic inflammatory responses, which have been 
observed to be released, or activated via IgE-/FcεRI receptor activation of platelets. 
The roles of platelet IgG receptors FcγRI, FcγRII, FcγRIII and FcαRI/CD89, have not 
been studied in great depth, although the functionality of the high affinity (FcεRI) and low 
affinity (FcεRII) platelet IgE receptors in response to allergen has been demonstrated. Platelets 
from patients with asthma, and mice sensitized to experimental allergen were shown to express 
FcεRI and FcεRII (Hasegawa and Matsubara, 2001; Pitchford et al., 2008). Human platelet 
FcεRI and FcεRII receptors are not expressed on all platelets from a given donor, but rather a 
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distinct population (Pitchford et al., 2008). Platelet activation via FcεRI and FcεRII 
stimulation leads to the release of cytotoxic mediators, such as reactive oxygen metabolites, 
free radicals and catonic proteins (Joseph et al., 1986, 1997). The significance of this release 
compared to cytotoxic mediator release from other allergic inflammatory cells is unknown, 
however platelet derived cytotoxic mediators have been shown to be critical in the killing of 
certain types of parasitic infections (Joseph et al., 1986, 1997).  
The activation of platelets via IgE can also lead to degranulation of platelet granules, 
leading to the release of chemokines such as RANTES and PF4, which can recruit leukocytes 
(Chihara and Nakajima, 1989; Kameyoshi et al., 1992, 1994; Burgers et al., 1993; Chihara et 
al., 1994). Platelet activation accompanies allergen exposure in patients with asthma, 
suggesting a IgE-/FcεRI mediated response on platelets occurs (Denis et al., 2005). Moreover, 
in patients sensitized to the allergen Der p 1, exposure to synthetic Der p 1 was found to 
activate platelets, but synthetic Der p 1 had no effect on platelets from healthy subjects or on 
platelets from patients not allergic to Der p 1 (Cardot et al., 1992). Therefore these studies 
suggest that platelet activation in allergic inflammation is IgE dependant and allergen specific. 
The ability of platelets to act as inflammatory cells has been demonstrated in allergic 
inflammatory diseases, such as eczema and allergic rhinitis, and more extensively in asthma 
which is discussed below. 
1.2.4  Platelets in asthma 
In patients with asthma, the storage of mediators in circulating platelets is diminished 
and there is a lack of responsiveness of platelets to aggregatory stimuli ex-vivo (Maccia et al., 
1977; Palma-Carlos et al., 1991). These platelets have been described to be in an ‘exhausted’ 
state, where platelets had previously become activated in-vivo, leading to release of mediators, 
and were subsequently refractory to further activation (Maccia et al., 1977; Gallagher et al., 
1978; Pareti et al., 1980; Palma-Carlos et al., 1991; Gresele et al., 1993; Page and Pitchford, 
2014). Such alterations in platelet activity have been observed in peripheral blood of allergic 
patients in allergy season, where platelet aggregatory responses were impaired (Gallagher et 
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al., 1978); similarly, patients with asthma had delayed thrombin generation (Szczeklik et al., 
1986; Ind, 1991). Furthermore, platelet lifespans in stable atopic asthmatic patients have been 
reported to decrease from 8.9 days to 4.7 days (Taytard et al., 1986), suggesting a continual 
consumption of platelets, presumably because of the ‘exhausted’ platelet state in asthmatic 
patients. 
Following allergen provocation in allergic patients, a mild thrombocytopenia has been 
reported, which can persist for several hours (Maestrelli et al., 1990; Sullivan et al., 2000; 
Kowal et al., 2006). Platelet counts taken from asthmatic patients following allergen challenge 
reduced during the late phase response and lasted up to 24 hours (Sullivan et al., 2000). Also 
in patients with asthma, 30 minutes following house dust mite or grass pollen challenge, 
circulating platelet numbers decreased and returned to baseline after 4 hours (Maestrelli et al., 
1990). Similarly, Kowal and colleagues demonstrated that 30 minutes following 
intrabronchial house dust mite extract challenge, circulating platelet counts decreased in 
asthmatic patients compared to healthy subjects, which gradually returned to baseline (Kowal 
et al., 2006). Furthermore, Kowal and colleagues investigated levels of platelet plasma 
markers, 30 minutes after allergen exposure, which showed elevated PF4, beta-TG and soluble 
P-selectin levels (Kowal et al., 2006). It has therefore been suggested that platelets get 
recruited to the lungs in asthmatic patients, to account for the mild peripheral 
thrombocytopenia and the increased levels of platelet markers following allergen challenge 
(Maestrelli et al., 1990; Sullivan et al., 2000; Kowal et al., 2006; Page and Pitchford, 2014). 
In accordance with this, platelets are found in the bronchoalveolar lavage fluid of patients with 
asthma and in extravascular compartments of lungs from bronchial biopsy samples of 
asthmatic patients (Metzger et al., 1987; Jeffery et al., 1989). Additionally, elevated levels of 
mediators derived from platelets such as RANTES, free radical species and 5-HT, are 
measured following bronchial provocation in patients with asthma (Joseph et al., 1983; 
Hasegawa and Matsubara, 2001; Dürk et al., 2013). Furthermore, immature and mature 
megakaryocytes are found in extravascular regions of the lung, which may directly contribute 
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to platelet production (Lefrançais et al., 2017). Indeed, formative studies by Martin and 
Trowbridge suggested that the process of megakaryocyte fragmentation to produce platelets 
(Trowbridge et al., 1982; Trowbridge and Martin, 1983), might be affected by inflammatory 
trauma of the airways, and lead to changes in platelets volume, mass and behaviour (Martin 
et al., 1983). Increased megakaryocyte trapping in the lungs has been reported in patients who 
have died of status asthmaticus, but it is not known if these events led to the production of 
platelets with altered behaviour that then influenced disease progression (Aschoff, 1893; 
Martin et al., 1983).  
CD11c+ dendritic cells are involved in antigen presentation following exposure to house 
dust mite and other allergens (Lambrecht and Hammad, 2012). In ovalbumin (OVA)-
sensitized mice and after subsequent allergen challenge, increased co-localization of platelets 
with CD11c+ cells was recorded in the airways (Amison et al., 2018a). When platelets were 
depleted (95% reduction in circulating platelets) during the sensitization period, following 
allergen challenge, IgE and IL-4 synthesis were supressed, and pulmonary recruitment of 
CD11c+ cells, eosinophils, macrophages and lymphocytes were reduced. Decreased FcɛRI 
receptor expression on the recovered platelet population from previously depleted mice, 
indicates CD11c+ cell recruitment and APC activity may be dependent on platelet recognition 
of allergen (Amison et al., 2018a). Furthermore, allergen sensitization of mice leads to a 
heightened responsiveness of platelets, suggesting platelets are important in the sensitization 
of host to allergen and in subsequent allergic inflammatory responses following allergen 
exposure (Amison et al., 2015).  
Platelets from patients with asthma, and mice sensitized to experimental allergen were 
shown to express FcεRI and the low affinity IgE receptor (FcεRII) (Hasegawa and Matsubara, 
2001; Pitchford et al., 2008), which in allergen sensitized mice exposed to allergen, caused 
platelet migration through the lung tissue via a platelet expressed IgE-/FcεRI-dependent 
mechanism, indicating direct platelet activation in allergic responses results in platelet 
recruitment to the lung (Pitchford et al., 2008), and their extravascular presence apparent in 
Chapter 1 – Introduction   15 
 
other models of allergic lung inflammation (Chae et al., 2016). The consequences of this 
accumulation are described below and illustrated in Figure 1.1, where platelets have been 
shown to contribute to symptoms associated with allergic asthma in animal models of allergic 
airways disease. 
Platelets in bronchoconstriction 
Platelets within the lung of asthmatic patients may contribute to the disease progression 
in a number of ways. Bronchoconstriction causes the narrowing of airways through 
constriction of airway smooth muscle cells surrounding the airways, which leads to 
breathlessness, wheezing and coughing. Studies have suggested that platelets are recruited to 
the airways following exposure to allergen, which might lead to platelet degranulation in the 
lungs and affect lung function (Pitchford et al., 2008; Page and Pitchford, 2014). This 
activation and degranulation of platelets can cause the release of stored bronchoactive 
mediators from granules, such as histamine and adenosine, along with metabolism of 
arachidonic acid to form 12-Hydroxyeicosatetraenoic acid (12-HETE), serotonin, 
thromboxane A2 (TXA2), PF4, beta-TG and cytotoxic compounds, which could potentially 
cause sensory nerve activation and smooth muscle contraction (Page and Pitchford, 2014; Keir 
et al., 2015). Indeed, platelet depletion in guinea pigs and rabbits prevented 
bronchoconstriction responses towards allergen, and bronchoactive mediators bombesin, 
bradykinin and capsaicin, and importantly, had no effect on direct acting spasmogens in the 
same model, which indicates that platelets can also influence the action of these mediators 
which did not cause platelet aggregation in-vitro (Coyle et al., 1990; Keir et al., 2010b, 2010a, 
2015). Furthermore, platelet depletion in a lethal anaphylaxis model of rabbits, led to the 
survival of rabbits, which had unaltered respiratory frequency (Pinckard et al., 1977). Recent 
studies have shown that platelet granules are primed with Munc (mammalian homolog of C. 
elegans uncoordinated gene) 13-4 (Munc13-4) before tethering, docking and fusing with the 
plasma membrane, leading to exocytosis and granular release. The selective deletion of 
platelet Munc13-4 in OVA-sensitized, OVA-challenged mice, caused decreased airway 
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hyperresponsiveness, which was measured to increasing doses of methacholine in a murine 
model of allergic lung inflammation (Cardenas et al., 2018). Therefore, platelets may in some 
way contribute to the bronchoconstriction that occurs in the early phase response in patients 
with asthma (Figure 1.1). 
Platelets in airway remodelling 
Airway remodelling occurs in patients with asthma as a result of chronic airway 
inflammation leading to a loss of respiratory function and an alteration of the lung architecture, 
Figure 1.1: Illustration of the effects of platelet activation in allergic asthma 
Exposure to noxious stimuli can cause non-thrombotic platelet (yellow cell) activation, which 
leads to platelet migration and platelet-induced leukocyte (red cell) migration, into lung tissue. 
Platelets can then effect bronchoconstriction, airway remodelling and airway inflammation, 
by assisting leukocyte recruitment and through inflammatory mediator release. 
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through collagen deposition, subepithelial fibrosis and goblet cell hyperplasia (Barnes, 2011). 
Platelets are known to be important for tissue regeneration after injury (Stellos et al., 2010) as 
they contain many pertinent mitogens responsible for cellular hyperplasia, angiogenesis and 
nerve regrowth (Page and Pitchford, 2014). Therefore, is has been suggested that platelets 
might also be involved with exaggerated regenerative responses that are apparent during 
airway wall remodelling. Indeed, several in-vitro studies have shown that platelets stimulate 
airway smooth muscle cell (ASMC) proliferation, through direct contact of platelet membrane 
associated factors with human and guinea pig ASMC (Svensson Holm et al., 2008, 2011). 
Furthermore, platelet depletion in an allergic mouse model caused decreased subepithelial 
fibre deposition, smooth muscle thickening and epithelial thickening (Pitchford et al., 2004). 
This effect could be attributed to the fact that platelets produce mitogens such as platelet-
derived growth factor, epidermal growth factor, TXA2, transforming growth factor-β, and 
vascular endothelial growth factor, which if released from extravascular platelets in the lung, 
could impact airway remodelling through proliferative effects on cells (Page and Pitchford, 
2014). Platelet activation following allergen challenge has been shown to persist and outlast 
the presence of platelet-leukocyte conjugates in the blood (Kowal et al., 2006). Coupling this 
persisting activation of platelets with mitogen release, suggests a possible mechanism through 
which platelets have adverse remodelling effects in the lung (Figure 1.1). 
Platelets in airway inflammation 
In the chronic phase of the asthmatic response, leukocyte recruitment to the lung is a 
characteristic feature, leading to excessive airway inflammation and adverse remodelling of 
the lung architecture. Eosinophil recruitment is typical in such responses, being associated 
with rhinitis, aspirin-induced exacerbated respiratory disease (AERD) and atopic asthma (Lu 
et al., 2010; Perić et al., 2011; Laidlaw and Boyce, 2013). Investigations into the roles of 
platelets in allergic asthma has uncovered that platelets are important in leukocyte (eosinophil) 
recruitment following allergen challenge, which is discussed below (Idzko et al., 2015).  
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In patients with asthma, markers of eosinophil and platelet activation are positively 
associated (Benton et al., 2010). Staining of whole blood leukocytes from patients with mild 
asthma and AERD patients, showed that between 5-25% of eosinophils had platelets attached 
(Wardlaw et al., 1992; Johansson and Mosher, 2011; Laidlaw et al., 2012). When platelets 
were depleted in an allergic guinea pig model of asthma, eosinophil recruitment to the lung 
was reduced (Lellouch-Tubiana et al., 1988). Likewise, in allergic rabbit and mouse models, 
platelet depletion caused decreased hyperresponsiveness into the lungs and decreased 
eosinophil infiltration (Coyle et al., 1990; Pitchford et al., 2003). Therefore, suggesting a 
possible role of platelets in lung eosinophilia.  
The direct physical association of platelets to eosinophils can form through platelet P-
selectin and leukocyte PSGL-1 surface expressed adhesion molecule interactions. Indeed, in 
an in-vitro assay investigating platelet and eosinophil adhesion, P-selectin blocking antibodies 
prevented platelets from ‘rosetting’ around eosinophils (Jawień et al., 2005). Eosinophils have 
increased surface associated platelets expressing P-selectin in blood taken from non-severe 
asthma patients, following whole lung antigen challenge (Johansson et al., 2012). Using 
immunofluorescence microscopy, β1-integrin and P-selectin was colocalized on activated 
eosinophils (Johansson and Mosher, 2011). Furthermore, α4β1-integrin activation was 
increased on eosinophils, following the addition of P-selectin to whole blood, which also 
increased eosinophil adhesion in-vitro to vascular cell adhesion molecule 1 (Johansson and 
Mosher, 2011). Blocking antibodies directed against P-selectin caused decreased eosinophil 
clustering and binding to the endothelium under flow conditions in the blood of patients with 
asthma (Ulfman et al., 2003), and following asthmatic patients whole lung antigen challenge, 
eosinophils associated with P-selectin decreased in the circulation (Johansson et al., 2012), 
suggesting platelet-eosinophil complexes migrate to the lungs. Since platelet P-selectin has 
been shown to be necessary in neutrophil recruitment to the lung via multiphoton and intravital 
microscopy (Sreeramkumar et al., 2014; Pan et al., 2015; Riffo-Vasquez et al., 2016; 
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Zuchtriegel et al., 2016), it is likely P-selectin acts in a similar fashion on eosinophils, leading 
to eosinophil activation and subsequent migration into the lungs (Pitchford et al., 2005). 
Following platelet and eosinophil activation, inflammatory mediators are released 
through degranulation. Platelets can release PF4 (Hayashi et al., 1994), IL-1β (Lindemann et 
al., 2001; Denis et al., 2005), TARC and RANTES (Chihara and Nakajima, 1989; Kameyoshi 
et al., 1992, 1994; Burgers et al., 1993; Chihara et al., 1994), which can activate eosinophils. 
Reciprocally, eosinophils can release platelet-activating factor (PAF), eosinophil peroxidase 
(EPO) and major basic protein (MBP), which can potentially activate platelets (Lee et al., 
1984; Rohrbach et al., 1990; Shah et al., 2017). Therefore, platelets can directly and indirectly 
interact with eosinophils, leading to eosinophil infiltration into the lungs following exposure 
to allergen. Indeed platelet-leukocyte conjugates formed through platelet P-selectin and 
leukocyte PSGL-1 adhesion molecule interactions, were shown to assist leukocytes tethering 
to the endothelium and consequently their diapedeses into inflamed tissue in sensitized mice 
exposed to allergen (Pitchford et al., 2005). Furthermore, after allergen challenge the 
infiltration of leukocytes into airways of platelet depleted mice was reduced and could be 
restored by infusing platelets from allergic mice (Pitchford et al., 2003). Eosinophil 
recruitment to the lungs in the late phase response of asthma leads to further recruitment of 
leukocytes through inflammatory mediator release and consequent release of free radicals 
causing epithelial cell damage and increased mucus production, contributing to airway 
inflammation. 
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1.3 Platelet recruitment and migration 
1.3.1  Cellular motility and chemotaxis 
In order for cells to migrate they must be able to extend protrusions, contract their 
cytoplasm and then detach from contact sites, which is a process involving actin filament 
assembly and disassembly causing shape change of the cell (Lauffenburger and Horwitz, 
1996). The first step in migration is the polarization of the cell, leading to a clear distinction 
between the leading edge and trailing edge, often characterised by F-actin redistribution to a 
particular region (Coates 1992). The leading edge develops lamellipodia and filopodia 
processes that project around the cell, along with expression of chemosensory signalling 
receptors (Sullivan et al., 1984). Extension of lamellipodia and filopodia processes are 
accompanied with actin polymerization, leading to actin filament growth via uncapping 
existing filaments, severing existing filaments or the formation of new actin filaments 
(Lauffenburger and Horwitz, 1996). This is a highly regulated process with a fast turn over 
due to depolymerization of actin. Focal adhesions allow interactions with the extracellular 
matrix, through integrin clusters tethered to the extracellular matrix, which can form at the 
leading edge and persist until they reach the trailing edge of the cell (De Pascalis and Etienne-
Manneville, 2017). Focal adhesions allow cells to apply traction forces to the extracellular 
matrix, and myosin intracellular contractile forces can pull the cell body forward. At the 
trailing edge, adhesions can be disassembled through endocytosis, enzymatic action and 
proteolytic action (Vicente-Manzanares et al., 2005). 
1.3.2  Can platelets migrate? 
Platelets have been shown in extravascular compartments and also in fibrous material 
within the airway luminal edge, in bronchial biopsies of patients with asthma (Metzger et al., 
1987; Jeffery et al., 1989). Similarly, platelets have been shown to accumulate into 
extravascular compartments of the lung in sensitized mice challenged with allergen (Pitchford 
et al., 2008), in apposition to areas of bronchial smooth muscle and eosinophil infiltration in 
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guinea pigs (Vargaftig et al., 1982; Lellouch-Tubiana et al., 1988), and separately after LPS 
exposure (Ortiz-Muñoz et al., 2014) or bacterial infection (Amison et al., 2018b). This 
phenomenon of platelet accumulation in extravascular compartments has also been recorded 
in other disease states unrelated to respiratory diseases such as in rheumatoid arthritis and 
multiple sclerosis, where platelets were found to have migrated extravascualrly into inflamed 
tissue (Boilard et al., 2010; Langer et al., 2012). It has been hypothesised that the presence of 
platelets in these areas is not due to leakage from blood vessels, but rather through mechanisms 
of specific recruitment and migration in non-thrombotic conditions (Pitchford et al., 2008). 
Platelets roll, firmly adhere and become sessile in aggregatory responses. However, 
platelets possess the requisite components to migrate and more recently have been reported to 
undergo actin-cytoskeletal rearrangements, filopodia formation and extend lamellipodia 
(Bettex-Galland and Luescher, 1959; Pleines et al., 2012; Gaertner et al., 2017), and this has 
been shown to be dependent on phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) 
activity (Czapiga et al., 2005; Kraemer et al., 2010). Platelets also contain enzymes such as β-
N-acetylhexosaminidase, cathepsin D, cathepsin E and heparinase, which may contribute to 
movement through connective tissue and the endothelium, as well as matrix metalloproteases, 
such as MMP2 and MMP9, which may have roles in extracellular matrix degradation of fibrin 
and collagen (Ciferri et al., 2000; Corry et al., 2002; Falcinelli et al., 2005). Therefore, platelets 
possess the necessary machinery to undergo migration, which in several studies, has been 
reported to be directional in response to stimuli or injury and further discussed below. 
1.3.3  Platelet chemotaxis 
Czapiga and colleagues investigated human platelet chemotaxis via FPR activation by 
a bacterially derived chemoattractant, N-formyl-methionyl-leucyl phenylalanine (fMLP). 
FPRs are G-protein coupled receptors (GPCR) that are found in various different cell types 
and, once activated, can lead to cellular chemotaxis (Panaro et al., 2006). FPR expression and 
functionality was shown on platelets (Czapiga et al., 2005). The Neuro Probe ChemoTx 
microplate was used for chemotaxis investigations, which allows cells to pass through a 2 µm 
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pore separating a top platelet compartment and bottom chemokine (fMLP) compartment. 
Following a 2 hour incubation period at 37 °C, platelets in the bottom chamber were counted 
by light microscopy. Significant platelet chemotaxis to fMLP was observed, revealing the 
ability of platelets to migrate towards stimuli arising from pathogens. Thrombin stimulation 
of platelets prior to the addition of platelets to the well, caused elevated responses to fMLP in 
this assay, suggesting priming of platelets might lead to elevated chemotactic responses 
(Czapiga et al., 2005). 
 Following investigative studies that showed platelets are important in airway 
hyperresponsiveness (AHR) and pulmonary leukocyte recruitment, Pitchford et al. 
investigated platelet migration to the lungs of sensitized mice in response to allergen 
challenge, and also the ability of platelets from sensitized mice and asthmatic patients, to 
migrate in-vitro toward the specific allergen to which they are sensitised. The Neuro Probe 
ChemoTx microplate was used, with platelets in the top well and allergen in the bottom well 
separated by a 3 µm pore sized filter (Boyden, 1962; Valone et al., 1974; Pitchford et al., 
2008). Following a 90 minute incubation period, the number of migrated platelets in the 
bottom well was quantified using light microscopy and expressed as absolute numbers and a 
‘chemotactic index’, defined as ‘The average number of migrated platelets in response to a 
chemotactic stimulus divided by the average number of migrated platelets in response to 
vehicle’ (Pitchford et al., 2008). Platelets from mice and humans significantly migrated toward 
allergen, compared to vehicle, which interestingly was shown to be a IgE-/FcεRI-dependent 
mechanism (Pitchford et al., 2008). Although the molecular mechanism governing this 
migration is not fully understood, GPCRs (including some chemokine receptors) have been 
shown to interact with FcεRI signalling, which may be involved in cellular chemotaxis (Kuehn 
and Gilfillan, 2007; Kuehn et al., 2010). The study of platelet migration in direct response to 
allergen, or as a result of allergen sensitization therefore needs further elucidation. 
Human platelet chemotaxis via platelet chemokine receptor activation was first 
investigated by Kraemer and colleagues. CXCL4 (stromal cell derived factor-1α, SDF-1α), a 
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CXCR4 receptor ligand, induced platelet chemotaxis which was tested using an improved in-
vitro assay that more closely mimics the environment in-vivo (Kraemer et al., 2010). Light 
transmission microscopy on fibrinogen-coated chamber slides was used as a platform to 
investigate platelet chemotaxis to a horizontal gradient. A gel bead containing SDF-1α was 
placed in the centre of the well, which slowly released chemokine. Immunofluorescent 
staining of platelets that surrounded the SDF-1α gel bead, showed polarized platelets with 
focal adhesion contacts, indicating platelets were in a migratory state. Platelets within the well 
were subsequently tracked. Of the motile platelets within the well, significantly more platelets 
migrated toward SDF-1α than vehicle. To verify this, the authors also investigated platelet 
chemotaxis to SDF-1α using transwell inserts. In the transwell assay platelet chemotaxis was 
successfully measured towards SDF-1α, which was importantly inhibited by CXCR4 receptor 
antagonist AMD3100 (Kraemer et al., 2010). This study demonstrates platelet chemotaxis to 
an inflammatory chemokine via platelet chemokine receptor activation, although this is yet to 
be explored in the setting of allergy. 
Gaertner and colleagues extensively investigated platelet migration in the context of 
injury and aggregation, and bacterial infection in-vivo. In an in-vivo needle and prick model 
using state of the art imaging techniques, platelets were observed migrating independently of 
the clot, or bacterial infection, and against the flow of blood along the vessel lumen. These 
platelets also differed in their mean velocity and migration paths compared to platelets rolling 
and adhering for clot formation, suggesting a separate phenotype of platelets at the site injury 
(Gaertner et al., 2017). Platelet spreading and migration was also investigated on a 2D surface 
in-vitro, in which platelets consistently adopted a crescent moon morphology with 
lamellipodia protrusions at one end and simultaneous retraction at the other end. The migration 
of platelets at the leading edge was inhibited using cytochalasin D, indicating migration is 
dependent on actin networks in lamellipodia. The integrin receptor GPIIb/IIIa was found in 
clusters on lamellipodia, and when this receptor was blocked, platelet migration ceased, 
demonstrating the importance of GPIIb/IIIa on platelet migration. A fibrinogen surface 
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induced robust spreading of platelets, but platelet migration only occurred after serum was 
added. Furthermore, the presence of albumin and calcium in the serum was crucial in platelet 
shape change and migration (Gaertner et al., 2017). Gaertner and colleagues therefore provide 
further evidence that platelets have the ability to migrate, which further supports exploring the 
roles of platelets in allergic inflammatory responses. 
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1.4 Chemokine receptors 
1.4.1  Chemokines and their receptors 
Chemokines are low molecular weight soluble chemotactic factors, and are part of the 
family of cytokines, that regulate leukocyte migration. The chemokine family can be divided 
into four main groups, which are derived from the location of cysteine residues involved in 
the formation of disulphide bonds in the primary structure. The largest subfamily, the CC 
group, consists of 29 ligands in which the first two cystine residues are adjacent. The CXC 
(21 ligands) and CX3C (1 ligand) groups first two cystine residues are separated by one or 
three amino acids, respectively. The first and third cystine residues are absent in the XC group, 
which consists of at least 2 ligands (Murphy et al., 2000; Zlotnik and Yoshie, 2000; Schall 
and Proudfoot, 2011; Blanchet et al., 2012). The structural homology of chemokines is similar, 
leading to overlapping functions as they can often display the ability to bind to several distinct 
chemokine receptor types (Table 2).  
Name Colloquial names Receptors 
CCL1 TCA3; I-309 CCR8 
CCL2 MCP-1; MCAF; JE CCR2, CCR3, DARC, CCBP2 
CCL3 MIP-1α; LD78α CCR1, CCR5, CCBP2 
CCL3L1 LD78β CCR1, CCR5 
CCL3L2 –  
CCL3L3 LD78β CCR1, CCR5 
CCL4 MIP-1β CCR5, CCBP2 
CCL4L1 LAG-1 CCR5, CCBP2 
CCL4L2 LAG-1 CCR5, CCBP2 
CCL5 RANTES CCR1, CCR3, CCR5, DARC, CCBP2, CCRL2 
CCL7 MCP-3; MARC CCR1, CCR2, CCR3, CCR5, DARC, CCBP2 
CCL8 MCP-2 CCR2, CCR3 
CCL11 Eotaxin CCR3, CCR5, DARC, D6 
CCL13 MCP-4 CCR2, CCR3, CCR5, DARC, CCBP2 
Table 2: Human chemokines and their receptors. 
CC (blue), CXC (green), XC (yellow) and CX3C (grey) chemokines, their colloquial names 
and the receptors which they activate are summarised below. Adapted from Schall and 
Proudfoot, 2011 and Blanchet et al., 2012. 
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CCL14 HCC-1 CCR1 
CCL15 HCC-2 CCR1, CCR3, DARC 
CCL16 HCC-4; LEC CCR1 
CCL17 TARC; ABCD-2 CCR4, DARC, CCBP2 
CCL18 DC-CK1; PARC; AMAC-1 DARC 
CCL19 MIP-3β; ELC; Exodus-3 CCR7, CCRL1, CCRL2 
CCL20 MIP-3α; LARC; Exodus-1 CCR6 
CCL21 6Ckine; SLC; Exodus-2 CCR7, CCRL1 
CCL22 MDC; STCP-1; ABCD-1 CCR4, DARC, CCBP2 
CCL23 CKβ8; MPIF-1 CCR1, FPR2 
CCL24 Eotaxin-2; MPIF-2 CCR3 
CCL25 TECK CCR9, CCRL1 
CCL26 Eotaxin-3; MIP-4α; IMAC CCR3 
CCL27 CTACK; ILC; ESkine CCR10 
CCL28 MEC CCR3, CCR10 
CXCL1 GRO-α; MGSA-α; MIP-2; KC CXCR2, DARC 
CXCL1P –  
CXCL2 GRO-β; MGSA-β; MIP-2α CXCR2, DARC 
CXCL3 GRO-γ; MGSA-γ; MIP-2β CXCR2, DARC 
PF4 PF4 CXCR3 
PF4V1 PF4-alt; CXCL4V1  
CXCL5 ENA-78 CXCR2, DARC 
CXCL6 GCP-2 CXCR1, CXCR2, DARC 
CXCL7 NAP-2; beta-TG; CTAP-III CXCR2, DARC 
PPBPL1 –  
IL8 IL8 CXCR1, CXCR2, DARC 
CXCL9 MIG CXCR3 
CXCL10 IP10; CRG-2 CXCR3 
CXCL11 I-TAC CXCR3, CXCR7, DARC 
CXCL12 SDF-1α CXCR4, CXCR7 
CXCL12 SDF-1β  
CXCL12 SDF-1γ  
CXCL13 BCA1; BLC CXCR5  
CXCL14 BRAK  
CXCL16 SR-PSOX CXCR6 
CXCL17 DMC  
XCL1 Lymphotactin; SCM-1α; ATAC XCR1 
XCL2 SCM-1β XCR1 
CX3CL1 Fractalkine; Neurotactin; ABCD-3 CX3CR1 
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Chemokine receptors are part of a bigger superfamily of GPCR, which include receptors 
for hormones, neurotransmitters and inflammatory mediators (Murdoch and Finn, 2000). 
There are roughly 20 chemokine receptors (Blanchet et al., 2012). With relevance to this 
thesis, and focusing on those expressed by platelets (discussed below), the chemokine 
receptors CCR1, CCR3 and CXCR4 signal through coupling to the Gi family with αi subunit 
and CCR4 coupling to Gq family αq subunit were investigated (Myers et al., 1995; Kowalska 
et al., 2000; Gillard et al., 2002). CCR1, CCR3 and CXCR4 couple to Gi which inhibits 
adenylyl cyclase activity and its production of cAMP. cAMP activates protein kinase A 
(PKA), which downregulates degranulation and can inhibit activation (Murdoch and Finn, 
2000). Activation of Gi also causes PI3K activation that activates phospholipase C (PLC), this 
produces diacyl-glycerol (DAG) and inositol trisphosphate (IP3). CCR4 couples to Gαq which 
causes PLC activation that catalysis the production of IP3 and DAG (Nardelli et al., 1999). 
DAG activates protein kinase C (PKC) and the production of IP3 leads to the release of 
calcium from its intracellular stores. PKC and calcium release can lead to various cellular 
responses (Brass, 2010). The interactions between chemokines and chemokine receptors are 
critical in directed migration of cells to sites of injury, signifying their importance in host 
defence. 
1.4.2  Chemokine receptors expressed on platelets  
Human platelets have been reported to express the CC chemokine receptors CCR1, 
CCR3 and CCR4, and CXC chemokine receptor CXCR4 (Clemetson et al., 2000; Kowalska 
et al., 2000; Abi-Younes et al., 2001). PKC and calcium release are vital to platelet 
degranulation and are both actions occurring as a result of αi and αq signalling pathways (Brass, 
2010). PKC phosphorylates actin and along with calcium mobilisation, leading to myosin light 
chain kinase activation. This results in myosin moving along actin filaments. This can cause 
trafficking of granules to the cell membrane for contents to be released, increased receptor 
expression on platelets and platelet shape change (Gear and Polanowska-Grabowska, 2002; 
Amison, 2014; Golebiewska and Poole, 2014). Through these intracellular pathways, 
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chemokine receptors can activate platelets, possibly leading to degranulation or migration 
toward a stimulus. 
Functional chemokine ligands; CCL3 (macrophage inflammatory protein 1α, MIP-1α) 
and RANTES bind CCR1; CCL11 (eotaxin) and RANTES bind CCR3 (Pease et al., 1998; 
Struyf et al., 1998); CCL22 (macrophage derived chemokine, MDC) and TARC bind CCR4 
(Imai et al., 1997, 1998); and SDF-1α binds CXCR4 (D’Apuzzo et al., 1997). MIP-1α, eotaxin, 
MDC and SDF-1α are relatively selective for CCR1, CCR3, CCR4 and CXCR4 receptors, 
respectively. Platelet chemokine receptors are functionally active, as stimulation with MIP-
1α, eotaxin, MDC and SDF-1α caused platelet activation as measured via calcium signalling, 
aggregation, and release of granule content (Clemetson et al., 2000). 
1.4.3  Chemokine receptor function on platelets and relevance to allergic inflammation. 
CCR1 receptor 
Human platelet CCR1 receptor activation via MIP-1α caused increased platelet 
cytoplasmic calcium levels, proving the functional activity of the receptor (Clemetson et al., 
2000). Other parameters of platelet activation have not been investigated with the CCR1 
specific chemokine MIP-1α, however stimulating platelets with RANTES, which also has 
activity on CCR3, caused a low level aggregatory response as measured with an aggregometer 
(Clemetson et al., 2000).  
The CCR1 receptor is expressed on a number of different cell types and has been shown 
to induce chemotaxis on cells such as eosinophils and mast cells (Phillips et al., 2003; Toda 
et al., 2004; Solari and Pease, 2015). In patients with asthma, elevated levels of both MIP-1α 
and RANTES were detected in the bronchoalveolar lavage fluid before and after allergen 
challenge (Cruikshank et al., 1995; Alam et al., 1996), suggesting a role of the CCR1 receptor 
in allergic inflammatory responses. Following FcεRI activation on mast cells, CCR1 receptor 
is upregulated, which enhances FcεRI mediated calcium generation and degranulation (Kuehn 
and Gilfillan, 2007). The CCR1 receptor has been shown to co-localize on mast cells with 
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FcεRI receptors, and when both receptors were activated, mast cell chemotaxis to CCL2 
(monocyte chemoattractant protein 1, MCP-1) decreased and degranulation increased 
(Fifadara et al., 2010), indicating the CCR1 receptor is involved in allergic inflammatory 
responses. Therefore, investigating the roles of the CCR1 receptor on platelet migration 
following allergen sensitization, would be of interest. 
CCR3 receptor 
Human platelet CCR3 receptor expression has been demonstrated by flow cytometry of 
washed platelets and polymerase chain reaction amplification of platelet mRNA (Clemetson 
et al., 2000). The functionality of the platelet CCR3 receptor was confirmed via increased 
intracellular calcium concentrations following eotaxin administration, and caused low level 
aggregatory responses (Clemetson et al., 2000). CCR3 is a promiscuous receptor in that it 
binds several chemokine ligands, including each of the eotaxin family (eotaxin-1, eotaxin-2 
and eotaxin-3) (Blanchet et al., 2012). The receptor is also expressed on a number of different 
cell types including eosinophils, T cells, basophils and mast cells (Solari and Pease, 2015). 
In allergic lungs of asthmatic patients, increased expression of ligands that bind to 
CCR3: eotaxin-1, eotaxin-2 and RANTES were measured, moreover, elevated eotaxin-1 
levels have been shown in acute compared with stable asthmatic patients (Ying et al., 1997, 
1999; Lilly et al., 1999). Eotaxin-1 and eotaxin-2 levels were elevated in sputum samples of 
patients with asthma (Yamada et al., 2000). Furthermore, CCR3 receptor expression levels 
have also been shown to be elevated on leukocytes in allergic conditions, suggesting the CCR3 
receptor has roles in allergic disease (Francis et al., 2007). 
The CCR3 receptor is crucial in eosinophil recruitment to the lungs (Humbles et al., 
2002; Fulkerson et al., 2006). Indeed in CCR3 deficient mice, an airway allergen challenge 
was unable to induce eosinophil migration (Humbles et al., 2002). Similarly, eotaxin-1 and 
eotaxin-2 deficient mice had reduced pulmonary tissue eosinophilia (Pope et al., 2005). Thus, 
CCR3 receptor expression and activity has been shown to increase in sensitized states, 
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furthermore the receptor has demonstrated key functional roles in eosinophil migration into 
inflamed tissue, suggesting platelet CCR3 receptor may be important in platelet recruitment 
and migration to sites of allergic inflammation. 
CCR4 receptor 
Stimulating human platelets with MDC, a CCR4 receptor chemokine, caused platelet 
activation as determined by calcium signalling, granule content release, platelet shape change 
and low levels of platelet aggregation (Clemetson et al., 2000; Kowalska et al., 2000; Abi-
Younes et al., 2001; Gear et al., 2001). The CCR4 receptor is expressed on dendritic cells, 
basophils, natural killer cells and T cells, and can be activated by MDC and TARC (Solari and 
Pease, 2015). The ability of CCR4 receptor stimulation to induce platelet chemotaxis is yet to 
be investigated. Both MDC and TARC are upregulated in the lungs following allergen 
challenge in asthmatic patients (Bochner et al., 2003; Pilette et al., 2004). CCR4 receptor 
expression is upregulated in Th2 cells, which are found in bronchoalveolar lavage fluid of 
asthmatic patients, likely induced by MDC and TARC release from dendritic cells (Bonecchi 
et al., 1998; Sallusto et al., 1998; Panina-Bordignon et al., 2001; Morgan et al., 2005). 
Likewise, T cells isolated from asthmatic patients had elevated expression of the CCR4 
receptor (Vijayanand et al., 2010). In CCR4 deficient mice and following antibody 
neutralisation of MDC and TARC, there was reduced leukocyte recruitment to the lung 
following allergen challenge (Lloyd et al., 2000; Kawasaki et al., 2001; Mikhak et al., 2009). 
The evidence suggests a role for the CCR4 receptor on cellular recruitment and 
migration in allergic asthma, together with the clear activation of platelets in-vitro via 
stimulation with MDC, the data suggests a role for the CCR4 receptor in allergic inflammatory 
responses of platelets which is worth investigating (Kowalska et al., 2000; Abi-Younes et al., 
2001).  
CXCR4  
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The CXCR4 receptor has been reported to bind SDF-1α and macrophage migration 
inhibitory factor (MIF), and is extensively expressed on different cell types (Blanchet et al., 
2012). There are several reports of platelet CXCR4 receptor activation following SDF-1α 
treatment, including measurements of intracellular calcium concentrations, P-selectin 
expression, platelet shape change and a low level aggregatory responses (Clemetson et al., 
2000; Kowalska et al., 2000; Gear et al., 2001; Kraemer et al., 2010). Platelet chemotaxis was 
successfully measured towards SDF-1α, demonstrating the ability of platelets to migrate 
through chemokine receptor activation (Kraemer et al., 2010). However, the involvement of 
CXCR4 receptor on platelet activation has not been studied in the context of allergic 
inflammation.  
In patients with asthma, eosinophils from the bronchoalveolar lavage fluid have 
increased expression of the CXCR4 receptor (Nagase et al., 2000). AMD3100 (CXCR4 
receptor antagonist) administration in an allergic murine model decreased inflammation and 
AHR, following allergen challenge (Lukacs et al., 2002). When neutralizing antibodies 
directed against SDF-1α were administered in OVA-sensitized mice challenged with OVA, 
lung eosinophilia and AHR were reduced (Gonzalo et al., 2000). Furthermore, IL-4 increased 
CXCR4 receptor expression on Th2 cells (Jourdan et al., 1998). The activation of CXCR4 
receptor in allergic inflammation effects multiple cells, therefore the effect of allergen 
sensitization on CXCR4 receptor induced platelet responses is of interest. 
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1.5 Aims and objectives 
An overall hypothesis to this project is that platelets express chemokine receptors that 
are functionally relevant for platelet chemotaxis in the context of platelet recruitment and 
migration during allergic inflammation. 
Specific objectives are described below: 
• To quantify platelet recruitment and migration to different lung compartments from 
healthy, non-fatal asthmatic and fatal asthmatic patients. 
• To create and characterise in-vitro platelet chemotaxis models. 
• To create a model for investigating platelet recruitment and migration in response to 
allergen challenge in-vivo.  
• To explore the roles of platelet chemokine receptors 
o To investigate the expression of platelet chemokine receptors and the effects 
of allergen sensitization on their expression. 
o To investigate if chemokine receptor activation can induce platelet 
chemotaxis. 
o To investigate the effects of allergen sensitization on platelet chemotaxis 
towards chemokines. 
o To explore the roles of platelet chemokine receptors on platelet recruitment 
and migration in an allergic inflammatory model. 
  Materials/Methods 




Acid alcohol differentiation solution Sigma Aldrich (UK) 
Acid citrate dextrose (ACD) Sigma Aldrich (UK) 
Adenosine diphosphate (ADP) Sigma Aldrich (UK) 
Albumin from chicken egg white (ovalbumin) Grade V Sigma Aldrich (UK) 
Aluminium hydroxide EMS Pharma (Brazil) 
AMD3100 (CXCR4 antagonist) Tocris Biosciences (UK) 
Bovine serum albumin (BSA) Sigma Aldrich (UK) 
C-021 (CCR4 antagonist) Tocris Biosciences (UK) 
CaCl2 Sigma Aldrich (UK) 
Cell Lysis Buffer New England Biolabs (UK) 
D. Pteronyssinus crushed whole bodies. Mite, dust. Stallergenes Greer (USA) 
DAB Peroxidase (HRP) Substrate Kit Sigma Aldrich (UK) 
Depex (DPX) mountant Sigma Aldrich (UK) 
Dextrose Sigma Aldrich (UK) 
Dimethyl sulfoxide (DMSO) Sigma Aldrich (UK) 
Evans Blue Dye ≥ 75% Sigma Aldrich (UK) 
Fibrinogen Sigma Aldrich (UK) 
Fibronectin Sigma Aldrich (UK) 
Flow-count Fluorospheres Beckman Coulter Inc (UK) 
Glucose Fisher (UK) 
Goat anti-rabbit IgG (biotinylated) Vector Laboratories (USA) 
Goat anti-rabbit IgG, HRP-linked antibody New England Biolabs (UK) 
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Haematoxylin Sigma Aldrich (UK) 
Hamster anti-mouse CD49b phycoerythrin BD Biosciences (UK) 
HEPES (4-(2-hydroxyethyl)-1piperazineethanesulfonic acid) Sigma Aldrich (UK) 
Hydrogen peroxide Sigma Aldrich (UK) 
Industrial ethanol ≥ 99.8% Sigma Aldrich (UK) 
Isocare isoflurane anaesthetic Baxter International, (USA) 
KCl Sigma Aldrich (UK) 
KH2PO4 Sigma Aldrich (UK) 
Kwik Diff differential stain ThermoFisher Scientific (UK) 
Li2CO3 Sigma Aldrich (UK) 
MgCl2 VWR International (UK) 
MgCl2 Sigma Aldrich (UK) 
MgSO4 Sigma Aldrich (UK) 
Mouse IgG1κ Isotype Control phycoerythrin BD Biosciences (UK) 
Mouse IgG2bκ Isotype Control fluorescein isothiocyanate BD Biosciences (UK) 
Na2HPO4 VWR International (UK) 
NaCl Fisher (UK) 
NaHCO3 Fisher (UK) 
Formylmethionyl-leucyl-phenylalanine (fMLP) Sigma Aldrich (UK) 
NH4Cl Sigma Aldrich (UK) 
NovaRED Peroxidase (HRP) Substrate Vector Laboratories (USA) 
NuPAGE™ 10% Bis-Tris Protein Gels, 12-well ThermoFisher Scientific (UK) 
NuPAGE™ Antioxidant ThermoFisher Scientific (UK) 
NuPAGE™ LDS Sample Buffer ThermoFisher Scientific (UK) 
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NuPAGE™ MOPS SDS Running Buffer ThermoFisher Scientific (UK) 
NuPAGE™ Sample Reducing Agent ThermoFisher Scientific (UK) 
NuPAGE™ Transfer Buffer ThermoFisher Scientific (UK) 
Paraformaldehyde Sigma Aldrich (UK) 
Phosphatase Inhibitor Cocktail 2 Sigma Aldrich (UK) 
Phosphatase Inhibitor Cocktail 3 Sigma Aldrich (UK) 
Phosphate buffered saline (PBS) tablets Oxoid (UK) 
Pierce™ BCA Protein Assay Kit ThermoFisher Scientific (UK) 
Pierce™ ECL Plus Western Blotting Substrate ThermoFisher Scientific (UK) 
Ponceau S solution Sigma Aldrich (UK) 
Precision Plus Protein Standard Bio-Rad Laboratories (UK) 
Prostaglandin E1 (PGE1) Sigma Aldrich (UK) 
Protease Inhibitor Cocktail Sigma Aldrich (UK) 
Rabbit anti-human CD42b antibody [SP219]  Abcam (UK) 
Rabbit anti-mouse CCR1 antibody  Novus Biologicals (UK) 
Rabbit anti-mouse CCR3 antibody Novus Biologicals (UK) 
Rabbit anti-mouse CCR4 antibody Novus Biologicals (UK) 
Rabbit anti-mouse CXCR4 antibody Novus Biologicals (UK) 
Rabbit anti-mouse β-actin antibody [Poly6221] BioLegend (UK) 
Rat anti-mouse CCR1 phycoerythrin antibody [643854] R&D Systems (UK) 
Rat anti-mouse CCR3 phycoerythrin antibody [83101] R&D Systems (UK) 
Rat anti-mouse CCR4 phycoerythrin antibody [2G12] BioLegend (UK) 
Rat anti-mouse CD41 fluorescein isothiocyanate BD Biosciences (UK) 
Rat anti-mouse CXCR4 phycoerythrin antibody [247506] R&D Systems (UK) 
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Recombinant human eotaxin/CCL11 PeproTech (UK) 
Recombinant Murine MDC/CCL22 PeproTech (UK) 
Recombinant Murine MIP-1α/CCL3 PeproTech (UK) 
Recombinant Murine SDF-1α/CXCL12 PeproTech (UK) 
Restore™ Western Blot Stripping Buffer ThermoFisher Scientific (UK) 
Roswell Park Memorial Institute (RPMI) 1640 Media Invitrogen Life Sciences (UK) 
Saline Baxter Healthcare Ltd (UK) 
SB 328437 (CCR3 antagonist) Sigma Aldrich (UK) 
Stromatol Mascia Brunelli SpA (Italy) 
Tris Base ( 2-Amino-2-(hydroxymethyl)-1,3-propanediol) Sigma Aldrich (UK) 
Tri-sodium citrate Fisher Scientific (UK) 
Türk’s solution Merck Millipore, (USA) 
Tween™ 20 Fisher Scientific (UK) 
Urethane Sigma Aldrich (UK) 
Vectastain Elite ABC HRP kit Vector Laboratories (USA) 
Vitronectin Sigma Aldrich (UK) 
Weigert’s iron hematoxylin kit EMD Millipore (USA) 
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2.2 Buffer preparations  
Phosphate buffered saline (PBS) was prepared for flow cytometry, 
immunohistochemistry, allergen-sensitization and challenge experiments. PBS tablets were 
dissolved in distilled water, producing a solution of 3 mM KCl, 1 mM KH2PO4, 8 mM 
Na2HPO4 and 160 mM NaCl at pH7.3. 
For intravital microscopy experiments, Tyrode’s buffer was used, which contained 
133.9 mM NaCl, 2.9 mM KCl, 0.86 mM Na2HPO4, 1 mM MgCL2, 5.5 mM dextrose and 20 
mM HEPES in distilled water, at pH7.3 and heated to 37°C. 
Modified Tyrode’s buffer was prepared for mouse platelet isolation and chemotaxis 
assays. Modified Tyrode’s buffer consisted of 133.9 mM NaCl, 2.9 mM KCl, 0.86 mM 
Na2HPO4, 11.9 mM NaHCO3, 20 mM HEPES, 1 mM MgCL2, 4 mM glucose and 10 g/L BSA, 
dissolved in distilled water and adjusted to pH7.3. 
Red cell lysis buffer used during platelet isolation for microfluidic chemotaxis assay 
experiments, contained 654 mM NH4Cl, 24.8 mM KCl, 3.9 mM Na2HPO4, 0.9 mM KH2PO4, 
27.8 mM glucose, 20.7 mM MgCl2, 5.7 mM MgSO4, 30.6 mM CaCl2 and 267.8 mM NaHCO3, 
dissolved in distilled water. 
Sodium citrate buffer that was prepared for antigen retrieval steps in 
immunohistochemistry, contained 113.9 mM tri-sodium citrate and 0.05% Tween 20, 
dissolved in distilled water at pH6.0.  
Tris-buffered saline with Tween 20 (TBST) consisted of 20 mM Tris, 150 mM NaCl 
and 0.1% Tween 20 at pH7.5. TBST and all other buffers used in western blot analysis, were 
dissolved in ultrapure water. 
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2.3 In vivo studies  
2.3.1  Animals 
Animal experiments were conducted in accordance with the Animals (Scientific 
Procedures) Act 1986 and amended regulations of 2012, with approval from the local Animal 
Welfare and Ethics Committees at King’s College London and the Babraham Institute, 
Cambridge. Male and Female BALB/c inbred mice (20-25 g) were procured from Envigo and 
Harlan Laboratories (UK). Male and female inbred C57BL/6 wild type (WT) mice (20-25g) 
were bred in pathogen-free facilities at the Babraham Institute. All mice were between 6-10 
weeks of age and given a 7 day acclimatisation period on delivery. Mice were housed in cages 
with environmental enrichment (Datesand, UK), autoclaved aspen woodchip bedding, had 
access to water and an RM1(E) diet (Special Diets Services, UK). Temperature was regulated 
to 19-22°C, at a relative humidity of 45-65% and a 12:12 hour light:dark cycle.  
2.3.2  Mouse sensitization and challenge to OVA  
Mice were sensitized to OVA (30 µg in 0.4 ml PBS with 0.1 M Al2(OH)3 adjuvant) 
intraperitoneally (i.p.) on days 0, 4 and 11. Sham-sensitized mice were administered 0.4 ml 
PBS with 0.1 M Al2(OH)3 i.p. For comparisons between sham-sensitization and OVA-
sensitization, and the influence of allergen exposure (e.g. chemotaxis studies, and assessment 
of chemokine receptor expression), mice were either culled on day 14 and platelets harvested 
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Figure 2.1: Mouse OVA-sensitization and challenge protocol. 
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mg/ml) for 30 minutes on days 14, 15, 16 and culled on day 17 before platelets were harvested 
(Amison et al., 2015) (Figure 2.1). 
2.3.3  Mouse sensitization to HDM 
Whole bodies of the house dust mite Dermatophagoides Pteronyssinus were crushed 
by mortar and pestle and prepared by Stallergenes Greer (USA). Dermatophagoides 
Pteronyssinus extract (HDM) peptidase 1 enzyme allergen, Der p 1, was quantified as 54 µg 
Der p 1 per 1 mg of total protein. Mice were anaesthetised with isoflurane before sensitization 
with 25 µg/25 µl HDM or 25 µl saline i.n. on days 0, 1, 2, 3, 4, 7, 8, 9, 10 and 11 (Gregory et 
al., 2009) (Figure 2.2).  
2.3.4  HDM challenge and bronchoalveolar lavage fluid collection  
Following the allergen sensitization protocol in section 2.3.3, on day 13, 25 µg/25 µl 
HDM or 100 µg/100 µl HDM was administered i.n. (Figure 2.3) with corresponding sham-
sensitized groups receiving 25 µl or 100 µl of saline, respectively. 24 hours later mice were 
terminally anaesthetised with 2.1 g/kg urethane i.p. and the trachea cannulated. 0.5 ml of saline 
was injected into the cannulated trachea and drawn back into the syringe for collection. This 
was repeated three times, given approximately 1.5 ml bronchoalveolar lavage (BAL) fluid, 
which was then placed on ice. 
Figure 2.2: Mouse HDM-sensitization protocol. 
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2.3.5  Total cell counts and differential cell quantification 
BAL fluid was mixed 1:1 with Türk’s solution and the total leukocyte cell number 
quantified using a Neubauer improved haemocytometer under a phase contrast light 
microscope (Ziess Axiovert) with a 20x objective lens. 
For differential cell quantification, 100 µl BAL fluid was centrifuged using a Shandon 
Cytospin 3 on Superfrost Plus slides at 1000rpm for 1 minute. The slides were then stained 
using Kwik Diff differential stain before cover slipping with DPX mounting medium. The 
percentage of neutrophils, macrophages, lymphocytes and eosinophils was calculated by 
counting 200 cells from four random fields of view, using a phase contrast light microscope 
(Ziess Axiovert) with a 40x objective lens. The total number of each cell type was then 
calculated from the total cell counts. 
2.3.6  Lung harvesting for histology and immunohistochemistry 
Anaesthetised mice, tracheas were cannulated and lungs inflated with 0.5 ml of 3.7% 
paraformaldehyde (PFA). The lungs were dissected and stored in 3.7% PFA, before tissue 
processing and wax embedding (section 2.6.1).  
2.3.7  HDM-sensitized mice HDM challenge following an extended recovery period 
Due to elevated numbers of leukocytes in the lungs of sham-sensitized mice following 
a day 13 challenge, an additional 7 day recovery period was used (Figure 2.4). Following the 
allergen-sensitization protocol in section 2.3.3, mice were challenged on day 20 with HDM 
(100 µg/ 100 µl i.n.). 24 hours later, the lungs were harvested for histology and 
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2.3.8  Intravital microscopy of mouse cremaster muscle 
The cremaster muscle is a thin piece of muscle tissue surrounding the testis, which can 
be externalised and viewed, to allow clear visualisation of the vasculature. In order to visualise 
platelets in cremaster muscle preparations, hamster anti-mouse CD49b (phycoerythrin ) PE 
conjugated antibody (1.6 μg/0.1 mL) was injected intravenously (i.v.) 1 hour before cremaster 
muscle dissection. Mice were terminally anaesthetised with urethane (2.1 g/kg i.p.) and had 
their temperature regulated with a heated mat. A small incision on the right ventral scrotal 
sack allowed extrusion of a single testis from the scrotal sack. The inferior part of the 
cremaster muscle surrounding the testis was pinned to the viewing window and an incision 
was made along the medial side of the cremaster muscle from the inferior pinned section. The 





 Processed for  
histology 
 
Figure 2.5: Illustration of mouse cremaster muscle preparation for intravital 
microscopy. 
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The cremaster muscle was mounted under a Zeiss Axioskop 2 inverted reflective 
fluorescence microscope with a digital CMOS ORCA-Flash 2.8 camera (Hamamatsu) and a 
water immersed 63x objective lens. The scale and area of cremaster muscle viewed was 
determined using a micro-ruler. The exposed tissue was superfused with 37°C Tyrode’s buffer 
using a Watson-Marlow pump at 12 ml/min and excess Tyrode’s buffer suctioned from the 
viewing window. Under 580 nm fluorescent light and a dimmed bright field light, both the 
platelets and the architecture of the post capillary venules could be observed. Post capillary 
venules were distinguished from arterioles by following the flow of blood to a convergence 
point, indicating the vessels under view were part of the venous blood circulation. 
A minimum of 3 different post capillary venules from each mouse were recorded for 10 
seconds. The number of leukocytes present in extravascular compartments of cremaster 
muscle were counted and expressed per area of cremaster muscle. Platelet adhesion events 
were classified as instances where a fluorescent platelet would remain bound to the same 
section of endothelium for the duration of a 10 second video and expressed per area of 
cremaster muscle. Platelet rolling events were classified as instances where a fluorescent 
platelet would slow down, stop or move off the endothelium during the 10 second video.  
2.3.9  Establishing an allergic inflammatory response in the cremaster muscle  
Sham-sensitized and OVA-sensitized mice (section 2.3.2) were challenged with 4x the 
sensitization dose, to establish whether an allergic inflammatory response could be generated. 
On day 14, OVA (150 µg/100 µl) was administered subcutaneously (s.c.) on the scrotum and 
4 hours later the cremaster muscle visualized. Aluminium hydroxide is used as an adjuvant in 
the OVA-sensitization protocol which tended to accumulate within the testis of sham-
sensitized and OVA-sensitized mice, causing a severe inflammatory response. Consequently 
HDM-sensitization of mice was explored to investigate allergic inflammatory responses in the 
cremaster muscle where there was no requirement for an adjuvant.  
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Sham-sensitized and HDM-sensitized mice (section 2.3.3) were challenged on day 13 
with saline or HDM (100 µg/100 µl s.c.) on the scrotum. 24 hours later the cremaster muscle 
was dissected and visualized (Figure 2.6).  
2.3.10  Cremaster muscle harvesting for histology and immunohistochemistry 
Following intravital microscopy video capture, the cremaster muscle was dissected off 
the testis and placed in 3.7% PFA. 24 hours later, the cremaster muscle was processed and 
wax embedded to allow for histological and immunochemical staining (section 2.6.1). 
2.3.11  Chemokine receptor antagonist treatment 
The CCR3 receptor antagonist SB328437 (N-(1-Naphthalenylcarbonyl)-4-nitro-L-
phenylalanine methyl ester) and the CCR4 receptor antagonist C-021 (2-[1,4'-Bipiperidin]-1'-
yl-N-cycloheptyl-6,7-dimethoxy-4-quinazolinamine dihydrochloride) were both prepared in 
DMSO, while the CXCR4 receptor antagonist AMD3100 (1,1′-[1,4-
Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride) was 
prepared in saline. SB328437, C-021 and AMD3100 are highly specific antagonists of CCR3, 
CCR4 and CXCR4 receptors respectively (White et al., 2000; Hatse et al., 2002; Yokoyama 
et al., 2009). Doses of 30 mg/kg SB328437, 30 mg/kg C-021 and 10 mg/kg AMD3100, were 
determined based on previous literature where these antagonists showed efficacy in-vivo 
(Mori et al., 2007; Yokoyama et al., 2009; Li et al., 2011; Yu and Hales, 2011; Chen et al., 
2016). Chemokine receptor antagonists were administered i.p. 30 minutes before allergen 
challenge, with control groups and the AMD3100 group, receiving equivalent amounts of 
DMSO. An allergen challenge with HDM (100 µg/100 µl) was administered s.c. to the 
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scrotum in intravital microscopy preparations, and an allergen challenge with HDM (100 
µg/100 µl) was administered i.n. in allergic lung studies. 
2.3.12  Exogenous eotaxin administration to the scrotum for intravital microscopy 
The effects of eotaxin administration to the scrotum of HDM-sensitized mice, on 
platelet intravascular activity was explored using intravital microscopy of mouse cremaster 
muscle. Based on previous literature from our group, mice received eotaxin (0.1 µg s.c.) in 
the scrotum on day 14 (Riffo-Vasquez et al., 2012). After 4 hours, the cremaster muscle was 
prepared for intravital microscopy as described above. 
2.3.13  Bleeding time measurements following injury  
Mice sensitized to HDM as previously described in section 2.3.3, were administered 
chemokine receptor antagonists before an allergen challenge with HDM (100 µg/100 µl i.n.) 
(section 2.3.9) and subsequently had their bleeding times measured 24 hours later. Mice were 
anaesthetised with isoflurane prior to resecting 2 mm from the distal end of their tail with a 
sharp blade. The tail was immediately immersed in 37°C saline and the time taken for 
cessation of bleeding recorded (Greene et al., 2010). 
2.3.14   Evans blue allergic skin test 
To show evidence of systemic sensitization of mice, skin testing with the allergen was 
carried out in animals receiving Evans blue dye to assess plasma protein extravasation. 
Following HDM-sensitization as described in section 2.3.3 above, on day 13 the dorsum fur 
of mice was shaved off. On day 14, 30 minutes before allergen challenge in skin, mice were 
administered Evans blue dye (0.5% w/v 0.1 ml i.v.). Sham-sensitized and HDM-sensitized 
mice were administered HDM intradermally (25 µg/25 µl i.d.), and the equivalent volume of 
saline at two separate injection sites on their dorsum. Visual assessments of plasma protein 
extravasation around the injection site were made from pictures captured on an iPhone X 
(Apple) of the extravascular blue dye. 
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2.4 In vitro chemotaxis assays 
2.4.1  Mouse washed platelet preparation  
Mice were terminally anaesthetised with urethane (2.1 g/kg i.p.), and 0.6-0.9 ml of 
blood was collected via cardiac puncture, into 0.1 ml ACD. Blood was then centrifuged at 
300g for 3 minutes and the platelet rich plasma (PRP) supernatant was collected. The blood 
was centrifuged again at 300g for 3 minutes, in order to collect the remaining PRP. PGE1 (60 
nM final concentration) was added to PRP and then centrifuged at 800g for 6 minutes and 
platelet poor plasma (PPP) aspirated off. The platelet pellet was re-suspended in 200 µl of 
modified Tyrode’s buffer. 2 µl of washed platelets was added 1:100 to Stromatol platelet 
counting solution, and the number of platelets determined using a haemocytometer and a phase 
contrast light microscope (Ziess Axiovert) with 40x objective lens.  
Centrifuging platelets at high speeds leads to platelet activation and aggregation, 
therefore PGE1 was added to PRP to minimise platelet activity. PGE1 stimulates adenyl 
cyclase activity and increases cyclic AMP concentrations, which inhibits platelet aggregation 
induced by P2Y1 receptor activation. 
For platelet preparations used in Ibidi µ-Slide VI0.4 microfluidic chamber (microfluidic 
chemotaxis assay) experiments, an additional step was used after centrifugation at 800g for 6 
minutes. The platelet pellet was re-suspended in 200 µl red cell lysis buffer and incubated for 
4 minutes before adding 1 ml of modified Tyrode’s buffer. PGE1 (60 nM) was again added to 
the platelets and centrifuged at 800g for 6 minutes, with the remainder of the protocol 
followed.  
2.4.2  Microplate chemotaxis assay for the evaluation of mouse platelet chemotaxis towards 
different chemokines 
Washed platelets were prepared as described above (section 2.4.1) from sham-
sensitized or OVA-sensitized mice (section 2.3.2) and diluted to 1x108 platelets/ml in 
modified Tyrode’s buffer. 96-well ChemoTx® System (Neuro Probe, USA) microplates, with 
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2 µm pore size, were blocked with 30 µl/well modified Tyrode’s buffer for 1 hour. 
Chemokines: MIP-1α, eotaxin, MDC and SDF-1α were prepared at 10 nM and 100 nM, with 
a separate control for each chemokine to minimize cross plate variability. 31.5 µl/well 
chemokine was added and the filter placed on top.  
Previous data from our laboratory reported that platelet priming via the P2Y1 receptor 
causes an increased response of platelets to chemoattractants (Amison et al., 2015, 2018a). 
Therefore platelets were stimulated with a sub-aggregatory concentration of ADP, to provide 
a more robust response in chemotaxis assays.  
Washed platelets were treated with ADP (0.1 µM) for 10 minutes, before adding 24 µl 
washed platelets on the filter (Figure 2.7). The chambers were then incubated at 37°C for 120 
minutes. The filter was then removed and bottom well contents added 1:1 to Stromatol. 
Platelets were enumerated on a haemocytometer using a phase contrast light microscope 
(Ziess Axiovert) with a 40x objective lens.  
2.4.3  Characterisation experiments of microfluidic chemotaxis assay to investigate platelet 
chemotaxis 
Washed platelets were prepared from WT mice (section 2.4.1) and diluted to 1x107 
platelets/ml. Washed platelets were then treated with 2 mM CaCl2 30 minutes before 
application to the microchamber. The Ibidi µ-Slide VI0.4 microfluidic chamber (Ibidi, 
Figure 2.7: Microplate chemotaxis assay arrangement. 
Chapter 2 – Materials/Methods   48 
 
 
Germany) was incubated with different coating solutions (e.g. 10% mouse serum 
(commercially unavailable), 10 µg/ml vitronectin and 10 µg/ml fibrinogen) for 30 minutes 
before rinsing through with modified Tyrode’s buffer. 50 µl of platelet suspension was added 
to one end of the well, then 50 µl was drawn through the other end, causing platelets to be 
pulled into the centre of the chamber, where they were allowed to settle on the well (time 
dependency was investigated as a variable). 1.14x108 beads/ml (Bangs Laboratories, UK) 
were added to modified Tyrode’s buffer control and to chemokines MDC, eotaxin and SDF-
1α, which were prepared at 1, 10, 100 and 1000 nM. Excess platelets from each side well were 
drained, leaving approximately 30 µl of platelets in the well. 5 µl of chemokine or control 
were added directly into the well at one end and 5 µl removed from the other end (Figure 2.8). 
Before starting recordings, slides were given time for the beads to settle and for a chemokine 
gradient to establish (time dependency was investigated as a variable).  
Figure 2.8: Diagrammatic representation of microfluidic chemotaxis assay. 
Slides were filled with a coating solution (green), washed through with modified Tyrode’s 
buffer and platelets added (red). Chemokine (blue) is then applied at one end creating a 
concentration gradient and platelets visualised using an inverted light microscope (40x 
magnification). 
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Recordings were made using an Olympus Cell-R inverted light microscope (Finland), 
with a 40x magnification lens, running Xcellence software (Olympus) and regulated to 37°C 
in a heating chamber. Images were taken at 12 frames/minute for 8.33 minutes (i.e. 100 
frames) and transferred to ImageJ (Fiji). 10-12 platelets were individually tracked over every 
frame using “Manual Tracking” plugin (Fabrice Cordelières, Institut Curie, Orsay, France), 
before transfer of tracks to Chemotaxis and Migration Tool (Ibidi, Germany). Data sets were 
calibrated to 5 seconds between frames with an x/y calibration of 6.2118 pixels/µm as 
determined from Xcellence software and the microscope specifications. Data were graphically 
presented using spider plots, showing all tracks from a centre start point.  
Various measurements of platelet chemotaxis were generated, which showcase 
different elements of cell migration. An average of the differences between the initial and final 
(x, y) values of migrating platelets, was termed the average centre of mass. The Euclidean 
distance was calculated as the straight line distance between the initial and final value of each 
platelet. The mean Euclidean distance (MED) was an average of all straight line distances of 
migrating platelets. The accumulated distance was a sum of the incremental distances moved 
by a platelet between each frame. The mean accumulated distance (MAD) was an average of 
the total distances migrated by platelets. The mean velocity was calculated as the MAD 
divided by time (µm/sec), of each platelet and averaged. The directionality represents the 
tendency of cells to migrate in a straight line and is calculated by dividing the MED by MAD. 
A directionality of 1 would indicate a straight line migration and a directionality of 0 would 
indicate random movement. 
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2.4.4  Human washed platelet preparation for in-vitro chemotaxis assay 
Human peripheral venous blood was collected from healthy volunteers into ACD (1:9), 
in accordance with the Human Tissue Act 2004 and with local ethical approval from King's 
College London. The blood was centrifuged at 120g for 20 minutes. PRP supernatant was 
collected and the blood centrifuged again at 120g for 20 minutes, in order to collect the 
remaining PRP. PGE1 (60 nM) was added to PRP before a centrifugation at 2200g for 10 
minutes at 25°C, the supernatant was then aspirated off and the platelet pellet re-suspended in 
1 ml RPMI 1640. PGE1 (60 nM) was then added and washed platelets made up to 10 ml in 
RPMI 1640. This was followed by another centrifugation at 2200g for 10 minutes at 25°C, the 
supernatant was aspirated off and the platelet pellet re-suspended in 1 ml RPMI 1640. A small 
sample of washed platelets was added 1:100 to Stromatol and platelet concentration quantified 
using a haemocytometer and a phase contrast light microscope with 40x objective. Human 
washed platelets were diluted to 1x108 platelets/ml. 
2.4.5  Characterisation experiments of transwell chemotaxis assay to measure human 
platelet motility to chemokines 
24-well cell culture plates (Corning) were blocked with 1% BSA in RPMI 1640 for 1 
hour. 600 µl of media or media with chemokine was added to the bottom well. Human platelets 
were prepared as previously described (section 2.4.4) and treated with CaCl2 (2 mM) and ADP 
(100 nM), 10 minutes prior to being added to the top well (inserts). Cell culture inserts 
Figure 2.9: Transwell chemotaxis assay arrangement. 
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(Falcon) with 3 µm pore sizes were positioned in the wells and 250 µl platelets subsequently 
added into the inserts (Figure 2.9). The plate was then incubated at 37°C for varying durations 
(time dependency was investigated as a variable), after which media from bottom chambers 
was collected 1:2 in Stromatol and quantified on a haemocytometer using a phase contrast 
light microscope (Ziess Axiovert) with 40x objective lens. 
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2.5 Chemokine receptor expression  
2.5.1  Chemokine receptor expression by flow cytometry 
Mouse washed platelets from sham-sensitized and OVA-sensitized mice (section 2.3.2 
and 2.4.1) were diluted to 1x107 platelets/ml in modified Tyrode’s buffer. Saturating 
concentrations of anti-mouse CD41 fluorescein isothiocyanate (FITC) conjugated antibody 
and the relevant anti-mouse CCR1 PE, anti-CCR3 PE, anti-CCR4 PE or anti-CXCR4 PE 
conjugated antibodies were added to separate 10 µl platelet samples. The relevant isotype 
controls (IgG2bκ FITC and IgG1κ PE conjugated antibodies) were also prepared. After 30 
minutes incubation at room temperature in a dark room, 500 µl of PBS was added to each 
sample before running on a Beckman Coulter FC500 flow cytometer with CXP acquisition 
software (Beckman Coulter, UK). Gating was set on isotype control antibody samples, 
excluding ≤ 2% of events.  
2.5.2  Total protein assay 
PRP from sham-sensitized and HDM-sensitized mice was separated from whole blood 
as described in section 2.4.1. PGE1 (60 nM) was added to PRP and then centrifuged at 800g 
for 6 minutes with PPP aspirated off. The platelet pellet was resuspended in cell lysis buffer 
containing Protease inhibitor, Phosphatase inhibitor cocktail 2 and Phosphatase inhibitor 
cocktail 3 (Sigma Aldrich, UK). The bicinchoninic acid (BCA) protein assay kit was used to 
quantify levels of protein according to the manufacturer’s instructions. A plate reader was 
used to measure absorbance (562 nm) and the levels of protein determined against BCA 
standards, with background values subtracted.  
2.5.3  Measurements of chemokine receptor expression by western blot analysis 
Lysed platelets were prepared as described in section 2.5.2. LDS sample buffer and 
sample reducing agent were added to 30 µg of protein and made up to 10 µl in sterile water. 
MOPS running buffer was used to fill the inner and outer chambers of the western blot tank, 
with antioxidant added to the middle chamber. Samples were denatured by heating for 10 
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minutes at 95°C and subsequently loaded into the gels, along with standards. The proteins 
were separated by gel electrophoresis at 200V, 3.00A and 300W for 50 minutes. The gel was 
then removed from the chamber and sandwiched between filter paper and transfer membrane. 
The tank was filled with transfer buffer containing 10% methanol and antioxidant. Along with 
additional filters and sponges, the membrane sandwich was placed into the tank and 
transferred at 30V, 3.00A, 300W for 70 minutes. 
The membrane was blocked with 3% BSA in TBST for 1 hour, washed in TBST and 
incubated overnight with 2 µg/ml of anti-mouse CCR1, CCR3, CCR4 or CXCR4 polyclonal 
antibodies. The membrane was then washed in TBST and incubated with anti-rabbit IgG, 
HRP-linked antibody. 1 hour later the membrane was washed in TBST and incubated with 
ECL plus solution for 5 minutes and transferred into a photographic cassette. 
Chemiluminescence film was placed over the membrane and left to develop for between 5-15 
minutes. Finally, the film was processed in an automated western blot processor.  
When re-probing the membrane for a different protein, the membrane was incubated in 
stripping buffer (ThermoFisher Scientific) for 15 minutes, washed in TBST, blocked with 3% 
BSA in TBST and finally incubated with the next primary antibody overnight.  
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2.6 Immunohistochemistry and histology  
2.6.1  Mouse lung and cremaster muscle processing and sectioning  
Fixed lung and cremaster muscle tissues (section 2.3.6 and 2.3.9) were dehydrated and 
paraffin wax embedded. 5 µm sections were cut using a Leica RM2125 RT rotary microtome 
and mounted on histological Superfrost Plus slides.  
2.6.2  Mouse lung and cremaster muscle CD42b platelet stain, and polymorphonuclear cell 
staining  
Mouse lung and cremaster muscle sections were passed through xylene, rehydrated and 
immersed in 3% H2O2 in ethanol for 10 minutes. Sections were washed with tap water and 
immersed in sodium citrate buffer at 100°C for 10 minutes using a pressure cooker. Sections 
were then blocked with 1% BSA in PBS for 1 hour, washed with PBS and incubated with 
rabbit anti-human CD42b antibody diluted 1:500 in 1% BSA in PBS. Control sections were 
incubated with 1% BSA in PBS. After 1 hour, sections were washed with PBS and then 
incubated with anti-rabbit IgG (biotinylated) diluted 1:200 in 1% BSA in PBS. After 1 hour, 
sections were washed with PBS and incubated with Vectastain ABC HRP kit (components A 
and B diluted 1:200) for another hour. Sections were then washed with PBS and developed 
using DAB Peroxidase (HRP) Substrate Kit containing 0.3% H2O2 for 10 minutes, followed 
by a tap water wash. Sections were counterstained with haematoxylin for 30 seconds, 
differentiated through immersion in acid alcohol solution for 5 seconds and washed in tap 
water. Finally, sections were dehydrated and cleared in xylenes, before coverslipping with 
DPX mountant. 
Due to haematoxylin counter staining, polymorphonuclear neutrophils (PMN) were 
distinguishable from other leukocytes and numerated in mouse lung sections (section 2.6.4).  
2.6.3  Mouse lung and cremaster muscle Luna stain for eosinophils 
Lung and cremaster muscle samples were processed as previously described (section 
2.6.1) and the tissue sections passed through xylene and rehydrated. Sections were immersed 
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in Weigart’s iron haematoxylin kit solution for 2.5 minutes, washed with distilled water and 
differentiated in acid alcohol solution for 8 seconds (Luna, 1968). Sections were washed with 
tap water and immersed in 0.5% Li2CO3 solution for 5 seconds. Following a tap water wash, 
sections were dehydrated and cleared through xylenes before cover slipping with DPX 
mountant. 
2.6.4  Quantification of platelets, eosinophils and PMNs in mouse lung and cremaster 
muscle sections 
Images of sections stained for platelet CD42b antigen and Luna eosinophil stained 
sections, were captured using a 40x objective lens on a Leica DM 2000 LED bright field 
microscope with Leica DFC295 camera. Platelets or eosinophils in extravascular 
compartments of cremaster muscle sections were numerated and expressed per mm2 of 
cremaster muscle tissue using ImageJ analysis software. In lung tissue samples, the number 
of extravascular platelets, eosinophils or PMNs in the airway walls were quantified and 
expressed per mm length of airway walls.  
2.6.5  Human lung CD42b platelet stain 
Post mortem human lung tissue was a generous gift from Professor Jan Shute 
(University of Portsmouth, UK). Formalin-fixed paraffin-embedded slides of human lung 
samples from control, non-fatal and fatal asthma patients were processed and sectioned at the 
Airway Disease Biobank (Department of Pulmonary and Sleep Medicine, West Australian 
Sleep Disorder Research Institute, Sir Charles Gardiner Hospital, Nedlands, Australia). 
Staining for the platelet CD42b antigen was performed using the same protocol as in section 
2.6.2. However, anti-human CD42b antibody was diluted 1:200 and the DAB developing step 
replaced. Sections were instead developed in NovaRED Peroxidase (HRP) Substrate (Vector, 
UK) solution for 20 minutes, washed in tap water and the remainder of the protocol followed. 
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2.7 Statistical analysis 
A Student’s t-test was used when comparing between single independent measurements from 
two groups. When comparing between three or more groups a one-way analysis of variance 
(ANOVA) or a repeated measures one-way ANOVA test was used, with Dunnett’s multiple 
comparison post hoc test. A two-way repeated measures ANOVA was used when comparing 
the effects of two independent variables on three or more groups All data are presented as 
Mean ± Standard Error of the mean (SEM). A P < 0.05 between individual groups was 
considered significant. Data from the microplate chemotaxis assay was presented as a 
chemotaxis index. This was calculated by dividing the number of platelets migrated by its 
respective control. Statistical analyses were performed on Prism 6.0 (GraphPad Software, 
USA).
  Results I: Presence of 
platelets in human lung samples and 
expression of platelet chemokine 
receptors in sham vs allergen-
sensitized mice 
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3.1 Immunohistochemical staining of platelets in human lung sections 
Platelets have been demonstrated in extravascular compartments of bronchial biopsy 
samples and in bronchoalveolar lavage fluid from patients with asthma (Metzger et al., 1987; 
Jeffery et al., 1989). However, these early studies did not quantify platelet recruitment, nor 
did they identify their precise anatomical localisation. Platelets have also been demonstrated 
to migrate into lungs of allergen-sensitized mice after allergen exposure (Pitchford et al., 
2008). The consequences of platelet migration following an asthma attack are unknown, but 
using sections of lung biopsy samples from patients with asthma (but who died of other 
causes), and patients who died following an asthma attack, antigen specific 
immunohistochemistry allows platelet quantification and location to be determined.  
Sections of lung biopsies from healthy, non-fatal asthmatic and fatal asthmatic patients 
were immunohistochemically stained using a platelet specific anti-human CD42b antibody. 
Single non-aggregated platelets were observed in the alveolar walls and in the alveolar space 
of lung sections taken from patients who died from asthma (Figure 3.1A). The number of 
platelets in the lungs of non-fatal asthmatic patients compared to healthy patients was slightly 
elevated, although not significantly (healthy vs. non-fatal asthmatic: 36.3 ± 6.4 platelets/mm2 
vs. 48.8 ± 7.9 platelets/mm2) (Figure 3.1B). There was an elevated number of platelets in fatal 
asthmatic patients compared to healthy patients (healthy vs. fatal asthmatic: 36.3 ± 6.4 
platelets/mm2 vs. 88.6 ± 12.2 platelets/mm2, P < 0.01). Interestingly, there were increased 
CD42b positive platelet staining events in fatal asthmatic compared with non-fatal asthmatic 
patients (non-fatal asthmatic vs. fatal asthmatic: 48.8 ± 7.9 platelets/mm2 vs. 88.6 ± 12.2 
platelets/mm2, P < 0.05), suggesting airway provocation causes platelet recruitment to the 
lungs through non-aggregatory activation pathways. 
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Unfortunately, sections of lung containing airway wall occurred with insufficient 
frequency to further elucidate the localisation of platelets to other lung structures. However, 
platelets were observed around the airway walls in histological sections from patients with 
asthma, and patients who died of non-fatal asthma (Figure 3.2). Single platelets and platelets 
associated with leukocytes, were also observed within the airways in non-fatal asthmatic and 
fatal asthmatic patients (Figure 3.2). 
Healthy Fatal asthmatic 
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Figure 3.1: Immunostaining CD42b+ platelets in human lung samples. 
Formalin-fixed, paraffin-embedded slides of post mortem human lungs from healthy, non-
fatal asthmatic (NFA) and fatal asthmatic (FA) patients were immunostained with platelet 
specific anti-human CD42b antibody. A- representative images of healthy, non-fatal asthmatic 
and fatal asthmatic patients magenta CD42b+ platelet staining events (highlighted with 
arrows). B- the number of platelet staining events in healthy, non-fatal asthmatic (NFA) and 
fatal asthmatic (FA) lung sections per mm2, from 10 fields of view per section. Data presented 
as mean ± SEM, n = 8-10, * = P < 0.05 and ** = P < 0.01. 




Figure 3.2: Representative immunostaining of CD42b+ platelets in airway walls. 
Formalin-fixed, paraffin-embedded slides of post mortem human lungs from healthy, non-
fatal asthmatic and fatal asthmatic patients were immunostained with platelet specific anti-
human CD42b antibody. Presented are representative images of airway walls from healthy, 
non-fatal asthmatic and fatal asthmatic patients with magenta CD42b+ platelet staining 
events. 
Chapter 3 – Results I  61 
 
 
3.2 Platelet chemokine receptor expression in sham and allergen-
sensitized mice 
3.2.1  Platelet chemokine receptor expression in OVA-sensitized mice by flow cytometry 
The mechanisms that underlie platelet migration to sites of allergic inflammation are 
unknown. Whilst pulmonary platelet recruitment, and migration towards an experimental 
allergen (OVA) has been reported to be platelet FcεR1-dependent, it is not understood how 
chemokines might be involved in platelet tissue localization in the context of allergic 
inflammation (Pitchford et al., 2008). Human platelets express CC chemokine receptors 
CCR1, CCR3 and CCR4, and CXC chemokine receptor CXCR4 (Kowalska et al., 1999; 
Clemetson et al., 2000; Gear et al., 2001), which may function in a similar manner to 
chemokine receptors expressed on leukocytes that lead to leucocyte recruitment and migration 
(Zhang et al., 2009). Human platelet chemotaxis was observed in-vitro through CXCR4 
receptor activation via stromal cell-derived factor 1α (SDF-1α), demonstrating platelet 
chemokine receptor functionality (Kraemer et al., 2010). To interrogate the roles of platelet 
chemokine receptors in allergic responses, platelets harvested from mice sensitized to 
experimental allergen were used to investigate whether the sensitization process might affect 
platelet chemokine receptor expression and chemotaxis (Kuehn and Gilfillan, 2007). 
Washed platelets from sham-sensitized and OVA-sensitized mice (on days 0, 4, and 11) 
were harvested from peripheral blood on day 14. Flow cytometry was then conducted to 
investigate the effects of allergen-sensitization on chemokine receptor expression. 
Representative flow cytometric traces of platelet specific anti-mouse CD41-FITC conjugated 
antibody with anti-mouse IgG-PE conjugated antibody isotype control and anti-mouse CD41-
FITC conjugated antibody with anti-mouse CCR1-PE conjugated antibody, show a separate 
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population of platelets that express CCR1 (Figure 3.3C), which was absent in the isotype 
control (Figure 3.3A).  
Each of the four chemokine receptors CCR1, CCR3, CCR4 and CXCR4 that are 
expressed on human platelets, were also expressed on mouse platelets (Figure 3.3 and 3.4). 
CCR3 receptor expression trended towards an increase in OVA-sensitized mice compared to 
sham-sensitized mice, although this effect was not significant (sham vs. OVA: 10.6 ± 7.6 vs. 
19.1 ± 9.5 %, Figure 3.5A). No similar elevated expression was noted in OVA-sensitized mice 
compared to sham-sensitized mice for CCR1, CCR4, or CXCR4 (Figure 3.5A). An indication 
Figure 3.3: Representative flow cytometry traces of isotype IgG-PE and CCR1-PE. 
Washed platelets taken on day 14 from sham-sensitized and OVA-sensitized mice (30 µg 
OVA on days 0, 4 and 11) chemokine receptor expression was measured by flow cytometry. 
Presented are representative traces of OVA-sensitized mouse washed platelets, incubated with 
anti-mouse IgG-PE conjugated antibody and anti-mouse CD41-FITC conjugated antibody (A 
and B), and with anti-mouse CCR1-PE conjugated antibody and anti-mouse CD41-FITC 
conjugated antibody (C and D). A and C display density plots of FL1 (FITC) plotted against 
FL2 (PE). B and D display histograms of events recorded in PE gate. 
A B 
C D 
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of the number of chemokine receptors expressed per individual platelet (or event), termed 
mean fluorescence intensity (MFI), was variable between animals making it difficult to 




Figure 3.4: Representative flow cytometry traces of CCR3-PE, CCR4-PE and CXCR4-
PE. 
Washed platelets taken on day 14 from sham-sensitized and OVA-sensitized mice (30 µg 
OVA on days 0, 4 and 11), chemokine receptor expression was measured by flow cytometry. 
Presented are representative samples containing anti-mouse CD41-FITC conjugated antibody 
with either anti-mouse CCR3-PE conjugated antibody (A and B), anti-mouse CCR4-PE 
conjugated antibody (C and D) or anti-mouse CXCR4-PE conjugated antibody (E and F). A, 
C and E display density plots of FL1 (FITC) plotted against FL2 (PE). B, D and F display 
histograms of events recorded in PE gate. 




Figure 3.5: The effects of OVA-sensitization of mice on platelet chemokine receptor 
expression and MFI. 
Washed platelets taken on day 14 from sham-sensitized and OVA-sensitized mice (30 µg 
OVA on days 0, 4 and 11), were incubated for 30 minutes with anti-mouse CD41 FITC and 
either anti-mouse CCR1-PE conjugated antibody, anti-mouse CCR3-PE conjugated antibody, 
anti-mouse CCR4-PE conjugated antibody conjugated antibody or anti-mouse CXCR4-PE 
conjugated antibody. Chemokine receptor expression was measured by flow cytometry. A- 
percentage chemokine receptor expression on CD41+ platelet population. B- mean 
fluorescence intensity. Data presented as mean ± SEM and n = 8. 
A 
B 
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3.2.2  Western blot analysis of CCR1, CCR3, CCR4 and CXCR4 platelet chemokine 
receptors in HDM-sensitized mice 
The effects of allergen-sensitization on platelet surface expression of CCR1, CCR4 and 
CXCR4 receptors was minimal. However, it is possible that translational events of chemokine 
receptor proteins may increase after allergen-sensitization, leading to increased platelet 
chemokine receptor protein content, which remains internalised until platelet activation. 
Furthermore, flow cytometric data revealed a doubling in CCR3 receptor expression in mice 
sensitized to experimental allergen. Western blot analysis was therefore conducted on lysed 
Figure 3.6: Representative immunoblots of CCR1, CCR3, CCR4 and CXCR4 receptor 
expression. 
Platelet rich plasma taken on day 14 from sham-sensitized and HDM-sensitized mice (25 µg 
HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 11) was lysed in cell lysis buffer, and protein 
concentration determined using the BCA assay. 30 µg of lysed platelet protein was loaded into 
gels, before gel electrophoresis and transfer steps. Membranes were incubated with anti-mouse 
CCR1, CCR3, CCR4, CXCR4 or β-actin antibodies. Membranes were then incubated with 
anti-rabbit IgG HRP-linked secondary antibody, followed by ECL plus solution, before 
chemiluminescence imaging. Representative immunoblots from sham-sensitized (lanes 1 and 
2) and HDM-sensitized (lane 3 and 4) mice are presented.  
Chapter 3 – Results I  66 
 
 
platelets to investigate internal protein amounts, to corroborate results produced from flow 
cytometry. However, the sensitization model for mice was changed from the OVA to the 
HDM-sensitization model, due to the formation of Al(OH)3 deposits in the cremaster muscle, 
which is further described in section 5.1.1.  
Washed platelets from sham-sensitized and HDM-sensitized mice (on days 0, 1, 2, 3, 
4, 7, 8, 9, 10 and 11) were harvested from peripheral blood on day 14. Platelet CCR1, CCR3, 
CCR4 and CXCR4 receptor expression was confirmed via western blot analysis (Figure 3.6). 
Figure 3.7: The effects of HDM-sensitization of mice on platelet chemokine receptor 
expression. 
Platelet rich plasma taken on day 14 from sham-sensitized and HDM-sensitized mice (25 µg 
HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 11) was lysed in cell lysis buffer, and protein 
concentration determined using the BCA assay. 30 µg of lysed platelet protein was loaded into 
gels, before gel electrophoresis and transfer steps. Membranes were incubated with anti-mouse 
CCR1, CCR3, CCR4, CXCR4 or β-actin antibodies. Membranes were then incubated with 
anti-rabbit IgG HRP-linked secondary antibody, followed by ECL plus solution, before 
chemiluminescence imaging and band analysis using ImageJ. Data are expressed per β-actin 
in each sample lane. Data presented as mean ± SEM and n = 6-7. 
Chapter 3 – Results I  67 
 
 
Chemokine receptor expression was similar in both sham-sensitized and HDM-sensitized 
mice, with a tendency for increased levels in HDM-sensitized groups (Figure 3.7). Western 
blot analysis shows that HDM-sensitization of mice does not cause an increase in total platelet 
chemokine receptor protein production compared to sham-sensitized mice. 
In summary, these results show CCR1, CCR3, CCR4 and CXCR4 receptor expression 
on mouse platelets that have previously been reported on human platelets and demonstrate 
that sensitization of mice to experimental allergen does not significantly alter chemokine 
receptor expression on the surface of platelets or platelet chemokine receptor protein 
production.
  Results II: The effects of 
allergen-sensitization on chemokine 
receptor induced platelet chemotaxis 
and in-vitro platelet chemotaxis assay 
model development 
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4.1 Microplate chemotaxis assay 
Following platelet chemokine receptor expression presented in Chapter 3, the ability of 
these receptors to induce platelet chemotaxis was investigated in-vitro. Platelet migration has 
been observed using a modified Boyden chamber, where allergen-sensitization of mice caused 
increased platelet chemotaxis towards allergen via an FcεRI-dependent mechanism (Pitchford 
et al., 2008). FcεRI and chemokine receptors on mast cells have synergistic roles in mast cell 
degranulation and chemotaxis, suggesting a possible mechanism through which allergen-
sensitization may impact platelet chemotactic responses (Kuehn and Gilfillan, 2007). Whilst 
platelets have been reported to undergo chemotaxis towards other chemoattractants and 
chemokines, notably fMLP and SDF-1α, the influence of allergen-sensitization on platelet 
chemotaxis towards chemokines has not been reported (Czapiga et al., 2005; Kraemer et al., 
2010). The ability of MIP-1α, eotaxin, MDC, and SDF-1α, which bind CCR1, CCR3, CCR4 
and CXCR4 chemokine receptors respectively (D’Apuzzo et al., 1997; Imai et al., 1997; Pease 
et al., 1998), to cause human and mouse platelet chemotaxis, and the influence of allergen-
sensitization was therefore investigated. 
4.1.1  An investigation into the effects of allergen-sensitization on platelet chemotaxis 
The Neuro Probe ChemoTx microplate (microplate chemotaxis assay, 2 µm pore size) 
was initially used to study the effects of allergen-sensitization on platelet chemotaxis. On days 
0, 4 and 11, sham mice received 0.4 ml PBS with 0.1 M Al2(OH)3 i.p. and OVA-sensitized 
mice received 30 µg OVA in 0.4 ml PBS with 0.1 M Al2(OH)3. On day 14, washed platelets 
prepared from sham and OVA-sensitized mice were stimulated with ADP (0.1 µM), 10 
minutes before microplate chemotaxis assay experiments, because previous data from our 
laboratory reported that platelet priming via the P2Y1 receptor provides a robust response 
towards fMLP and MDC (Amison et al 2015; 2018).  
MIP-1α, a ligand of the CCR1 receptor, did not induce platelet chemotaxis at either 10 
nM or 100 nM (Figure 4.1A). Eotaxin, a ligand of the CCR3 receptor caused a concentration 
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dependant increase on chemotaxis in platelets harvested from OVA-sensitized mice (P < 0.01), 
with a significant difference between sham and OVA-sensitized groups at 100 nM 
(chemotactic index: sham vs. OVA: 1.2 ± 0.1 vs. 1.6 ± 0.2, P < 0.05) (Figure 4.1B). MDC, a 
ligand of the CCR4 receptor caused a significant concentration dependent effect on platelet 
chemotaxis (P < 0.05), with no differences between sham and OVA-sensitized groups (Figure 
4.1C). SDF-1α, a ligand of the CXCR4 receptor, appeared to have no effect on platelet 
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Figure 4.1: The effects of MIP-1α, eotaxin, MDC, and SDF-1α on platelet chemotaxis in 
OVA-sensitized mice.  
Washed platelets were taken on day 14 from sham-sensitized and OVA-sensitized mice (30 
µg OVA on days 0, 4 and 11). A range of MIP-1α, eotaxin, MDC, and SDF-1α concentrations 
were added to the bottom wells, before washed platelets were treated with ADP (0.1 µM) and 
added to the top well of a chemotaxis chamber. The chamber was then incubated for 120 
minutes, before the quantification of platelets in the bottom well. Responses of sham-
sensitized and OVA-sensitized mice to MIP-1α (A), eotaxin (B), MDC (C), and SDF-1α (D) 
are displayed. Data was analysed as a chemotactic index and expressed as mean ± SEM, n = 
8, * = P < 0.05 and ** = P < 0.01. 
A B 
C D 
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4.1.2  An investigation into the effects of allergen challenge on platelet chemotaxis 
OVA-sensitized challenged mice have exhibited platelet migration to lung tissue 
(Pitchford et al., 2008). Thus, it was hypothesised that allergen challenge may enhance the 
platelet chemotactic responses observed in section 4.1.1. Sham and OVA-sensitized mice were 
challenged with 30 µg aerosolised OVA on days 14, 15 and 16, and blood collected on day 
17. MIP-1α was again ineffective at causing platelet chemotaxis (Figure 4.2A), suggesting 
that the platelet CCR1 receptor is not involved in platelet migration in the conditions measured 
here, therefore the CCR1 receptor was not investigated further within this thesis.  
The effect of eotaxin on platelet chemotaxis followed a similar trend to effects observed 
in OVA-sensitized mice. Platelet migration at 10 nM and 100 nM eotaxin trended toward an 
increase in OVA-sensitized and challenged groups, although this effect was not significant, 
and therefore there was also no difference in platelet chemotaxis towards eotaxin between 
sham and OVA-sensitized mice (Figure 4.2B). MDC produced a significant concentration 
effect on platelet chemotaxis irrespective of sensitization status (P < 0.05) (Figure 4.2C). SDF-
1α trended toward an increase in platelet chemotaxis that appeared elevated in OVA-sensitized 
and challenged groups, however this effect was not significant (Figure 4.2D). This suggests a 
potential role of the CXCR4 receptor after allergen challenge that was not observed in OVA-
sensitized mice without subsequent allergen exposure. The results of eotaxin and MDC were 
decreased to those seen in OVA-sensitized mice without subsequent allergen exposure, 
suggesting OVA challenge does not further elevate in-vitro platelet chemotaxis, rather this 
could be interpreted that CCR3 and CCR4 responsive platelets had been recruited to the lungs 
in-vivo, leaving a ‘non’ responsive circulating platelet population.  
Chapter 4 – Results II  72 
 
 
Thus, using the microplate chemotaxis assay, mouse platelet chemotaxis was 
demonstrated to eotaxin and MDC via CCR3 and CCR4 receptor stimulation, respectively. 
Interestingly, platelet chemotaxis towards eotaxin, was elevated in allergen-sensitized groups, 
suggesting that CCR3 might be involved in platelet recruitment and motility during allergic 
inflammatory responses. It is also noted that whilst platelet chemotaxis could be demonstrated 
using the Neuro Probe ChemoTx microplates, the chemotactic indices were low, especially 
compared to the motility of leukocytes. Further experiments were therefore conducted to 
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Figure 4.2: The effects of MIP-1α, eotaxin, MDC, and SDF-1α on platelet chemotaxis in 
OVA-sensitized and OVA-challenged mice.  
Washed platelets were taken on day 17 from sham-sensitized and OVA-sensitized mice (30 
µg OVA on days 0, 4 and 11), challenged with aerosolised OVA (30 mg/ml OVA on days 14, 
15 and 16). A range of MIP-1α, eotaxin, MDC, and SDF-1α concentrations were added to the 
bottom wells, before washed platelets were treated with ADP (0.1 µM) and added to the top 
well of a chemotaxis chamber. The chamber was then incubated for 120 minutes, before the 
quantification of platelets in the bottom well. Responses of sham-sensitized and OVA-
sensitized mice to MIP-1α (A), eotaxin (B), MDC (C), and SDF-1α (D) are displayed. Data 
was analysed as a chemotaxis index and expressed as mean ± SEM, n = 8 and * = P < 0.05. 
A B 
C D 
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4.2 Transwell chemotaxis assay 
4.2.1  Platelet chemotaxis towards fMLP using a transwell assay design 
In-vitro human platelet chemotaxis has been shown towards fMLP and SDF-1α, using 
the microplate chemotaxis assay, and fibrinogen coated chamber slides, respectively (Czapiga 
et al., 2005; Kraemer et al., 2010). The transwell chemotaxis assay features Falcon cell culture 
inserts in a 24-well plate, to create a chemotactic gradient. Such a system provides more 
flexibility with assay development as volumes in top and bottom wells can be adjusted. 
Previous studies in house, demonstrated that increasing the lower well volume from 450 µl to 
600 µl, increases the precision of the assay. The transwell chemotaxis assay was therefore 
adopted to try to improve assay conditions for investigating the effects of chemokine receptor 
stimulation, initially on human platelet chemotaxis. The assay would then be used to 
investigate further the role of allergen-sensitization on platelet chemotaxis using platelets from 
allergen-sensitized mice, after investigating the effects of eotaxin, MDC, and SDF-1α on 
human platelet chemotaxis. 
A concentration response to fMLP in human washed platelets demonstrated a 
significant difference between control and 30 nM fMLP (control vs 30 nM fMLP: 6.3 ± 0.1 x 
105 platelets/ml vs 9.9 ± 1.4 x 105 platelets/ml, P < 0.05), indicating platelets are sensitive to 
fMLP in this assay (Figure 4.3A). The results were also expressed as a chemotactic index 
(Figure 4.3B). Stimulating platelets may lead to increased activity and random movement. 
This phenomenon may manifest in increasing the number of platelets that move into the 
chemokine well. In order to eliminate the chance that platelet migration is due to increased 
chemokinetic activity and not chemotaxis, a chemokinetic control group (CKC) with equal 
concentrations of fMLP in the top and bottom wells was used in transwell chemotaxis assay 
studies. Thus, platelet chemotaxis towards fMLP was ablated in these conditions (Figure 4.3A 
& 4.3B), suggesting that platelet chemotaxis towards fMLP in the bottom well alone was the 
result of directed rather than random movement. In order to use fMLP as a positive control 
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when testing other stimuli, a greater window of effect between negative and positive control 
is required. 
Figure 4.3: Human platelet chemotaxis fMLP concentration response. 
Washed platelets were prepared from citrated human blood. A range of fMLP concentrations 
were added to the bottom chamber, before the transwell insert was placed into the bottom 
chamber, and platelets treated with CaCl2 (2 mM) and ADP (0.1 µM), subsequently added to 
the insert. The whole chamber incubated for 90 minutes. A chemokinetic control group (CKC) 
had equimolar concentrations of fMLP (100 nM) in top and bottom wells. Following 
incubation, the number of platelets in the bottom well was enumerated. Data are plotted as the 
number of platelets/ml (A) and as a chemotaxis index (B). Data are expressed as mean ± SEM, 
n = 6 and * = P < 0.05. 
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4.2.2  The effects of incubation times on platelet migration in the transwell chemotaxis assay 
In order to establish a more defined response to fMLP, the effects of different incubation 
times on platelet chemotaxis was investigated. Based on the previous incubation time of 90 
minutes, earlier and later incubation time points of 45 minutes and 180 minutes were used. 
The CKC was adjusted from 100 nM to 30 nM fMLP in top and bottom chambers, because 
30 nM fMLP produced the greatest response in section 4.2.1.  
A 45 minute incubation period caused significant differences in platelet chemotaxis 
between 0 nM and 30 nM fMLP (0 nM vs 30 nM fMLP: 5.18 ± 0.48 x 105 platelets/ml vs 
13.57 ± 2.13 x 105 platelets/ml, P < 0.01), with a 2.4 fold increase in platelet chemotaxis 
(Figure 4.4A). Similarly, a 90 minute incubation period caused platelet chemotaxis between 0 
nM and 30 nM fMLP to significantly increase (0 nM vs 30 nM fMLP: 9.57 ± 2.33 x 105 
platelets/ml vs 20.14 ± 6.3 x 105 platelets/ml, P < 0.05), with a 2.1 fold increase in platelet 
chemotaxis (Figure 4.4B). Finally, a 180 minute incubation period caused a 1.7 fold increase 
in platelet chemotaxis between 0 nM and 30 nM fMLP (0 nM vs 30 nM fMLP: 20.29 ± 6.05 
x 105 platelets/ml vs 34 ± 7.2 x 105 platelets/ml, P < 0.001) (Figure 4.4C). The largest platelet 
chemotaxis window between 0 nM and 30 nM fMLP was produced after a 45 minute 
incubation period, which was subsequently used in later studies. 
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4.2.3  fMLP concentration response with optimized incubation time 
In order to investigate the optimum concentration of fMLP to act as a positive control 
in future experiments, a concentration response to fMLP was repeated using a 45 minute 
incubation period. Significant differences were observed in platelet chemotaxis when 
comparing 0 nM to 30 nM fMLP (0 nM vs 30 nM fMLP: 1.6 ± 0.2 x 105 platelets/ml vs 4.0 ± 
0.5 x 105 platelets/ml, P < 0.001) and to 100 nM fMLP (0 nM vs 100 nM fMLP: 1.6 ± 0.2 x 
105 platelets/ml vs 2.9 ± 0.6 x 105 platelets/ml, P < 0.01) (Figure 4.5A). When plotted as a 
chemotaxis index, there was a significant difference between 0 nM and 30 nM fMLP 
Figure 4.4: The effects of different incubation times on platelet chemotaxis to fMLP.  
Washed platelets were prepared from citrated human blood. 0 nM or 30 nM fMLP was added 
to the bottom chamber, before the transwell insert was placed into the bottom chamber, and 
platelets treated with CaCl2 (2 mM) and ADP (0.1 µM), subsequently added to the insert. A 
chemokinetic control group (CKC) had equimolar concentrations of fMLP (30 nM) in top and 
bottom wells. The chambers was incubated for 45 minutes (A), 90 minutes (B) or 180 minutes 
(C). Following incubation, the number of platelets in the bottom well was enumerated. Data 
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(chemotaxis index: control vs. 30 nM fMLP: 1.0 ± 0.0 vs. 3.0 ± 0.7, P < 0.001) (Figure 4.5B). 
30 nM fMLP was subsequently used as a positive control in transwell chemotaxis assay 
investigations, as it produced the greatest platelet chemotactic response. 
Figure 4.5: fMLP concentration response in optimized transwell chemotaxis assay.  
Washed platelets were prepared from citrated human blood. A range of fMLP concentrations 
were added to the bottom chamber, before the transwell insert was placed into the bottom 
chamber, and platelets treated with CaCl2 (2 mM) and ADP (0.1 µM), subsequently added to 
the insert. The whole chamber was then incubated for 45 minutes. A chemokinetic control 
group (CKC) had equimolar concentrations of fMLP (30 nM) in top and bottom wells. 
Following incubation, the number of platelets in the bottom well was enumerated. Data are 
plotted as the number of platelets/ml (A) and as a chemotaxis index (B). Data are expressed 
as mean ± SEM, n = 10, ** = P < 0.01 and *** = P < 0.001. 
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4.2.4  An investigation into the effects of eotaxin, MDC and SDF-1α on human platelet 
chemotaxis 
CCR3, CCR4 and CXCR4 receptor stimulation produced effects on murine platelet 
migration in the microplate chemotaxis assay, therefore these chemokines were studied in the 
optimized human transwell insert chemotaxis assay. The CCR3 receptor chemokine eotaxin 
caused significant platelet chemotaxis at 30 nM (0 nM vs 30 nM eotaxin: 2.1 ± 0.3 x 105 
platelets/ml vs 3.6 ± 0.3 x 105 platelets/ml, P < 0.01) and 100 nM (0 nM vs 100 nM eotaxin: 
2.1 ± 0.3 x 105 platelets/ml vs 5.4 ± 0.4 x 105 platelets/ml, P < 0.001) (Figure 4.6A). Similarly, 
when expressed as a chemotaxis index 30 nM (chemotaxis index: control vs. 30 nM eotaxin: 
1.0 ± 0.0 vs. 1.8 ± 0.3, P < 0.05) and 100 nM (chemotaxis index: control vs. 100 nM eotaxin: 
1.0 ± 0.0 vs. 2.8 ± 0.3, P < 0.001) eotaxin caused significant platelet chemotaxis (Figure 4.6B). 
30 nM and 100 nM MDC also caused significant platelet chemotaxis when expressed 
as platelets/ml (0 nM vs 30 nM MDC: 2.1 ± 0.3 x 105 platelets/ml vs 4.1 ± 0.5 x 105 
platelets/ml, P < 0.01) (0 nM vs 100 nM MDC: 2.1 ± 0.3 v x 105 platelets/ml s 5.6 ± 0.6 x 105 
platelets/ml, P < 0.001) (Figure 4.6C) and as a chemotaxis index (chemotaxis index: control 
vs. 30 nM MDC: 1.0 ± 0.0 vs. 2.1 ± 0.3, P < 0.05) (chemotaxis index: control vs. 100 nM 
MDC: 1.0 ± 0.0 vs. 2.9 ± 0.5, P < 0.001) (Figure 4.5D), presumably via MDC mediated CCR4 
receptor activation. CXCR4 receptor activation via SDF-1α also caused significant platelet 
chemotaxis compared to control at 30 nM (0 nM vs 30 nM SDF-1α: 2.1 ± 0.3 x 105 platelets/ml 
vs 4.4 ± 0.3 x 105 platelets/ml, P < 0.001) and 100 nM (0 nM vs 100 nM SDF-1α: 2.1 ± 0.3 x 
105 platelets/ml vs 5.5 ± 0.3 x 105 platelets/ml, P < 0.001) (Figure 4.6E). Likewise, when 
plotted as a chemotaxis index 30 nM (chemotaxis index: control vs. 30 nM SDF-1α: 1.0 ± 0.0 
vs. 2.2 ± 0.3, P < 0.01) and 100 nM (chemotaxis index: control vs. 100 nM SDF-1α: 1.0 ± 0.0 
vs. 2.8 ± 0.3, P < 0.001) SDF-1α caused significant platelet chemotaxis (Figure 4.6F). 
These results demonstrate that human and murine platelets are able to undergo 
chemotaxis via CCR3, CCR4 and CXCR4 receptor activation in-vitro. CCR3 and CCR4 
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receptor mediated platelet migration are novel findings, with CXCR4 receptor data supporting 
previous literature (Kraemer et al., 2010). 
Figure 4.6: The effects of eotaxin, MDC and SDF-1α on human platelet chemotaxis.  
Washed platelets were prepared from citrated human blood. A range of eotaxin, MDC and 
SDF-1α concentrations were added to the bottom chamber, before the transwell insert was 
placed into the bottom chamber, and platelets treated with CaCl2 (2 mM) and ADP (0.1 µM), 
subsequently added to the insert. 30 nM fMLP (+Ve) was used as a positive control. A 
chemokinetic control group (CKC) had equimolar concentrations of fMLP (30 nM) in top and 
bottom wells. Following a 45 minute incubation, the number of platelets in the bottom wells 
was enumerated. Responses to eotaxin (A and B), MDC (C and D) and SDF-1α (E and F) 
were plotted as the number of platelets/ml and as a chemotaxis index. Data are expressed as 
mean ± SEM, n = 6, * = P < 0.05, ** = P < 0.01 and *** = P < 0.001. 
Chapter 4 – Results II  80 
 
 
4.3 Microfluidic chemotaxis assay characterisation studies 
4.3.1  Ibidi microslide preparation 
The microplate chemotaxis assay, and the transwell chemotaxis assay are high 
throughput methods for assessing cellular chemotaxis in-vitro, however important parameters 
of chemotaxis such as velocity, direction and the total distance covered by platelets (or 
leukocytes), cannot be studied in these assay systems. Microfluidic chambers offer more 
deterministic models that allow a deeper insight into the manner through which cell migration 
occurs, by providing information on the directionality, velocity and total distance covered by 
migrating cells. The Ibidi µ-Slide VI0.4 microfluidic chamber (microfluidic chemotaxis assay) 
was chosen as various parameters of chemotaxis can be measured, and due to the assays 
flexibility in adjusting volumes and coatings specifically for platelet migration. The 
microfluidic chemotaxis assay was therefore characterized for platelet chemotaxis studies, to 
enable the visualisation of single platelet migration. These studies were conducted under the 
supervision of Dr Heidi Welch (Babraham, Institute, Cambridge), whose laboratory have 
expertise in using microfluidic chambers for the study of neutrophil motility (Johnsson et al., 
2014). 
IbiTreat (standard surface) microfluidic chemotaxis assay slides were incubated with 
10% mouse serum before washing. Then, 50 µl of washed platelets (1 x 107 /ml) was applied 
and the platelets allowed time to settle on the surface of the slide. Beads were added to both 
chemokine and buffer (control) solutions, before their addition at one end of the well and the 
equivalent volume drawn through the other end. The beads nearest the centre of the well were 
used as an indicator of the initial distance the chemokine had travelled. Platelet migration 
toward the chemokine stimulus was recorded using an inverted light microscope, at 12 frames 
per minute for 8.33 minutes, producing 100 frames. 10-12 platelets were selected at random 
to be tracked over this time course (Figure 4.7). X and Y coordinates from individual platelet 
start points were recorded and used to assess platelet migration. 




Figure 4.7: Example of platelet tracking in the microfluidic chemotaxis assay.  
Washed platelets taken from wild type mice were applied to the microfluidic chemotaxis assay 
well, followed by MDC (100 nM) applied at one end of the well. In the images presented 
migration is expected southerly toward MDC. Image A was taken at 0 minutes and image B 
after 8 minutes. 5 platelets were tracked over this duration, with start points displayed in image 
A and tracks with end points displayed in image B.  
A: 0 minutes 
B: 8 minutes 
100 nM MDC 
100 nM MDC 
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4.3.2  Microfluidic chemotaxis assay pilot study 
In model characterisation studies, MDC (100nM) was used to induce platelet 
chemotaxis, due to its effectiveness to induce platelet chemotaxis taken from naïve mice in 
the microplate chemotaxis assay. 10% mouse serum coating was applied to the slide for 30 
minutes, the slide was then rinsed through and followed by the addition of wild type mouse 
(WT) washed platelets. The platelets were given 15 minutes to settle on the surface of the 
slide, then chemokine or control was added and recordings made after 5 minutes. Figure 4.8 
displays spider plots of platelets from control and 100 nM MDC treated wells, with individual 
platelet tracks and average centre of mass (blue dot) presented. Table 3 displays the various 
measurements of platelet motility that can be created using the microfluidic chemotaxis assay.  
Directionality, which specifies if the movement of platelets was random or toward a 
general direction, was increased in MDC (100 nM) treated wells (Table 3). Mean accumulated 
Figure 4.8: Microfluidic chemotaxis assay pilot study spider plots. 
Washed platelets taken from wild type mice were added to 10% mouse serum coated 
microfluidic chambers. The addition of control (A) compared to 100 nM of MDC (B) at one 
end of the chamber was compared. 10 individual platelets were tracked in each instance. 
Migration is expected southerly from the origin toward MDC. Red dots show the final location 
of platelets after tracking from the centre start point. The blue dots represent the average centre 
of mass. Distance was recorded in µm. Images were taken at 12 frames/minute for 8.33 
minutes. 
A B 
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distance (MAD) of platelets takes into consideration the total distance covered by platelets. 
There were only slight differences in the MAD, although the mean Euclidean distance (MED), 
which is the ‘straight line’ distance between the start and end points of platelets, displayed 
differences between control and MDC (100 nM) treated wells. The speed platelets migrated 
in the well was similar in both control and MDC treated wells (Table 3).  
 
The microfluidic chemotaxis assay pilot study revealed single platelet chemotaxis and 
displayed the usefulness of this assay in providing more information on platelet motility, as 
differences in the centre of mass, directionality and MED were quantified, and could be 
assessed visually. Thus, characterisation studies of the microfluidic chemotaxis assay were 
subsequently performed, to elucidate how the conditions can be altered to optimize the assay.  
4.3.3  Effects of time for platelets to settle on the microfluidic chemotaxis assay slide 
The length of time platelets settled in the microfluidic chemotaxis assay slide, was 
investigated to help refine the model. Following a 30 minute coating with 10% mouse serum, 
platelets were left to settle on slides for varied amounts of time before the addition of buffer 
(control) or chemokine. The centre of mass Y coordinate was used as an indicator of the extent 
to which platelet chemotaxis had occurred from the origin toward the chemokine stimulus.  
Leaving the platelets for 37 minutes to settle caused the greatest platelet chemotaxis 
(35.8 μm), along with the highest platelet motility measurements (Table 4). 18 minutes was 

























0.547 44.08 ± 5.47 24.37 ± 8.72 0.36 ± 0.04 
Table 3: Measurements of platelet motility from pilot microfluidic chemotaxis assay 
study. 
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reduced (Figure 4.8). Based on these findings, 30 minutes was selected as the time period for 




























































24.32 ± 10.35 0.27 ± 0.07 
Table 4: Measurements of platelet motility from platelet settling time study. 




Figure 4.8: The effects of increased platelet settling time on platelet chemotaxis. 
Washed platelets taken from wild type mice were added to 10% mouse serum coated 
microfluidic chambers. In the control sample, platelet chemotaxis was measured following 30 
minutes settling time, to control. Platelet chemotaxis following 18, 37, 60 and 105 minutes 
settling time to MDC (100 nM) was recorded. Migration is expected southerly from the origin. 
12 individual platelets were tracked in each instance. Distance was recorded in µm. Images 
were taken at 12 frames/minute for 8.33 minutes. 
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4.3.4  Concentration gradient viability study 
After chemokine is added to the well, a concentration gradient is formed before 
diffusion of chemokine and consequently a loss of gradient. The time the concentration 
gradient is viable after application of MDC (100 nM) to WT washed platelets was investigated. 
The centre of mass Y coordinate was used as an indicator of platelet chemotaxis. Chemotactic 
responses persisted for up to 55 minutes (15.2 μm), indicating the concentration gradient was 
viable long after the addition of chemokine to the slides (Figure 4.9 and Table 5). This allows 
for recordings to be made over a longer time period as the concentration gradient would be 
maintained. For microfluidic chemotaxis assay validation studies, platelet migration was 




























0.38 42.93 ± 11.06 16.85 ± 11.52 0.30 ± 0.08 
Table 5: Measurements of platelet motility from concentration gradient viability study. 
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4.3.5  Effect of increasing concentrations of MDC and SDF-1α 
To uncover the optimum concentration of MDC for microplate chemotaxis assay 
validation studies, platelet chemotaxis was investigated to a range of concentrations of MDC. 
SDF-1α was also investigated because it has been reported to cause platelet chemotaxis in-
vitro (Kraemer et al., 2010). Washed platelets were applied to 10% mouse serum coated 
Figure 4.9: The effect of time on the concentration gradient viability in the microfluidic 
chemotaxis assay. 
Washed platelets taken from a wild type mouse were added to a 10% mouse serum coated 
microfluidic chamber. In the same microfluidic chemotaxis assay chamber, recordings were 
made after 5, 30 and 55 minutes, following the addition of MDC (100 nM) to washed platelets. 
Migration is expected southerly from the origin toward MDC. 12 individual platelets were 
tracked in each instance. Distance was recorded in µm. Images were taken at 12 frames/minute 
for 8.33 minutes. 
Chapter 4 – Results II  88 
 
 
microfluidic chambers and given 30 minutes to settle on the surface of the slide. 
Concentrations of 1 nM, 10 nM, 100 nM and 1000 nM were selected and compared to the 
addition of buffer (control). 1000 nM of MDC caused the greatest effect on platelet chemotaxis 
taken from WT mice (25.4 μm) (Figure 4.10), and also had the highest directionality and MED 
(Table 6). SDF-1α appeared to cause platelet chemotaxis, but this was not to as great an extent 
as MDC, with 1000 nM causing the greatest effect (Figure 4.11, Table 7). This subtle SDF-1α 
effect on platelet chemotaxis may explain the difficulty in detecting responses in the 




































































































25.49 ± 14.59 0.23 ± 0.05 
Table 7: Measurements of platelet motility in concentration response to SDF-1α study. 
Table 6: Measurements of platelet motility in concentration response to MDC study. 




Figure 4.10: Concentration response to MDC in the microfluidic chemotaxis assay. 
Washed platelets taken from wild type mice were added to 10% mouse serum coated 
microfluidic chambers, and allowed 30 minutes to settle on the surface of the well. Washed 
platelet chemotaxis to a range of MDC concentrations was measured. Migration is expected 
southerly from the origin toward MDC. 12 individual platelets are tracked in each instance. 
Distance was recorded in µm. Images were taken at 12 frames/minute for 8.33 minutes. 




Figure 4.11: Concentrations response to SDF-1α in the microfluidic chemotaxis assay. 
Washed platelets taken from wild type mice were added to 10% mouse serum coated 
microfluidic chambers and allowed 30 minutes to settle on the surface of the well. Washed 
platelet chemotaxis to a range of SDF-1α concentrations was measured. Migration is expected 
southerly from the origin toward SDF-1α. 12 individual platelets are tracked in each instance. 
Distance was recorded in µm. Images were taken at 12 frames/minute for 8.33 minutes. 
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4.3.6  Platelet firm adhesion to microfluidic chemotaxis assay slide 
When moving and adapting the microfluidic chemotaxis assay to a new site (i.e. from 
the Babraham Institute to KCL), issues regarding the coating of the slides arose. Following a 
30 minute incubation with 10% mouse serum, slides were washed and washed platelets added. 
Platelets are left to settle on the surface of the slide for 30 minutes at which point the platelets 
become loosely adhered to the surface and chemokine is added. When the methodology was 
Figure 4.13: Platelet adhesion to the surface of the microfluidic chemotaxis assay slide. 
A- representative images of platelets loosely adhered and adhered to the microfluidic 
chemotaxis assay slide surface. B- washed platelets taken from wild type mice were applied 
to uncoated and 10% mouse serum coated microfluidic chemotaxis assay slides. Adhered was 
classified as when over 90% of platelets were firmly adhered to the slide. When less than 90% 
of platelets were firmly adhered, it was classified as loosely adhered. n = 5. 
Loosely adhered Adhered A 
B 
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transferred to KCL, platelets tended to firmly adhere upon addition to the slide, preventing 
any movement in response to chemokine (Figure 4.13A).  
To investigate if this effect was coating or platelet dependant, washed platelets were 
added to uncoated and 10% mouse serum coated slides. Platelets were classified as adhered 
in instances when over 90% in each viewing window remained stationary for the duration of 
a 8.33 minute video. Otherwise the well was classified as loosely adhered, which typically had 
0-5% firmly adhered platelets. Platelets were loosely adhered to uncoated slides, but when 
coated with mouse serum, platelets became firmly adhered in the majority of wells (Figure 
4.13B). This indicated that 10% mouse serum was not a reliable coating solution for the 
microfluidic chemotaxis assay. 
4.3.7  Testing different well coatings for platelet chemotaxis 
A more reproducible coating for the microfluidic chemotaxis assay was sought after 
issues with 10% mouse serum coating. A range of coating solutions were tested using 100 nM 
MDC to induce platelet chemotaxis. Pre-treated Ibidi collagen IV and Ibidi fibronectin coated 
slides were tested, along with uncoated, 10% mouse serum, 10 µg/ml vitronectin and 10 µg/ml 
fibrinogen coated slides. Coating solution was added to microfluidic chemotaxis assay slides 
for 30 minutes and then washed. Washed platelets were then applied and allowed 30 minutes 
to settle on the surface of the well, before the addition of control or MDC (100 nM). After 5 
minutes, platelet migration was recorded and videos analysed using the centre of mass Y 
coordinate as an indicator of platelet chemotaxis. 
Coating slides with either mouse serum, collagen, fibronectin or vitronectin did not 
influence platelet migration towards MDC (100 nM) compared to control (0 nM MDC) 
(Figure 4.14). However, platelets that were added to slides with 10 µg/ml fibrinogen coating 
revealed a difference between control and MDC treated wells (control 0 nM vs. MDC 100 nM 
:15.9 ± 2.5 µm vs. 27.2 ± 4.5 µm). It is noted that Kraemer and colleagues also used fibrinogen 
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to coat wells when performing platelet chemotaxis to SDF-1α, therefore 10 µg/ml fibrinogen 
was used moving forward (Kraemer et al., 2010).  
4.3.8  Elucidation of the basal movement of platelets in control groups 
Before moving forward with the assay, the basal effect of adding control to the 
microfluidic chemotaxis assay well was investigated, because it was noted in all studies that 
a basal movement of platelets occurred, and methodological enhancements to reduce this 
effect might make the assay more precise when measuring cellular chemotaxis across small 
distances by increasing the measurement ratio between control and chemokine-stimulated 
groups. Therefore, multiple elements of the assay were separated to determine their effects on 
the basal movement platelets. 
Figure 4.14: The effects of different well coatings on platelet chemotaxis. 
Washed platelets chemotaxis to control and MDC (100 nM) was performed on pre-treated 
Ibidi collagen IV and Ibidi fibronectin coated slides and on uncoated, 10% mouse serum, 10 
µg/ml vitronectin and 10 µg/ml fibrinogen coated slides in the microfluidic chemotaxis assay. 
12 individual platelets were tracked in each instance. The centre of mass Y coordinate, from 
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After 30 minutes of settling time, recordings of platelets before any further addition to 
the well (unstimulated platelets) were undertaken, which had minimal effects on the 
movement of platelets (Figure 4.15). Similarly, when platelets were incubated with 2 mM 
calcium chloride before addition to the well, minimal effects on the movement of platelets 
occurred, indicating that stimulation with 2 mM calcium chloride does not contribute to the 
basal movement of platelets by enhancing platelet activation due to experimental procedure 
and handling per se.  
When comparing the addition of control to unstimulated platelets, there was a 
significantly greater movement of platelets in the Y coordinate direction toward control 
(unstimulated vs. control: 1.5 ± 0.8 µm vs. 17.9 ± 0.9 µm, P < 0.01) (Figure 4.15). This 
Figure 4.15: Elucidation of control drifting effect. 
Washed platelets were taken from wild type mice. Unstimulated and unstimulated platelets 
incubated with calcium, were applied directly to 10 µg/ml fibrinogen coated microfluidic 
chemotaxis assay wells and recordings made after 30 minutes. Control, control -beads or 
MDC (100 nM) was applied at one end of the microfluidic chemotaxis assay well containing 
unstimulated washed platelets. 12 individual platelets were tracked in each instance. The 
centre of mass Y coordinate, from the start position was recorded in µm. Data presented as 
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suggests that the addition of fluid (control) is causing a drifting flow effect of platelets toward 
the side of the well where the fluid (control) was injected. 
The potential effects of beads on the movement of platelets was investigated, as beads 
are added along with assay diluent (control) and chemokine in the microplate chemotaxis 
assay. Control assay diluent without beads (control-beads) caused a similar effect on the 
movement of platelets as control, indicating the addition of beads were not the cause of the 
movement of platelets in control samples. MDC (100 nM) stimulation caused a significant 
increase in platelet chemotaxis compared to control in fibrinogen coated slides (control vs. 
100 nM MDC: 17.9 ± 0.9 µm v.s. 30.3 ± 5.9 µm, P < 0.05), demonstrating the ability of the 
assay to induce platelet chemotaxis, irrespective of platelet drifting effects.  
The underlying cause of this platelet drifting phenomena remain unknown. The 
microfluidic chemotaxis assay has the potential to be an effective model of platelet chemotaxis 
and has been used here to provide quantifiable visual evidence of platelet motility towards a 
chemotactic gradient, as measured by Euclidian distance, and directionality. Cellular velocity 
was not modulated by chemokine stimulation of platelets, suggesting that random movement 
of platelets occurs extensively in this assay. The optimal conditions for platelet migration in 
the microfluidic chemotaxis assay requires further investigation before the effects of allergen 
sensitization on platelet motility can be studied. 
 
  
 Results III: Development of a 
HDM-sensitization and exposure 
model, to assess platelet recruitment, 
adhesion and migration in response to 
allergen challenge 
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5.1 HDM allergen-sensitization model validation 
5.1.1  Initial studies investigating the effects of OVA-sensitization on intravital cremaster 
muscle preparations 
In order to produce a model for evaluating the vascular activity of platelets in response 
to allergen challenge in-vivo, intravital microscopy of the mouse cremaster muscle was 
investigated. The cremaster muscle is a thin piece of muscle tissue that can be dissected and 
viewed whilst maintaining the blood circulation of the muscle in anaesthetized mice. Due to 
the thickness of the muscle, clear visualization of the vasculature can be obtained, and with 
the addition of a fluorescent platelet specific antibody, the activity of platelets can also be 
studied (Jenne et al., 2011). This is an important consideration, since more pertinent tissues 
for studying allergic inflammation (e.g. the lung), are inherently more unstable preparations 
due to their delicate nature, the physical movement due to respiratory manoeuvres, the vital 
physiological role of the lungs that requires sympathetic surgical techniques, and their 
enclosed position within the body, making clear visualization of cellular adhesive events 
difficult to interpret without the use of sophisticated technology and adaptations (Looney et 
al., 2011; Looney and Bhattacharya, 2014; Rodriguez-Tirado et al., 2016). This is further 
confounded when trying to focus on smaller cells such as platelets.  
Because OVA-sensitization of mice was used successfully for investigations of platelet 
migration in-vitro, using the microplate chemotaxis assay, attempts were made to use the same 
sensitization protocol for in-vivo intravital experiments. However, when using this same 
OVA-sensitization protocol for preparations of cremaster muscle, an accumulation of white 
solids within the scrotal sack was observed in both sham and OVA-sensitized mice, that was 
absent in naïve mice (Figure 5.1A, B and D). Furthermore, the cremaster muscle appeared 
inflamed with leukocytes extensively covering the muscle tissue (Figure 5.1C). The protocol 
for both sham and OVA sensitized mice involves the intraperitoneal co-administration of 
aluminium hydroxide solution as an adjuvant. Thus, the deposits were deduced to be 
aluminium hydroxide accumulating in the testis, causing localized inflammation. This 
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inflammation would mask investigatory effects of allergen-induced inflammation, and 
allergen-induced stimulation of platelets, therefore the OVA-sensitization model was no 
longer considered.  
5.1.2  HDM-sensitization protocol development 
Due to difficulties with the OVA-sensitization protocol, the use of alternative allergens 
was explored to allow for intravascular platelet activity investigations in response to allergen 
challenge. One drawback of the OVA model is that humans are not sensitized to OVA, making 
the model less relevant to that which occurs clinically (Gregory and Lloyd, 2011). As humans 
can become sensitized to HDM, and due to supporting literature demonstrating the allergic 
profile in murine models of allergic airways inflammation with pertinence to asthma, a HDM-
Figure 5.1: Aluminium hydroxide deposits in the scrotum. 
Representative images of sham-sensitized mouse cremaster muscle, with black circles 
highlighting areas of aluminium hydroxide deposits (A, B and D). C- sham-sensitized mouse 
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sensitization protocol was investigated to enable intravital microscopy studies in response to 
allergen challenge (Gregory et al., 2009).  
A two week HDM-sensitization period (25 µg i.n., 5 days/week) was used because this 
protocol was previously demonstrated to induce a significant number of eosinophils within 
the lung and BAL samples of HDM-sensitized mice compared to other time periods (Gregory 
et al., 2009). On day 13, mice were exposed again to HDM (25 µg i.n.) and 24 hours later 
BAL samples were taken. Sham-sensitized mice received saline i.n. for two weeks, before 
subsequent 25 µg HDM exposure on day 13. There was a significant increase in pulmonary 
leukocyte recruitment of HDM-sensitized mice compared to sham-sensitized mice (sham vs. 
HDM: 16.1 ± 1.1 x 104 cells/ml vs. 32.5 ± 5.6 x 104 cells/ml, P < 0.05) (Figure 5.2A). The 
proportion of eosinophils and neutrophils was also elevated in the BAL fluid after HDM-
sensitization (sham vs. HDM: 0 ± 0 x 104 eosinophils/ml vs. 12.6 ± 8.0 x 104 eosinophils/ml, 
P < 0.05 and 0 ± 0 vs. 5.0 ± 2.7 neutrophils, P < 0.05) (Figure 5.2B). The increased numbers 


















Figure 5.2: The effects of HDM-sensitization on pulmonary leukocyte recruitment. 
Sham-sensitized and HDM-sensitized mice (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 
11) were challenged with HDM (25 µg i.n.) on day 13, and 24 hours later BAL fluid was 
collected. A- total BAL leukocytes. B- differential cell counts. Data presented as mean ± 
SEM, n = 4 and * = P < 0.05. 
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of eosinophil therefore indicate an allergic inflammatory response was generated following a 
two week sensitization protocol.  
5.1.3  Histological staining of eosinophils in lungs of HDM-sensitized mice 
The elevated numbers of eosinophils present in the BAL fluid, was supported by 
histological staining of HDM-sensitized mouse lungs. The Luna stain marks the cytoplasm of 
eosinophils red, distinguishing them from other leukocytes (Figure 5.3A). The number of 
eosinophils within the airway walls was elevated in HDM-sensitized mice compared to sham-
sensitized mice (sham vs. HDM: 0.1 ± 0.0 eosinophils/mm vs. 12.7 ± 1.7 eosinophils/mm, P 
< 0.001), again suggesting this model is effective at producing an allergic inflammatory 
response (Figure 5.3B).  
Figure 5.3: The effects of HDM-sensitization on eosinophil recruitment to the airway 
walls. 
Sham-sensitized and HDM-sensitized mice (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 
11) were challenged with HDM (25 µg i.n.) on day 13, and 24 hours later the lungs dissected, 
formalin fixed and paraffin wax embedded. Sections of lung were histologically stained for 
eosinophils. A- representative image of eosinophils stained red within the airway wall of 
HDM-sensitized mouse lung. B- the number of eosinophils in the airway wall was quantified 
and expressed per mm along the airway wall. Data presented as mean ± SEM, n = 4 and *** 
= P < 0.001. 
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5.1.4  Platelets in extravascular lung compartments of HDM-sensitized mice 
The lungs of HDM-sensitized mice were immunohistochemically stained for platelets 
using an anti-mouse CD42b antibody, specific for platelet recognition (Figure 5.4A). Platelets 
have previously been shown in extravascular regions of lungs from OVA-sensitized mice in 
response to OVA-challenge (Pitchford et al., 2008). There was an increased presence of 
platelets located around the airway walls of HDM-sensitized mice compared with sham-
sensitized mice (sham vs. HDM: 0.4 ± 0.2 platelets/mm vs. 3.8 ± 0.4 platelets/mm, P < 0.001) 
(Figure 5.4B), indicating that HDM-sensitization can induce platelet recruitment to the lungs.  
Figure 5.4: The effects of HDM-sensitization on platelet recruitment to the airway walls. 
Sham-sensitized and HDM-sensitized mice (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 
11) were challenged with HDM (25 µg i.n.) on day 13, and 24 hours later the lungs dissected, 
formalin fixed and paraffin wax embedded. Sections of lung were immunohistochemically 
stained using platelet specific anti-human CD42b antibody. A- representative image of 
platelets stained brown within the airway wall of HDM-sensitized mouse lung (highlighted 
with arrows). B- the number of platelets in the airway wall was quantified and expressed per 
mm along the airway wall. Data presented as mean ± SEM, n = 4 and *** = P < 0.001. 
A B 
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5.1.5  HDM systemic sensitization investigation 
HDM-sensitized mice were assessed to investigate if the allergen-sensitization had 
become systemic and not limited to localization to the lung, since the purpose of the change 
in allergen model was for use in the cremaster muscle model of intravital microscopy. Proof 
of the ability of intranasally delivered allergen (HDM) to induce systemic sensitization was 
investigated by observing oedema formation at an anatomical site distant from the lungs 
injected with HDM (the shaven skin on the backs of mice), using Evans Blue dye as a marker 
of extravasated protein (albumin). Sham-sensitized and HDM-sensitized mice were therefore 
administered Evans blue dye (0.5% in saline, i.v.) 30 minutes before i.d. challenge with 25 µl 
saline and 25 µg/25 µl HDM on either side of the shaved backs of mice.  
In sham-sensitized mice, oedema formation at 15 and 60 minutes following saline and 
HDM injection was similar, suggesting any oedema formation was the result of localized 
trauma, rather than the sensitizing agent per se (Figure 5.5). In HDM-sensitized mice, oedema 
formation around the injection site with HDM was visibly more pronounced than with saline 
injection at 15 minutes and this increased further at 60 minutes after injection with HDM 
(Figure 5.5). This suggests an allergic inflammatory response was achieved in a distant 
anatomical region in response to intranasally administered HDM and thus the mice were 
systemically sensitized to HDM. 




Figure 5.5: The effects allergen exposure on s.c. oedema formation. 
Sham-sensitized and HDM-sensitized mice (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 
11) were administered 0.5% Evans blue dye i.v. (0.1 ml) on day 14, and 30 minutes later 25 
µl of saline and 25 µg/25 µl of HDM were administered i.d. on the left and right sides of the 
dorsum, respectively. Images of the dorsum were taken after 15 and 60 minutes on a sham-
sensitized and an HDM-sensitized mouse. 
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5.2 Intravital microscopy protocol development for assessing platelet 
recruitment in response to allergen challenge 
5.2.1  Cremaster muscle imaging set up 
Using the optimized HDM-sensitization protocol detailed in section 5.1, intravital 
microscopy of the mouse cremaster muscle was investigated to study the intravascular activity 
of platelets in response to allergen challenge. In order to visualise platelets, mice were 
administered with a platelet specific anti-mouse CD49b PE conjugated antibody i.v., 1 hour 
before each cremaster muscle dissection (Jenne et al., 2011). Observing the cremaster muscle 
under bright field light allows the tissue architecture to be clearly observed (Figure 5.6A). 
When switching to 580nm fluorescent light, the platelets are visible, however the tissue 
architecture is lost (Figure 5.6B). By dampening the bright field light and applying the 
fluorescent light, a merged display was created allowing platelets and the architecture of the 
tissue to be observed (Figure 5.6C). A minimum of three 10 second videos of different post 
capillary venules per mouse were captured and used for analysis. 
A. Bright field B. Fluorescence C. Merged 
Figure 5.6: Representative images of cremaster muscle in bright field light, 580 nm 
fluorescence light and merged displays. 
A HDM-sensitized mouse (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 11) was 
challenged with HDM (100 µg s.c. to the scotum) on day 13. 24 hours later anti-mouse CD49b 
PE-conjugated antibody was administered (i.v.) and the cremaster muscle dissected for 
intravital microscopy. Representative images of post capillary venules viewed under A- 
bright field light, B- 580 nm fluorescent light and C- merged displays, using a 63x objective 
lens. 
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5.2.2   Allergic inflammatory response in the cremaster muscle 
The number of leukocytes in extravascular compartments of cremaster muscle was used 
as an indicator of the severity of the inflammatory response. Naïve, sham-sensitized and 
HDM-sensitized mice were challenged with 100 µg HDM subcutaneously (s.c.) on the 
scrotum or saline s.c., 24 hours before cremaster muscle dissection. A comparison between 
acute saline and HDM challenge s.c., revealed elevated numbers of extravascular leukocytes 
in the cremaster muscle of HDM-challenged mice (saline vs. HDM: 2.6 ± 0.9 cells/30 µm2 vs. 
16.1 ± 2.6 cells/30 µm2, P < 0.001) (Figure 5.7). This indicated HDM alone causes an elevated 
inflammatory response in the cremaster muscle, in non allergen-sensitized mice.  
When mice were HDM-sensitized and challenged with HDM s.c. on the scrotum, a 
further elevation in the numbers of leukocytes that were present in extravascular 
compartments of the cremaster muscle in HDM-sensitized mice was observed (saline-
Figure 5.7: The effects of s.c. HDM challenge on leukocyte migration to the cremaster 
muscle. 
Sham, sham-sensitized and HDM-sensitized mice (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 
10, and 11) were challenged with saline or HDM (100 µg) s.c. on the scrotum on day 13. 24 
hours later anti-mouse CD49b PE-conjugated antibody was administered (i.v.), the cremaster 
muscle was dissected and a minimum of 3 post capillary venules recorded for 10 seconds. The 
number of leukocytes in extravascular compartments was quantified and expressed per µm2. 
Data presented as mean ± SEM, n = 4-7 and *** = P < 0.001. 
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sensitized, HDM challenged vs. HDM-sensitized, HDM challenged: 11.8 ± 0.9 cells/30 µm2 
vs. 27.8 ± 1.9 cells/30 µm2, P < 0.001). The increased inflammatory response in HDM-
sensitized mice suggested that an allergic inflammatory response was generated using this 
model. A final HDM-sensitized and saline challenged group was included to act as an 
additional control, showing comparable responses to acute saline control group. 
5.2.3  Eosinophil staining of cremaster muscle 
Following intravital microscopy experiments, the cremaster muscle was processed and 
stained for eosinophils via histological analysis. The Luna staining technique stains the 
cytoplasm of eosinophils red, distinguishing them from other cell types (Figure 5.8A). The 
number of eosinophils in extravascular compartments of cremaster muscle was compared 
between groups. In HDM-sensitized and HDM-challenged mice, the number of eosinophils 
was significantly elevated compared to sham-sensitized HDM-challenged mice (saline-
sensitized, HDM challenged vs. HDM-sensitized, HDM challenged: 3.90 ± 1.0 
eosinophils/mm2 vs. 27.8 ± 7.7 eosinophils/mm2, P < 0.001) (Figure 5.8B).  
As the recruitment of eosinophils are a requisite feature in allergic inflammatory 
responses, these data supported the conclusion in section 5.2.2, that HDM challenge in the 
cremaster muscle of intranasally HDM-sensitized mice was capable of causing an allergic 
inflammatory response (Calhoun et al., 1991). 




Figure 5.8: The effects of s.c. HDM challenge in HDM-sensitized mice on  
eosinophil migration to the cremaster muscle. 
Sham, sham-sensitized and HDM-sensitized mice (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 
10, and 11) were challenged with saline or HDM (100 µg) s.c. to the scrotum on day 13. 24 
hours later the cremaster muscle was formalin fixed and paraffin wax embedded. Sections of 
cremaster muscle were histologically stained for eosinophils. A- representative image of 
eosinophils stained red within the cremaster muscle of HDM-sensitized and HDM-challenged 
mouse. B- the number of eosinophils in extravascular compartments of cremaster muscle was 
quantified and expressed per mm2 of tissue. Data presented as mean ± SEM, n = 4-7 and *** 
= P < 0.001. 
A 
B 
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5.2.4  Platelet activity in response to allergen challenge in the cremaster muscle 
The labelling of platelets with anti-mouse CD49b PE conjugated antibody in intravital 
microscopy preparations of cremaster muscle, allowed for detailed tracking of adhesion events 
of individual platelets. In response to HDM challenge in the cremaster muscle, distinct single 
platelet adhesion and rolling events on the endothelium were observed. Due to the dimmed 
bright field light, leukocytes could also be observed, allowing single platelet events to be 
distinguished from platelets attached to leukocytes. Platelet adhesion events were classified 
as instances where a single platelet would remain bound to the endothelium for the duration 
of a 10 second video recording. Platelet rolling events were classified when single platelets 
would slow and interact with the wall of the endothelium, and then either remain bound or 
continue on in the bloodstream. Thus, vascular platelet activity in response to allergen 
challenge was determined by assessing platelet adhesion and platelet rolling events. 
Following 100 µg HDM administration s.c. to the scrotum of healthy mice, an increase 
in both platelet adhesion and platelet rolling events was recorded compared to saline s.c. 
(saline challenge vs. HDM challenge: 0.1 ± 0.1 cells/30 µm2 vs. 1.3 ± 0.2 cells/30 µm2, 
platelets adhered, P < 0.01 and 10.2 ± 1.0 rolling/10 seconds vs. 18.8 ± 1.1 rolling/10 seconds, 
platelet rolling events, P < 0.01), indicating that after an acute inflammatory challenge, an 
increase in platelet activity occurred. In HDM-sensitized and HDM challenged mice, platelet 
adhesion and platelet rolling events were further significantly elevated (saline-sensitized, 
HDM challenged vs. HDM-sensitized, HDM challenged: 1.0 ± 0.2 cells/30 µm2 vs. 2.1 ± 0.3 
cells/30 µm2, platelet adhesion, P < 0.01 and 17.9 ± 1.9 rolling/10 seconds vs. 32.1 ± 2.3 
rolling/10 seconds, platelet rolling events, P < 0.001) (Figure 5.9), indicating allergen 
challenge caused increased intravascular platelet adhesion to the vasculature. No incidence of 
intravascular platelet aggregation, or embolus formation was noted in these video recordings. 
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5.2.5  Platelet migration to cremaster muscle following allergen challenge 
Following intravital microscopy experiments described in section 5.2.4, the cremaster 
muscle was harvested and processed for immunohistochemical staining, using a platelet 
Figure 5.9: The effects of s.c. HDM challenge in HDM-sensitized mice on intravascular 
platelet adhesion and platelet rolling events. 
Sham, sham-sensitized and HDM-sensitized mice (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 
10, and 11) were challenged with saline or HDM (100 µg) s.c. to the scrotum on day 13. 24 
hours later anti-mouse CD49b PE-conjugated antibody was administered (i.v.), the cremaster 
muscle was dissected and a minimum of 3 post capillary venules recorded for 10 seconds. A- 
the number of platelet adhesion events was quantified and expressed per µm2. B- the number 
of platelet rolling events during each 10 second video was quantified. Data presented as mean 
± SEM, n = 4-7, ** = P < 0.01 and *** = P < 0.001. 
A 
B 
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specific anti-mouse CD42b antibody (Amison et al., 2018b). The number of platelet specific, 
brown staining events in extravascular portions of cremaster muscle was quantified and 
compared between groups (Figure 5.10).  
The numbers of platelets in extravascular regions of cremaster muscle tended to 
increase following acute HDM challenge (1.5 ± 0.4 platelets/mm2 vs. 5.0 ± 1.5 platelets/mm2). 
The number of migrated platelets in the HDM-sensitized and HDM-challenged group 
increased compared with the sham-sensitized HDM-challenged group (sham-sensitized, HDM 
challenged vs. HDM-sensitized, HDM challenged: 4.7 ± 1.4 platelets/mm2 vs 11.7 ± 2.4 
platelets/mm2, P < 0.01). These data showed that an allergic inflammatory response resulted 
in the accumulation of platelets in the cremaster muscle. 
Mice were successfully sensitized to HDM allergen and upon exposure to allergen in 
the cremaster muscle, an allergic inflammatory response was generated. Single platelet rolling 
and adhesion events on the endothelium were visualized within the cremaster muscle 
vasculature in-vivo, and such events were increased following allergen exposure. This allergic 
inflammatory response of platelets was supported by immunohistochemical data showing 
platelet accumulation in extravascular compartments of the cremaster muscle following 
allergen exposure, which is likely preceded by distinct platelet rolling and adhesion events. 
The intravital microscopy model was optimized for platelet investigations, and will allow the 
mechanisms by which platelets respond in allergic inflammatory conditions in-vivo, to be 
explored.  




Saline Control HDM-sensitized HDM challenged 
Figure 5.10: The effects of HDM-sensitization and HDM challenge on platelet migration 
to the cremaster muscle. 
Sham, sham-sensitized and HDM-sensitized mice (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 
10, and 11) were challenged with saline or HDM (100 µg) s.c. on the scrotum on day 13. 24 
hours later the cremaster muscle was formalin fixed and paraffin wax embedded. Sections of 
cremaster muscle were immunohistochemically stained using platelet specific anti-mouse 
CD42b antibody. Representative images of platelets stained brown in saline control and 
HDM-sensitized HDM challenged mice are presented. The number of platelets in 
extravascular compartments of cremaster muscle was quantified and expressed per mm2 of 
tissue. Data presented as mean ± SEM, n = 4-7 and ** = P < 0.01. 
  
 Results IV: The roles of 
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6.1 The effects of platelet chemokine receptor antagonists in the lung 
6.1.1  Effect of chemokine receptor antagonists on platelet migration following allergen 
challenge 
The mechanisms which underlie platelet migration to sites of allergic inflammation are 
unknown, but data suggests a potential role of platelet chemokine receptors in this process. 
Platelet chemokine receptor expression was shown through flow cytometry and western blot 
analysis, with subtle differences in expression levels following allergen-sensitization. Murine 
and human platelet chemotaxis was observed in-vitro to chemokine receptor ligands, 
demonstrating the functional activity of platelet chemokine receptors. This activity was 
increased when murine platelets were harvested from allergen-sensitized mice. An allergic 
inflammatory model to study platelet activity in-vivo showed increased platelet rolling and 
adhesion to the vasculature, and the increased extravascular accumulation of platelets in 
allergen-sensitized mice subsequently exposed to allergen. Building on these findings, chapter 
6 explores the roles of platelet chemokine receptors on in-vivo platelet recruitment, adhesion 
and extravascular accumulation in allergen-sensitized mice exposed to allergen, using 
chemokine receptor antagonists. 
SB328437, C-021 and AMD3100 are small molecule antagonists to CCR3, CCR4 and 
CXCR4 receptors, respectively (Figure 6.1). Following the HDM-sensitization protocol, on 
day 13 mice were treated with vehicle, 30 mg/kg SB328437, 30 mg/kg C-021 or 10 mg/kg 
AMD3100 (all i.p.). Mice were then challenged with saline or HDM (100 µg i.n.) and 24 hours 
later the lungs were harvested and stained via immunohistochemistry using an anti-mouse 
CD42b platelet specific antibody. In the sham group, mice were sensitized to HDM before 
administration of vehicle (i.p.) and challenged with saline (i.n.) on day 13, with lungs 
harvested on day 14. 




The number of platelets in extravascular compartments along the airway walls was 
quantified and compared between groups using a phase contrast light microscope (Ziess 
Axiovert) with a 40x objective lens. There was no significant difference between 
administering HDM-sensitized mice saline or HDM (100 µg i.n.) (HDM-sensitized, saline-




Figure 6.1: SB328437, C-021 and AMD3100 chemical structures. 
Chemical structure images taken from National Center for Biotechnology Information, 
PubChem Compound Database; CID=5311092 (SB328437), CID=56972238 (C-021) and 
CID=129856585 (AMD3100) (accessed Oct. 19, 2018). 
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± 0.4 platelets/mm) (Figure 6.2), therefore the effects of chemokine receptor antagonists on 
platelet migration were difficult to determine. 
6.1.2  The effects of chemokine receptor antagonists following a one week recovery period 
Following ten separate i.n. doses of 25 µg HDM over a two week period, an 
accumulation of platelets and other inflammatory cells occurs in the lungs as a result of each 
subsequent HDM-exposure, contributing to both allergen-sensitization and pulmonary 
recruitment of inflammatory cells (Gregory et al., 2009). It was therefore hypothesised that 
with HDM-challenge occurring three days (day 13) post the final sensitization (day 10), 
inflammatory cells within the lung would not have sufficient time to clear, therefore masking 
the effects of any one particular HDM challenge on leukocyte recruitment, or the influence of 
Figure 6.2: The effects of chemokine receptor antagonists on platelet migration following 
allergen challenge. 
HDM-sensitized mice (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 11) were administered 
vehicle, SB328437 (30 mg/kg i.p.), C-021 (30 mg/kg i.p.) or AMD3100 (10 mg/kg i.p.) on 
day 13, 30 minutes before saline or HDM (100 µg i.n.) challenge. On day 14, the lungs were 
dissected, formalin fixed and paraffin wax embedded. Sections of lung were 
immunohistochemically stained using platelet specific anti-mouse CD42b antibody. The 
number of platelets in the airway wall was quantified and expressed per mm along the airway 
wall. Data presented as mean ± SEM and n = 8.  
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chemokine receptors on this response. In order to overcome this issue, following the final 
sensitization, mice were given an additional 7 days to recover from the initial 2-week HDM-
sensitization period. On day 20 mice were administered chemokine receptor antagonists 
(vehicle, 30 mg/kg SB328437, 30 mg/kg C-021 or 10 mg/kg AMD3100, all i.p.) and 
challenged with saline or HDM (100 µg i.n.) and 24 hours later lungs were harvested. In the 
sham group, mice were sensitized to HDM before administration of vehicle (i.p.) and 
challenged with saline (i.n.) on day 20, with lungs harvested on day 21. 
There was a significant difference in the number of platelets in extravascular 
compartments of the airway walls between saline and HDM-challenged mice (HDM-
sensitized, saline-challenged vs. HDM-sensitized, HDM-challenged: 1.6 ± 0.3 platelets/mm 
Figure 6.3: The effects of chemokine receptor antagonists on platelet migration after 
allergen challenge, following a recovery period. 
HDM-sensitized mice (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 11) were administered 
vehicle, SB328437 (30 mg/kg i.p.), C-021 (30 mg/kg i.p.) or AMD3100 (10 mg/kg i.p.) on 
day 20, 30 minutes before saline or HDM (100 µg i.n.) challenge. On day 21, the lungs were 
dissected, formalin fixed and paraffin wax embedded. Sections of lung were 
immunohistochemically stained using platelet specific anti-mouse CD42b antibody. The 
number of platelets in the airway wall was quantified and expressed per mm along the airway 
wall. Data presented as mean ± SEM, n = 8-12, * = P < 0.05, ** = P < 0.01 and *** = P < 
0.001. 
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vs. 37.0 ± 5.7 platelets/mm, P < 0.001), thus showing the impact of a longer recovery period 
on platelet migration to the lungs (Figure 6.3). Administration of the CCR3 receptor antagonist 
(SB328437) and the CCR4 receptor antagonist (C-021), caused a significant reduction in the 
number of migrated platelets within the airway walls (vehicle vs. SB328437: 37.0 ± 5.7 
platelets/mm vs. 22.8 ± 3.6 platelets/mm, P < 0.05 and vehicle vs. C-021: 37.0 ± 5.7 
platelets/mm vs. 16.5 ± 2.1 platelets/mm, P < 0.01), suggesting that CCR3 and CCR4 receptor 
activation is important for platelet migration following allergen challenge in the lung. 
The CXCR4 receptor antagonist (AMD3100), had no significant effect on the number 
of platelets within the airway walls (vehicle vs. AMD3100: 37.0 ± 5.7 platelets/mm vs. 28.6 
± 4.7 platelets/mm), suggesting the CXCR4 receptor is not involved in platelet migration 
following allergen challenge to the lung. 
The number of PMNs within the airway walls of mice administered the chemokine 
receptor antagonists, was quantified to study their effects on granulocyte recruitment 
following allergen challenge. There was a significant increase in PMN accumulation in HDM-
challenged compared to saline-challenged mice that had been previously sensitized to allergen 
(HDM-sensitized, saline-challenged vs. HDM-sensitized, HDM-challenged: 10.1 ± 2.9 
PMN/mm vs. 47.3 ± 8.3 PMN/mm, P < 0.001) (Figure 6.4). Neither SB328437, nor C-021 
had an effect on PMN cell recruitment, suggesting that platelet recruitment following allergen 
challenge, via CCR3 and CCR4 receptors, is independent of PMN cell recruitment. The 
administration of the CXCR4 receptor antagonist (AMD3100) significantly reduced PMN cell 
accumulation to the airway walls following allergen challenge (HDM challenged + vehicle vs. 
HDM challenged + AMD3100: 47.3 ± 8.3 PMN/mm vs. 25.1 ± 3.2 PMN/mm, P < 0.05), 
suggesting PMN migration into tissue occurs independently of platelet migration via the 
CXCR4 receptor. 
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6.1.3  Bleeding times after chemokine receptor antagonist treatment 
In order to assess if the administration of chemokine receptor antagonists affected the 
critical physiological role of platelets in haemostasis, bleeding times of mice were measured. 
An increase in bleeding time would indicate that platelet aggregation is affected by chemokine 
receptor antagonist treatment. Following HDM-sensitization and a one week recovery period, 
mice were treated with vehicle (sham group), SB328437 (30 mg.kg), C-021 (30mg/kg) or 
AMD3100 (10mg/kg) and challenged with HDM (100 µg i.n.). 24 hours later, mice were 
anaesthetized, the tail was resected (2mm from the distal end) and the tail immediately 
immersed in saline (Greene et al., 2010). The time taken for cessation of bleeding was 
recorded.  
Figure 6.4: The effects of chemokine receptor antagonists on PMN migration after 
allergen challenge. 
HDM-sensitized mice (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 11) were administered 
vehicle, SB328437 (30 mg/kg i.p.), C-021 (30 mg/kg i.p.) or AMD3100 (10 mg/kg i.p.) on 
day 20, 30 minutes before saline or HDM (100 µg i.n.) challenge. On day 21, the lungs were 
dissected, formalin fixed and paraffin wax embedded. Sections of lung were 
immunohistochemically stained for platelets and counter stained with haematoxylin. The 
number of PMNs in the airway wall was quantified and expressed per mm along the airway 
wall. Data presented as mean ± SEM, n = 8, * = P < 0.05 and *** = P < 0.001. 
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There were no differences between vehicle and SB328437, C-021 and AMD3100 
groups (HDM challenged + vehicle vs. HDM challenged + SB328437 or C-021 or AMD3100: 
167.5 ± 16.4 seconds vs. 165.1 ± 38.2 seconds or 175.1 ± 24.2 seconds or 207.0 ± 49.3 
seconds) (Figure 6.5), indicating that chemokine receptor antagonists did not interfere with 
haemostasis. 
Figure 6.5: The effects of chemokine receptor antagonists on bleeding times following 
allergen challenge after a recovery period. 
HDM-sensitized mice (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 11) were administered 
vehicle, SB328437 (30 mg/kg i.p.), C-021 (30 mg/kg i.p.) or AMD3100 (10 mg/kg i.p.) on 
day 20, 30 minutes before saline or HDM (100 µg i.n.) challenge. On day 21, the tail was 
resected and immersed in warm saline. The time until cessation of bleeding was measured. 
Data presented as mean ± SEM and n = 8-12. 
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6.2 The effects of platelet chemokine receptor antagonists on platelet 
recruitment and accumulation to the cremaster muscle following 
allergen challenge 
6.2.1  The effects of platelet chemokine receptor antagonists on leukocyte recruitment to the 
cremaster muscle 
Using the intravital microscopy model created in section 5.2, the effects of chemokine 
receptor antagonists on leukocyte recruitment in response to allergen challenge was 
investigated. HDM-sensitized mice were administered either SB328437 (30 mg.kg), C-021 
(30mg/kg) or AMD3100 (10mg/kg) (all i.p.), followed 30 minutes later with the 
administration of HDM (100 µg s.c.) to the scrotum. After 24 hours the cremaster muscle was 
dissected and 3 separate post capillary venules were recorded per mouse. In the sham group, 
mice were sensitized to HDM, before administration of vehicle (i.p.) and saline challenged 
(s.c.) on the scrotum, with the cremaster muscle dissected on day 14. There was a significant 
increase in the presence of leukocytes in extravascular compartments of cremaster muscle in 
HDM challenged than in saline challenged mice (saline challenged vs. HDM challenged: 3.0 
± 0.6 cells/30 µm2 vs. 15.3 ± 1.8 cells/30 µm2, P < 0.001) (Figure 6.6).  
The administration of the CCR3 and CCR4 antagonists SB328437 and C-021 had no 
effect on leukocyte recruitment to the cremaster muscle following allergen challenge (Figure 
6.6). The administration of the CXCR4 antagonist (AMD3100) resulted in a significant 
decrease in leukocyte recruitment to the cremaster muscle (HDM challenged vs. AMD3100: 
15.3 ± 1.8 cells/30 µm2 vs. 4.3 ± 0.8 cells/30 µm2, P < 0.001), indicating that the CXCR4 
receptor is important for leukocyte recruitment following allergen challenge in this model.  
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6.2.2  The effects of chemokine receptor antagonists on intravascular platelet recruitment 
and accumulation in the cremaster muscle 
 Platelet adhesion and platelet rolling events in response to HDM challenge were 
recorded in HDM-sensitized mice treated with chemokine receptor antagonists. In the sham 
group, mice were sensitized to HDM, before administration of vehicle (i.p.) and saline 
challenged (s.c.) on the scrotum, with the cremaster muscle dissected on day 14. Comparing 
saline challenge and HDM challenge, significantly more platelet adhesion and platelet rolling 
events were recorded (saline-challenged vs. HDM-challenged: 0.1 ± 0.1 cells/30 µm2 vs. 1.1 
± 0.1 cells/30 µm2, platelet adhesion, P < 0.001; and 7.8 ± 1.1 rolling/10 seconds vs. 20.7 ± 
2.3 rolling/10 seconds, platelet rolling events, P < 0.001) (Figure 6.7). 
Figure 6.6: The effects of chemokine receptor antagonists on leukocyte accumulation 
following allergen challenge in the cremaster muscle. 
HDM-sensitized mice (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 11) were administered 
vehicle, SB328437 (30 mg/kg i.p.), C-021 (30 mg/kg i.p.) or AMD3100 (10 mg/kg i.p.) on 
day 13, 30 minutes before saline or HDM (100 µg) challenge s.c. on the scrotum. On day 14, 
anti-mouse CD49b PE-conjugated antibody was administered (i.v.), the cremaster muscle was 
dissected and a minimum of 3 post capillary venules recorded for 10 seconds. The number of 
leukocytes in extravascular compartments was quantified and expressed per µm2, n = 6-8 and 
*** = P < 0.001. 
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There were significantly fewer platelet adhesion and platelet rolling events in 
SB328437 treated groups (HDM challenge vs. SB328437: 1.1 ± 0.1 cells/30 µm2 vs. 0.6 ± 0.2 
cells/30 µm2, platelet adhesion, P < 0.05; and 20.7 ± 2.3 rolling/10 seconds vs. 12.3 ± 2.9 
rolling/10 seconds, platelet rolling events, P < 0.05), indicating that the CCR3 receptor is 
involved in platelet recruitment to sites of allergic inflammation (Figure 6.7). Administration 
of the CCR4 receptor antagonist C-021, had no effect on platelet adhesion and platelet rolling 
events in the cremaster muscle following allergen challenge (Figure 6.7). Administration of 
AMD3100, a CXCR4 receptor antagonist, also had no effect on platelet adhesion and platelet 
rolling events (Figure 6.7). Given that the administration of the CXCR4 antagonist caused a 
decrease in leukocyte recruitment to the cremaster muscle, this might suggest that platelet 
recruitment to the cremaster muscle is independent of leukocyte recruitment in this model. 




Figure 6.7: The effects of chemokine receptor antagonists on platelet adhesion and 
platelet rolling events in the cremaster muscle. 
HDM-sensitized mice (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 11) were administered 
vehicle, SB328437 (30 mg/kg i.p.), C-021 (30 mg/kg i.p.) or AMD3100 (10 mg/kg i.p.) on 
day 13, 30 minutes before saline or HDM (100 µg) challenge s.c. to the scrotum. On day 14, 
anti-mouse CD49b PE-conjugated antibody was administered (i.v.), the cremaster muscle was 
dissected and a minimum of 3 post capillary venules recorded for 10 seconds. A- the number 
of platelet adhesion events was quantified and expressed per µm2. B- the number of platelet 
rolling events during each 10 second video was quantified. Data are presented as mean ± 
SEM, n = 6-8, * = P < 0.05 and *** = P < 0.001. 
A 
B 
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6.2.3  The effects of chemokine receptor antagonists on extravascular platelet accumulation 
following allergen challenge in the cremaster muscle 
The cremaster muscle of chemokine receptor antagonist treated mice, was harvested 24 
hours after allergen challenge. The cremaster muscle was then processed for 
immunohistochemical staining using a platelet specific anti-mouse CD42b antibody. There 
was a significant increase in extravascular platelets in the cremaster muscle of HDM-
sensitized and challenged mice compared to HDM-sensitized saline-challenged mice (saline 
challenged vs. HDM challenged: 1.6 ± 0.4 platelets/mm2 vs. 12.4 ± 1.4 platelets/mm2, P < 
0.001) (Figure 6.8). Treatment with the CCR3 receptor antagonist (SB328437) decreased 
platelet accumulation within the extravascular compartments of cremaster muscle (HDM 
Figure 6.8: The effects of chemokine receptor antagonists on platelet migration 
following allergen challenge in the cremaster muscle. 
HDM-sensitized mice (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 11) were administered 
vehicle, SB328437 (30 mg/kg i.p.), C-021 (30 mg/kg i.p.) or AMD3100 (10 mg/kg i.p.) on 
day 13, 30 minutes before saline or HDM (100 µg) challenge s.c. to the scrotum. On day 14, 
the cremaster muscle was dissected, formalin fixed and paraffin wax embedded. Sections of 
lung were immunohistochemically stained using platelet specific anti-mouse CD42b 
antibody. The number of platelets in extravascular compartments of cremaster muscle was 
quantified and expressed per mm2 of tissue. Data are presented as mean ± SEM, n = 6-8, * = 
P < 0.05 and *** = P < 0.001.  
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challenged + vehicle vs. HDM challenged + SB328437: 12.4 ± 1.4 platelets/mm2 vs. 8.9 ± 0.7 
platelets/mm2, P < 0.05), supporting intravital microscopy findings on platelet adhesion and 
platelet rolling events. 
CCR4 receptor antagonism decreased platelet migration to the lungs of HDM-sensitized 
mice challenged with HDM (Figure 6.3), although such an effect was absent in the intravital 
microscopy cremaster muscle model. The administration of the CXCR4 receptor antagonist 
(AMD3100) again had no effect on the extravascular accumulation of platelets, further 
supporting the inference that leukocyte recruitment to the cremaster muscle occurs via 
separate migratory pathways involving chemokine receptors compared to platelets. 
6.2.4  The effects of s.c. eotaxin administration to the scrotum of HDM-sensitized mice 
CCR3 receptor antagonism caused a reduction in platelet rolling, platelet adhesion and 
platelet accumulation into the cremaster muscle; moreover a similar inhibitory effect was 
observed on platelet accumulation into the lungs, in mice sensitized and exposed to HDM. 
Furthermore, platelets harvested from allergen-sensitized mice migrated towards the CCR3 
ligand eotaxin to a greater extent than platelets harvested from sham-sensitized mice in-vitro, 
and a doubling in CCR3 expression was also revealed on the surface of allergen-sensitized 
platelets. The role of the CCR3 receptor was further investigated by administering a CCR3 
ligand eotaxin in-vivo, and it was hypothesised that CCR3 receptor activation via exogenous 
eotaxin administration, might elevate platelet recruitment in HDM-sensitized mice compared 
to sham-sensitized mice. Based on previous literature, following the HDM-sensitization 
protocol, mice were challenged with eotaxin (0.1 µg, s.c. to the scrotum) and 4 hours later the 
cremaster muscle was dissected and prepared for intravital microscopy as described elsewhere 
(Riffo-Vasquez et al., 2012). 
The number of leukocytes in extravascular compartments was significantly higher in 
sham-sensitized mice exposed to eotaxin compared to saline (sham-sensitized mice + vehicle 
vs. sham-sensitized mice + eotaxin: 0.7 ± 0.1 cells/30 µm2 vs. 2.1 ± 0.5 cells/30 µm2, P < 0.05) 
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(Figure 6.9A). However, HDM-sensitization had no further effect (Figure 6.9A). Although 
HDM-sensitization had no effect on platelet adhesion and platelet rolling events, eotaxin 
administration appeared to cause an increase in intravascular platelet rolling and adhesion 
(Figure 6.9B and C). Eotaxin administration to mice caused an inflammatory response, which 
involved both leukocyte and platelet recruitment into the cremaster muscle assessed by 
intravital microscopy. HDM-sensitization of mice had no effect on the action of eotaxin in this 
Figure 6.9: The effects of eotaxin on leukocyte recruitment, platelet adhesion and platelet 
rolling events in the cremaster muscle. 
Sham-sensitized and HDM-sensitized mice (25 µg HDM on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 
11) were administered eotaxin (100 ng s.c. to the scrotum) on day 14. 4 hours later the 
cremaster muscle was dissected and a minimum of 3 post capillary venules recorded for 10 
seconds. A- the number of leukocytes in extravascular compartments was quantified and 
expressed per µm2. B- the number of platelet adhesion events was quantified and expressed 
per µm2. C- the number of platelet rolling events during each 10 second video was quantified. 
Data are presented as mean ± SEM, n = 4 and * = P < 0.05. 
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model, indicating either that HDM-sensitization of mice does not cause increased platelet 
CCR3 receptor activity, or that the dose of eotaxin delivered was supramaximal, masking any 
potential synergism that may occur between allergen sensitization and chemokine receptor 
expression and activity (Sehmi et al., 2003; Francis et al., 2007; Wang et al., 2007). 
Chemokine receptor antagonist administration to allergen-sensitized mice exposed to allergen, 
produced effects on platelet and leukocyte recruitment. The administration of the CCR3 
receptor antagonist (SB328437) prevented platelet recruitment and migration in response to 
allergen challenge, suggesting a role for CCR3 in allergen induced platelet responses. 
Administration of the CCR3 ligand eotaxin in-vivo, caused an inflammatory response 
involving both platelets and leukocytes. CCR4 receptor antagonist (C-021) administration 
reduced platelet migration following allergen challenge to the lung, although this effect was 
not observed in response to allergen challenge in the cremaster muscle, which may suggest 
that a different allergic inflammatory pathway governs platelet responses in different organs. 
The administration of the CXCR4 receptor antagonist (AMD3100) had no effect on platelet 
responses in allergic inflammatory models. However, AMD3100 caused a reduction in 
leukocyte migration following allergen challenge which occurs independently of platelet 
migration via the CXCR4 receptor. Platelet chemokine receptor expression, in-vitro functional 
activity and in-vivo activity in allergic inflammatory models was demonstrated, suggesting 
that chemokine receptors may be involved in the platelet migration that occurs in a number of 
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7.1 Platelet recruitment in fatal asthmatic patients 
Platelets have well established roles in thrombosis and haemostasis, which has led to 
the successful development of anti-platelet and anti-thrombotic drugs for a number of 
conditions (Eikelboom et al., 2012). Most notably the inhibition of platelet aggregation via the 
platelet P2Y12 receptor antagonists such as clopidogrel and prasugurel, are established 
standard therapies for patients with acute coronary syndromes and those undergoing 
percutaneous coronary intervention. Low dose aspirin inhibits cyclooxygenase-1 production 
of TXA2 but the inhibition of cyclooxygenase-2 production of prostacyclin (PGI2) by 
endothelial cells is recovered through de novo synthesis of cyclooxygenase-2, and the altered 
ratio of  PGI2/TXA2 leads to reduced platelet aggregation and vasoconstriction. Aspirin can 
be given prophylactically to patients at high risk of cardiovascular disease and stroke, which 
reduces the chance of embolus formation. The pharmacological control of platelet aggregatory 
responses has led to improved clinical outcomes in patients suffering with disease, therefore 
novel drug treatments to combat platelet inflammatory responses, may produce therapeutic 
effects that do not affect haemostasis. 
In this thesis, human lung samples from patients with asthma were stained and 
quantified for the presence of platelets. Airway provocation (of unreported stimuli) in patients 
who died of asthma caused increased platelet recruitment to the lung parenchyma (alveoli), 
compared to tissue sections from non-fatal asthmatic and non-atopic donors. These platelets 
did not appear within blood vessels, but rather in abluminal regions of the alveolar wall, and 
indeed within alveolar air spaces. Furthermore, no platelet aggregates were observed in the 
human lung, suggesting that platelet accumulation was not a result of an aggregatory response, 
but rather an inflammatory response. Whilst there are limits with two-dimensional histological 
analysis to fully conclude the positioning of platelets within the lung structure, such a 
recruitment of platelets has been observed in the lungs of allergen-sensitized mice after 
allergen exposure, which was IgE FcεR1-dependant (Pitchford et al., 2008). Clinically, 
platelets have been reported in extravascular compartments of bronchial biopsy samples, 
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supporting the deduction that platelet recruitment to the lungs occurs in allergic states (Jeffery 
et al., 1989). However, this is the first study in which the presence of platelets has been 
quantified via antigen-specific immunohistochemistry, comparing different patient cohorts. It 
is interesting to note that such a phenomenon has been observed in other disease states, where 
platelets were found to have migrated extravascularly into inflamed tissue. Inhalation of LPS 
and bacteria can promote migration of platelets into airspaces; whilst other studies reveal the 
presence of platelets in the synovial fluid of patients with rheumatoid arthritis and the brain of 
patients with multiple sclerosis (Boilard et al., 2010; Langer et al., 2012; Ortiz-Muñoz et al., 
2014; Amison et al., 2018b). 
Circulating platelets have diminished stores of mediators and a heightened 
responsiveness in allergic states, which is thought to lead to the migration of platelets to the 
lungs of asthmatic patients (Taytard et al., 1986; Page and Pitchford, 2014; Amison et al., 
2015). Indeed platelets are present in bronchoalveolar lavage fluid of patients with asthma, 
therefore it was hypothesised that non-fatal asthmatic patients would have increased platelet 
staining events in the lungs compared to healthy patients (Metzger et al., 1987). A moderate 
increase in platelet recruitment was observed, however this effect was not significant. Carroll 
and colleagues measured eosinophil staining events around membranous small airways and 
determined no significant differences between healthy and non-fatal asthmatic patients, and a 
significant increase in the number of eosinophils in fatal asthmatic patients compared to 
healthy donors (Carroll et al., 1997). Although the recruitment of platelets was not increased 
in non-fatal asthmatic patients compared to healthy patients, this recruitment mirrors 
eosinophils recruitment in heathy, non-fatal and fatal-asthmatic patients. Such studies suggest 
the difficulties in measuring cellular recruitment to the lungs that occurs in the absence of a 
temporally relevant stimulus. For example, platelet activation, and peripheral 
thrombocytopenia occur in patients with asthma during allergen challenge with the house dust 
mite allergen Der p 1, presumably as a result of localized pulmonary platelet recruitment 
(Kowal et al., 2006). Further studies would therefore be required to obtain lung biopsies from 
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patients with asthma having undergone antigen exposure in clinically controlled conditions to 
fully elucidate the nature of platelet recruitment and migration into lung tissue. 
Sections of human lung did not have sufficient amounts of airway wall to confidently 
assess platelet recruitment to this lung structure, however single non-aggregated platelets were 
observed within the airway walls of non-fatal and fatal asthmatic patients. Platelets are 
important for leukocyte recruitment (Lellouch-Tubiana et al., 1988; Pitchford et al., 2003, 
2005; Dürk et al., 2013; Tian et al., 2015; Takeda et al., 2016; Cardenas et al., 2018), 
bronchospasm (Halonen et al., 1981; Coyle et al., 1990; Keir et al., 2015; Cardenas et al., 
2018) and airway wall remodelling (Pitchford et al., 2004) in animal models of allergic 
inflammation, demonstrating their potential roles in disease progression. Understanding the 
mechanisms that underlie this migration of platelets to sites of allergic inflammation could 
therefore present novel targets for allergic inflammatory diseases because platelets might 
directly contribute to the pathophysiology of asthma. 
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7.2 In-vitro and in-vivo model development 
7.2.1  In-vitro platelet chemotaxis assays 
To begin investigating the migration of platelets to allergic inflammatory sites, an 
existing in-vitro model of platelet chemotaxis was used to test the effects of different stimuli 
on platelet chemotaxis. The microplate chemotaxis assay (Neuroprobe) is a high throughput 
model, where cells and chemokine are separated by a porous filter. The model has previously 
been used to show human platelet chemotaxis towards fMLP and similar use of Boyden 
chambers reveal platelet chemotaxis toward OVA, when platelets are harvested from OVA-
sensitized mice, or to specific allergen to which human donors with asthma are allergic 
(Czapiga et al., 2005; Pitchford et al., 2008). However, this assay lacks flexibility required for 
assay development, which is confined to comparing pore size, incubation times and cell 
number. In comparison, the use of transwell chambers and inserts provides the experimenter 
with a degree of control to adjust the volumes of solution within each compartment, which 
might influence fluid contact across the membrane due to pressure differences, and therefore 
modulate chemokine dispersion from the bottom compartment. Increasing the volume in the 
bottom well increased the sensitivity of the assay (conducted in house), and the assay was 
further optimized by adjusting the 90 minute incubation time, which was originally 
determined using the Neuroprobe microplate system, to a 45 minute incubation time for 
platelets. The transwell chemotaxis assay successfully showed human platelet chemotaxis 
towards a number of stimuli, notably fMLP, where a characteristic bell-shaped concentration 
response was observed. Furthermore, the introduction of a chemokinetic control in the bottom 
well, inhibited directional movement. Human platelet chemotaxis towards eotaxin (CCR3 
ligand), MDC (CCR4 ligand), and SDF-1α (CXCR4 ligand) were all demonstrated. This 
provided further rationale to also investigate the effects of these chemokine receptors in in-
vivo models. However, this model also has its limitations. The release of chemokine in-vivo 
forms a steady concentration gradient within a tissue, whereas with the microplate and 
transwell chemotaxis assays, initially two compartments with 0% chemokine and 100% 
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chemokine are separated by an artificial surface producing a steep gradient, which likely 
shallows over the incubation period. Furthermore, a proportion of platelets may ‘fall through’ 
the porous membrane by means of insufficient platelet adhesion to substrate and gravity.  
In order to further elucidate platelet chemotaxis in-vitro, the microfluidic chemotaxis 
assay (Ibidi) was considered as it allows single cell tracking, which allows several 
measurements of motility to be attained that cannot be produced with the microplate or 
transwell chemotaxis assays. In the microfluidic chemotaxis assay a gradual horizontal 
concentration gradient can be generated, eliminating gravitational effects and perhaps more 
closely mimicking chemokine gradients produced in-vivo. Kraemer and colleagues studied 
platelet chemotaxis towards CXCR4 in an assay that shares some similarities. They 
successfully measured platelet chemotaxis on fibrinogen-coated chamber slides to an agarose 
pellet containing SDF-1α (Kraemer et al., 2010). Platelet chemotaxis was measured over a 3 
hour period, which in most cases platelets would migrate less than 5 µm in total. They also 
allowed platelets to settle for 30 minutes, then wash through to remove non-adherent platelets, 
however the platelets that are non-adherent may be expressing a different phenotype to those 
that have adhered (Kraemer et al., 2010). The aim was therefore to produce a similar assay 
that could detect motile platelets and assess several facets of platelet chemotaxis.  
After applying platelets to the microfluidic well, one of the main challenges was to 
cause sufficient platelet adherence to the surface of the well. A lack of adherence to the slide 
resulted in platelets moving freely in solution, which would move less directionally and were 
difficult to focus. It was also important to prevent platelets adhering too firmly to the surface 
of the well, because too firm an adhesion would prevent the movement of platelets and likely 
lead to platelet activation. Allowing the platelets to settle on the surface of the well increased 
the number of sufficiently adhered platelets, although a proportion of platelets still remained 
non-adhered. Initial studies using a mouse serum coating of microfluidic wells successfully 
enabled platelet chemotaxis to be measured. However, when using the same mouse serum 
solution at a different site, platelets tended to adhere too firmly to the surface of the well. 
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Clearly, unknown differences in laboratory conditions affected the ability to transfer the assay. 
Consequently, different well coatings were investigated with a more uniform composition to 
reduce the chances of variability. Fibrinogen coating of microfluidic slides produced the 
greatest platelet chemotaxis effect compared to other coating solutions, and was consequently 
used for further studies. Indeed resting platelets can bind to fibrinogen independently of 
platelet activation, and therefore has been used previously for platelet chemotaxis 
investigations (Savage and Ruggeri, 1991; Zaidi et al., 1996; Kraemer et al., 2010). 
 Very recently, platelets have been reported to migrate along the luminal surface of 
blood vessels, to act as mechano-scavengers that collect and bundle bacteria to influence 
neutrophil behaviour (Gaertner et al., 2017). This same group developed a similar 
methodology for measuring platelet shape change and chemotaxis in-vitro on immobilized 
blood plasma components. The balanced co-absorption of pro-adhesive fibrinogen and anti-
adhesive albumin (Park et al., 1991), presumably provides a mixture to allow cellular 
polarization and integrin dependent adhesion of spread platelets (Gaertner et al., 2017). 
Conditions where adhesion dominates over traction have historically been used to measure 
platelet spreading and adhesion, and thus migration is likely impeded, and have been reported 
for other cell types (Palecek et al., 1997; Gupton and Waterman-Storer, 2006). Future 
experiments using the Ibidi chambers would involve the use of fibrinogen with varying 
concentrations of albumin, to elucidate optimum conditions that can be repeatedly recreated 
and not dependent on batches of mouse serum. 
When using the microfluidic chemotaxis assay, several different measurements are 
generated that can be used as a measure of platelet chemotaxis, which require careful 
consideration before choosing as they exhibit different elements of platelet motility. 
Interestingly, when platelets migrated in the presence of a chemokine, the centre of mass, 
Euclidean distance and directionality of migrating platelets all increased simultaneously, 
indicating a relationship between these parameters. Both the accumulated distance and 
velocity of migrating platelets also appear to share a relationship (as expected). For validation 
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studies, the centre of mass Y coordinate was selected as a general measure of platelet 
chemotaxis, as it specifically shows movement in the direction of chemokine.  
Platelets tended to migrate toward the end of the well that buffer or chemokine was 
added. This phenomenon may be attributed to circulating flow caused by the pipetting motion 
of adding to the well. The assay was originally validated for leukocytes (Johnsson et al., 2014), 
which are larger cells (~10 µm) that are often more firmly adhered to the surface and therefore 
less easily effected by flow. Platelets however are smaller (~3 µm) and less firmly adhered, 
so are more likely effected by flow within a well with a total height of 400 µm. Minimizing 
the flow or increasing the platelet chemotaxic effect, will improve the window between control 
and chemokine stimuli, which is key in validating the microfluidic chemotaxis assay. 
Nonetheless this assay enabled platelets to migrate 40 µm over a period of 8 minutes towards 
chemokine (Figure 4.15). This is the first time the microfluidic chemotaxis assay has been 
employed for measuring platelet chemotaxis, thus the model requires considerable validating 
experiments before in depth studies can be performed, such as investigating the effects of 
allergen sensitization on platelet chemotaxis. 
7.2.2  Intravital microscopy of mouse cremaster muscle 
The observation of platelet chemotaxis measured in-vitro, which was elevated in 
sensitized mice towards eotaxin (discussed below), justified further investigations into platelet 
motility and migration to sites of allergic inflammation in a more physiologically relevant in-
vivo system. Intravital microscopy of airways was considered as a possible means to 
investigate platelet recruitment. Generating clear visualisations of cell recruitment to the lung 
is possible through the use of sophisticated technologies and adaptations of the lung, however 
this can be technically challenging due to the vital physiological role of the lungs and their 
enclosed position within the body (Looney et al., 2011; Looney and Bhattacharya, 2014; 
Rodriguez-Tirado et al., 2016). Platelets are especially challenging to view due to their small 
size, and the breathing motion of the lung would greatly impact visualisations of platelet 
recruitment. Therefore the cremaster muscle was investigated as a means to study platelet 
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migration as it is easily accessible, motionally stable, and due its thinness, clear visualisations 
of the vasculature can be obtained. Admittedly, the cremaster muscle and lung architecture 
and functions are very different, and the testes do not normally become sensitized to allergen, 
which needs to be considered when interpreting data. 
Due to experimental issues when sensitizing mice to OVA that have been explained in 
the results section, HDM-sensitization was considered to produce an allergic inflammatory 
response in the cremaster muscle, because this is a clinically relevant source of antigen (Der 
p 1), which has been used successfully to develop in-vivo models of allergen sensitization and 
inflammation via intranasal inhalation (Gregory et al., 2009; Gregory and Lloyd, 2011). 
HDM-sensitization caused increased eosinophil recruitment to the lungs, demonstrating that 
an allergic inflammatory response was generated. However, it was necessary to test whether 
the sensitization was systemic in nature, given the intended application for intravital 
microscopy on the cremaster muscle. The successful sensitization of mice was therefore 
supported by allergic skin tests on the flanks of mice demonstrating that systemic sensitization 
was achieved. Thus, the HDM sensitization protocol was used for intravital microscopy 
studies of the mouse cremaster muscle. Following HDM administration s.c. on the scrotum, 
there was increased leukocyte recruitment and eosinophil migration in HDM-sensitized mice 
compared to saline-sensitized mice, indicating an allergic inflammatory response was 
generated in the cremaster muscle. 
In saline-sensitized mice challenged with HDM, there were elevated numbers of 
leukocytes in the cremaster muscle and increased platelet events, when compared to saline-
sensitized mice challenged with saline. This indicates that HDM extract alone causes an 
inflammatory response without prior sensitization, which has been suggested to occur through 
HDM protease and endotoxin activity (Gregory and Lloyd, 2011). Der p 1 cleaves epithelial 
tight junctions, which impairs epithelial barrier function and allows delivery of allergen to 
APCs. HDM extracts also contain endotoxin and Gram-negative Bartonella species that are 
thought to be a source of LPS, which can trigger proinflammatory signals (Gregory and Lloyd, 
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2011). These components of HDM preparations elucidate the inflammatory responses 
generated without prior sensitization. Importantly however, when mice were HDM-sensitized 
and HDM-challenged, both leukocyte and platelet responses were further elevated, suggesting 
an allergic inflammatory response was generated. 
For the first time, platelet recruitment following allergen exposure was measured by 
intravital microscopy using a platelet specific fluorescent antibody (anti-CD49b-FITC 
antibody). Because this model offers a motionally stable tissue bed, allowing clear 
visualisations of platelets in the vasculature, distinct single platelet rolling and platelet 
adhesion events were recorded following allergen challenge. These events were independent 
of leukocyte rolling and adhesion as could be determined in merged fluorescent and bright 
field displays of cremaster muscle. The rolling and adhesion of platelets did not lead to platelet 
aggregate formation, suggesting that the mechanisms involved in platelet recruitment 
following allergen challenge are separate from platelet aggregatory responses (Page, 1988).  
Single platelets were observed in extravascular compartments of cremaster muscle and 
in extravascular compartments surrounding airway wall structures, following allergen 
exposure in HDM-sensitized mice, demonstrating that platelets have the ability to migrate to 
sites of allergic inflammation, supporting previous studies which have shown platelets 
localised to inflamed tissue (Metzger et al., 1987; Jeffery et al., 1989; Boilard et al., 2010; 
Langer et al., 2012). It is noted however, that the physical act of migration itself, through the 
endothelium was not possible to record here, and the assumption of platelet migration through 
tissue is based on events preceding diapedesis (e.g. vascular rolling and adhesion) and the 
post-adhesive quantification of platelet accumulation within the tissue. This is the first report 
of platelet adhesion in response to exposure to a clinically relevant allergen, which suggests 
that following allergen challenge, platelets are recruited in a similar manner to leukocytes, 
leading to increased rolling along venules located in the inflamed area, followed by firm 
adhesion of platelets to the endothelium and finally diapedesis into extravascular 
compartments of inflamed tissue. Studies could be taken further by making use of in-vitro 
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endothelial monolayer preparations and flow based systems to record the ability of platelets 
to undergo diapedesis to physiologically relevant, and allergic stimuli. It is interesting to note 
however, that platelets might undergo transcellular diapedesis, as revealed in electron 
microscopy studies of platelets undergoing diapedesis in response to fMLP induced acute 
inflammation in guinea pigs (Feng et al., 1998). 
Platelets are highly specialised for aggregatory responses, although they possess the 
necessary components to function as immune cells. Platelets appear to contribute to allergic 
inflammatory responses by propagating the effects of other inflammatory cells. Platelet-
dependent leukocyte recruitment to the lung presents a specialised role for platelets in allergic 
inflammatory responses. Further investigations into the roles of platelets in allergic conditions 
may uncover additional unique functionalities of platelets that are directly related to platelet 
function, rather than platelet cooperation of leukocyte dependent pathogenesis. Data from this 
thesis supports the notion that platelets indeed migrate to sites of allergic inflammation, which 
may occur through a number of different mechanisms, although the platelet chemokine 
receptors have been investigated in this instance. 
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7.3 Platelet chemokine receptors 
The overarching aim of this work was to investigate if chemokine receptors expressed 
on platelets are involved in platelet migration to sites of allergic inflammation. Allergen 
sensitization induces platelet recruitment and accumulation in allergen-sensitized mice 
exposed to allergen, via an FcεRI-dependent process (Pitchford et al., 2008), and it has been 
suggested that FcεRI can interact directly with GPCRs, on mast cells (Kuehn and Gilfillan, 
2007). In particular MIP-1α binding to CCR1 has been shown to synergise with FcεRI in a rat 
basophilic leukaemia cell line (RBL-2H3 cells), and murine bone marrow derived mast cells 
(Laffargue et al., 2002; Toda et al., 2004). Furthermore, CCR3 receptor expression in response 
to allergen on leukocytes has been widely reported (Sehmi et al., 2003; Francis et al., 2007; 
Wang et al., 2007). Therefore, the influence of allergen sensitization on chemokine receptor 
expression was initially explored, before functional experiments using novel in-vitro and in-
vivo assays was conducted. Investigations were restricted to chemokine receptors known to be 
expressed on human platelets: CCR1, CCR3, CCR4, and CXCR4 (Clemetson et al., 2000; 
Kowalska et al., 2000; Abi-Younes et al., 2001). The roles of each platelet chemokine receptor 
will be discussed in the following section. 
7.3.1  Platelet CCR1 receptor 
Stimulation of platelets with MIP-1α causes increased intracellular calcium 
concentrations, indicating that the CCR1 receptor is functional on platelets, but has not been 
explored for motility or shape change (Clemetson et al., 2000). MIP-1α has been detected in 
the lungs of asthmatic patients and in the serum of patients with atopic dermatitis, suggesting 
that the CCR1 receptor may be involved in allergic inflammatory responses (Alam et al., 1996; 
Tillie-Leblond et al., 2000; Kaburagi et al., 2001). MIP-1α has been shown to induce 
chemotaxis of other cell types, therefore the ability of MIP-1α to induce platelet chemotaxis 
via the CCR1 receptor was investigated (Phillips et al., 2003; Toda et al., 2004). 
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Murine platelet CCR1 receptor expression was demonstrated via flow cytometry and 
western blot analysis. Sensitization of mice to allergen appeared to have no effect on CCR1 
receptor expression, indicating neither surface expression of CCR1 or total cell CCR1 content 
is effected by sensitization. Platelet chemotaxis via CCR1 receptor activation was investigated 
using the microplate chemotaxis assay. MIP-1α was unable to induce platelet chemotaxis in 
this assay. Furthermore neither the sensitization of mice to OVA, nor subsequent exposure of 
OVA-sensitized mice with OVA induced CCR1 receptor dependent platelet chemotaxis (via 
MIP-1α stimulation). Due to the lack of effect on platelet CCR1 receptor expression and 
chemotaxis, the CCR1 receptor was not investigated further. 
It has been suggested that co-stimulation of CCR1 and CCR3 receptors impacts 
eosinophil recruitment to the lungs of asthmatic patients, so although CCR1 receptor 
stimulation alone did not induce platelet chemotaxis, it is possible that activating CCR1 along 
with CCR3 receptor on platelets, may present a function of CCR1 on platelet chemotaxis, 
which was not tested in this thesis (Sabroe et al., 2000; Phillips et al., 2003). 
7.3.2   Platelet CCR4 receptor 
Stimulation of platelets with MDC causes platelet activation as measured by calcium 
signalling, granule content release, platelet shape change and low level platelet aggregation, 
demonstrating the functional activity of the CCR4 receptor on platelets (Clemetson et al., 
2000; Abi-Younes et al., 2001; Gear et al., 2001). Activation of the CCR4 receptor can induce 
chemotaxis in other cell types, therefore the ability of the CCR4 receptor to induce platelet 
chemotaxis was investigated (Colantonio et al., 2002; Juremalm et al., 2002; Kim et al., 2002).  
Mouse platelet CCR4 receptor surface expression and total cell CCR4 content was 
confirmed through flow cytometry and western blot analysis, respectively. Mouse and human 
platelet chemotaxis was measured to MDC in each of the chemotaxis assays tested, 
demonstrating the ability of CCR4 activation to induce platelet chemotaxis. Patients with 
asthma have increased CCR4 receptor expression on T cells (Vijayanand et al., 2010), which 
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suggests allergen sensitization causes increased CCR4 receptor function in allergic states. 
However, the sensitization of mice had no effect on the expression of CCR4 on platelets or 
the modulation of platelet chemotaxis towards MDC. Similarly, the CCR4 receptor antagonist 
C-021 had no effect on platelet rolling, adhesion or migration to the cremaster muscle 
following HDM-challenge in HDM-sensitized mice. Conversely, C-021 caused decreased 
platelet migration to the lungs following allergen challenge of sensitized mice.  
Investigations into the role of the CCR4 receptor in allergic inflammatory models has 
exhibited contrasting effects. Adoptively transferred antigen specific Th2 cells from CCR4 
deficient mice, prevented trafficking following allergen challenge in an OVA model of allergic 
pulmonary inflammation (Mikhak et al., 2009). Similarly, antibody neutralisation of MDC 
and TARC caused reduced leukocyte recruitment to the lung following allergen challenge 
(Lloyd et al., 2000; Kawasaki et al., 2001). Furthermore, in mice administered with peripheral 
blood mononuclear cells from asthmatic patients, CCR4 blocking antibodies caused decreased 
airway eosinophilia, goblet cell hyperplasia and bronchial hyperreactivity (Perros et al., 2009). 
In contrast, using a CCR4 receptor antagonist in a guinea pig model of allergic airway 
inflammation and in an allergic inflammatory model using CCR4 knockout mice, there was 
no protection against airway inflammation (Chvatchko et al., 2000; Conroy et al., 2003). The 
differences in CCR4 receptor action in models of allergic inflammation have been suggested 
to be species dependant (Solari and Pease, 2015). These contrasting effects may reflect the 
differences in platelet migration to the cremaster muscle and the lung following allergen 
challenge.  
The CCR4 receptor is believed to have roles in T lymphocyte (Th2 subsets) recruitment 
to allergic lungs, as MDC is upregulated in lungs following allergen challenge and T cells co-
localize with MDC in bronchial biopsy samples from asthmatic patients (Panina-Bordignon 
et al., 2001; Pilette et al., 2004). Allergic inflammatory responses in the lung are strongly 
driven by the Th2 immunophenotype, but it is unknown how the HDM-induced allergic 
inflammatory response generated in the cremaster muscle may compare (Busse and 
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Rosenwasser, 2003). C-021 administration may impair the Th2 response which could have a 
downstream effect on platelet migration into the lung. If the inflammatory response generated 
in the cremaster muscle is not as strongly driven by Th2 T cells, this may explain the lack of 
effect C-021 caused on platelet migration to the cremaster muscle. However, this theory does 
not explain why leukocyte recruitment to the lungs and cremaster muscle was unaffected by 
C-021 treatment. Further investigations into the dose and timing of C-021 administration to 
sensitized mice, or the use of transgenic mice, may reveal different responses of platelets and 
leukocytes following allergen challenge via CCR4, which is not appreciated in an acute 
pharmacological study. 
To summarise, the platelet CCR4 receptor is capable of causing platelet chemotaxis, 
however the role of CCR4 in platelet migration to sites of allergic inflammation requires 
further elucidation.  
7.3.3  Platelet CXCR4 receptor 
Treating human platelets with SDF-1α causes increased intracellular calcium 
concentrations, P-selectin expression, platelet shape change and low level platelet 
aggregation, via CXCR4 receptor activation (Clemetson et al., 2000; Kowalska et al., 2000; 
Gear et al., 2001). Stimulating washed platelets with SDF-1α has also been shown to induce 
platelet chemotaxis in-vitro, however the role of platelet CXCR4 in allergic inflammatory 
responses has not been investigated. In murine models of allergic inflammation, treatment of 
mice with a CXCR4 receptor antagonist or neutralising antibodies, caused decreased airway 
hyperresponsiveness, eosinophilia and Th2-associated cytokine release (Gonzalo et al., 2000; 
Lukacs et al., 2002). Indeed in patients presenting with lung eosinophilia, there was increased 
expression of CXCR4 on eosinophils, suggesting a role of CXCR4 receptor in allergic 
inflammatory responses (Nagase et al., 2000).  
Surface expression and total cell content of CXCR4 was shown on murine platelets, yet 
sensitization of mice to OVA and HDM had no effect on CXCR4 receptor expression. In the 
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microplate chemotaxis assay, SDF-1α did not induce chemotaxis of platelets from sham-
sensitized or OVA-sensitized mice, however following allergen challenge there was a subtle 
increase in platelet chemotaxis to SDF-1α. Human platelet chemotaxis was also recorded in 
the transwell chemotaxis assay, demonstrating the ability of SDF-1α to induce platelet 
chemotaxis via CXCR4 receptor activation. 
The CXCR4 receptor antagonist (AMD3100) had no effect on platelet recruitment and 
migration in the lung and cremaster muscle following allergen challenge, suggesting that the 
platelet CXCR4 receptor is not involved in platelet migration to sites of allergic inflammation. 
AMD3100 administration did however significantly decrease leukocyte recruitment to the 
cremaster muscle and PMN cell recruitment to the lungs following allergen challenge, 
indicating CXCR4 receptor has important roles in allergic inflammation. Interestingly, 
reduced leukocyte recruitment did not result in reduced platelet recruitment and migration to 
the lungs or cremaster muscle following allergen challenge, indicating platelets can migrate 
independently of CXCR4 mediated leukocyte migration. It is therefore interesting that the 
migratory response to allergen in-vivo has been reported to commence before initial leukocyte 
recruitment and migration, whilst at later time points, around 50% of platelets quantified were 
not complexed to leukocytes, furthermore, there are instances where platelet migration 
occurred in the absence of leukocytes (Pitchford et al., 2008; Page and Pitchford, 2014). In 
summary, the platelet CXCR4 receptor is functionally activate, however our data suggests it 
is not important in platelet migration to sites of allergic inflammation. 
7.3.4  Platelet CCR3 receptor 
Platelet CCR3 receptor simulation causes increased intracellular calcium 
concentrations, low level platelet aggregation and granule release, demonstrating the receptors 
functional activity on platelets (Clemetson et al., 2000). The CCR3 receptor has well 
documented roles in allergic inflammation where the receptor is important for eosinophil 
recruitment to the lungs (Humbles et al., 2002; Fulkerson et al., 2006). Indeed, a number of 
CCR3 receptor antagonists have been tested clinically on patients with asthma, producing 
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mixed results (Neighbour et al., 2014; Gauvreau et al., 2018). However, the ability of CCR3 
receptor activation to induce platelet chemotaxis and the role of CCR3 on platelet migration 
to sites of allergic inflammation has not been studied. 
Western blot analysis showed mouse platelet CCR3 receptor expression, with no 
differences between sham-sensitized and HDM-sensitized mice. Similarly, there was no 
significant difference between sham-sensitized and OVA-sensitized mice platelet CCR3 
receptor surface expression as measured by flow cytometry, however there was a doubling in 
expression following OVA-sensitization. Similarly, CCR3 receptor expression is elevated on 
other cells in allergic states. Bone marrow CD34+ cell expression of CCR3 measured pre and 
post antigen challenge on dual responder asthmatics, showed increased CCR3 receptor 
expression (Sehmi et al., 2003). Likewise, CCR3 receptor expression on CD4+ T cells was 
elevated in symptomatic atopic grass pollen-sensitive subjects compared with patients on 
high-dose allergen injection immunotherapy and healthy controls (Francis et al., 2007). 
Therefore, increased platelet CCR3 receptor expression following allergen sensitization, may 
be important in CCR3 mediated platelet migration to allergic inflammatory sites. 
CCR3 receptor stimulation via eotaxin caused human and mouse platelet chemotaxis in 
the transwell chemotaxis and microplate chemotaxis assays, respectively. Interestingly, OVA-
sensitization of mice caused significant platelet chemotaxis towards eotaxin compared to 
sham-sensitized mice, indicating that allergen-sensitization of mice leads to increased CCR3 
receptor activity. Other studies investigating the role of CCR3 in allergic inflammation have 
also shown enhanced activity towards CCR3 ligands of leukocytes from animals sensitized to 
allergen compared to control groups (Sehmi et al., 2003; Francis et al., 2007; Wang et al., 
2007). In eotaxin-1 and eotaxin-2 deficient mice, airway eosinophilia was reduced following 
allergen challenge in OVA-sensitized mice (Pope et al., 2005). Similarly, eotaxin-1, eotaxin-
2 and RANTES expression are increased in the lungs of allergic asthmatic patients (Ying et 
al., 1999). Eotaxin-1 levels were also elevated in sputum samples from patients with asthma 
and in the plasma of asthmatic patients experiencing an acute inflammatory response, 
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compared with stable asthmatic patients (Ying et al., 1997, 1999; Lilly et al., 1999; Yamada 
et al., 2000). In CCR3 deficient mice, eosinophil recruitment to the lungs following allergen 
challenge was impaired, and mast cell homing after allergen sensitization and challenge was 
effected (Humbles et al., 2002). Thus the enhanced activity of the CCR3 receptor on other cell 
types may also exist on platelets.  
The importance of the CCR3 receptor on platelet recruitment and migration in-vivo, 
was investigated. Antagonism of the CCR3 receptor using SB328437, caused a reduction in 
platelet rolling, platelet adhesion, and platelet accumulation into the cremaster muscle; and 
platelet accumulation into the lungs, in mice sensitized and exposed to HDM. Exogenous 
eotaxin administration also caused increased platelet rolling and platelet adhesion events in 
the cremaster muscle. However the sensitization of mice to HDM had no further effect. This 
would suggest that the sensitization of mice to allergen does not cause increased CCR3 
receptor activity. However it is also possible the dose of eotaxin may have been supramaximal, 
because the dose of eotaxin was previously chosen to induce extensive leukocyte recruitment 
and transmigration in an inflammatory murine model, and therefore masking differences 
between sham-sensitized and HDM-sensitized mice in this assay (Riffo-Vasquez et al., 2012). 
Further experiments could therefore be conducted to examine a full dose relationship between 
eotaxin and platelet recruitment, and the influence of allergen sensitization on this 
phenomenon. These studies do reveal that there is a dependency of platelet CCR3 stimulation 
on platelet recruitment in the context of allergic inflammation, and that pulmonary platelet 
recruitment and accumulation in a distinct murine model of allergic inflammation requires 
platelet stimulation via FcεRI (Pitchford et al., 2008). Whilst the sensitizing allergens are 
different (OVA vs HDM), and whilst both murine and human platelets have been shown to 
undergo chemotaxis directly to allergen in-vitro, to which the platelet donor is sensitized to, it 
is plausible in the earlier model that the FcεRI-dependent platelet migration was also 
dependent on platelet stimulation by chemokines. Therefore the relationship between allergen-
sensitization, FcεRI stimulation, and platelet CCR3 activity requires further attention. 
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Curiously, CCR3 receptor inhibition had no effect on leukocyte migration in the 
cremaster muscle or PMN cell migration to the lung, following allergen challenge. CCR3 
receptors are functionally expressed in a number of cell types including eosinophils, mast 
cells, Th2 cells and basophils, therefore it was hypothesised CCR3 receptor inhibition would 
impair the recruitment of leukocytes to the lungs and cremaster muscle following allergen 
challenge (Sallusto et al., 1997; Uguccioni et al., 1997; Pease et al., 1998; Ochi et al., 1999). 
A single dose of the CCR3 antagonist SB328437 (30mg/kg) at the time of allergen challenge, 
may not have been sufficient to effect leukocyte recruitment in our models of allergic 
inflammation, therefore further experiments elucidating the dose and timing of antagonist 
treatment should be conducted. Nevertheless, exogenous eotaxin administration caused 
increased platelet and leukocyte responses to the cremaster muscle, supporting previous 
literature that CCR3 receptor activation indeed leads to leukocyte recruitment. To conclude, 
platelet CCR3 receptor expression, in-vitro activity and in-vivo activity are affected by the 
sensitization of mice, suggesting an important role for the CCR3 receptor in platelet migration 
to sites of allergic inflammation. 




Increased platelet recruitment to the lungs of fatal asthmatic patients, with no evidence 
of platelet aggregation, suggests a protective inflammatory effect of platelets in asthma. The 
mechanisms which govern the migration of platelets to sites of allergic inflammation was 
investigated using in-vitro and in-vivo assays developed and optimized in this thesis. Platelets 
were shown to undergo chemotaxis in-vitro, and to be recruited and migrate in-vivo. Moreover 
the sensitization of mice to experimental allergen further increased such effects. Platelet 
chemokine receptors were investigated as a possible mechanism involved in these responses. 
Platelet CCR3 receptor activity was increased following allergen sensitization, suggesting a 
possible mechanism through which platelets migrate to sites of allergic inflammation. 
Interestingly, CXCR4 antagonism was shown to have a biological effect in reducing leukocyte 
recruitment, yet had no effect on platelet recruitment of migration. Further elucidation of the 
roles of platelets and chemokine receptors is clearly required, however, the data represented 
here suggests pulmonary platelet recruitment can occur independently of leukocyte 
recruitment via different mechanisms involving chemokine stimulation. 
Chapter 7 – Discussion  148 
 
 
7.5 Future work 
1) Due to a lack of sufficient airway wall tissue, extravascular platelets in the airway 
walls of healthy, non-fatal asthmatic and fatal asthmatic patients lung biopsy 
samples could not be quantified, therefore further staining on more sections should 
be considered. 
2) As previously mentioned, studies on asthmatic patient lung biopsy samples 
following antigen exposure in clinically controlled conditions, would aid the 
difficulties in measuring platelet recruitment to the lungs. 
3) In the microfluidic chemotaxis assay, further validation experiments to determine 
the optimum conditions for platelet chemotaxis are required, before the effects of 
allergen sensitization on platelet chemotaxis can be investigated.  
4) Investigate conditions under which platelets might transmigrate across a barrier 
using flow chambers coated with endothelial cell monolayers. 
5) Use near-infrared whole body imaging to conduct a temporal analysis of platelet vs 
eosinophil, or leukocyte recruitment to the lungs after allergen exposure, using 
probes to identify activated platelet and leukocyte populations. 
6) Investigate whether sensitization to allergen affects megakaryocyte phenotype in 
the first instance, whether this is subset specific or not, or whether platelet activity 
is affected on existing platelets. 
7) In the allergic intravital microscopy model of the cremaster muscle, a dose response 
to chemokine receptor antagonists and experimenting with the timing of dose, may 
clarify the effects of platelet chemokine receptors. 
8) To further investigate the role of the CCR3 receptor in-vivo, by performing a dose 
response to eotaxin, and dissecting and viewing the cremaster muscle at different 
time intervals post allergen challenge. 
9) Use chemokine receptor deficient mice to investigate platelet chemokine receptors 
roles on platelet migration in in-vitro and in-vivo assays. 
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10) Study the intracellular pathways connecting platelet chemokine receptor activity 
and FcεRI receptor stimulation in allergic inflammatory states. 
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